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ABSTRACT 
 
 
Immune responses towards Cytomegalovirus (CMV) often increase in magnitude with age; a 
phenomenon termed ‘memory inflation’. Elevated CMV-specific immunity is correlated with 
an increased mortality rate in elderly individuals and there is considerable interest in 
therapeutic approaches that may reverse this. Latent CMV infection is characterised by 
intermittent episodes of subclinical viral reactivation which may play a role in boosting CMV- 
specific immunity however, the relative importance of reactivation in the development of 
‘memory inflation’ is currently uncertain. In order to investigate these questions valaciclovir 
 
was administered as to aged mice with established murine CMV (MCMV) infection to block 
stochastic lytic reactivation from latency. Following 12 months of treatment there were 
highly significant reductions in the frequency of the MCMV-specific CD8+ T-lymphocytes and 
the residual MCMV-tetramer specific response exhibited a less differentiated phenotype. 
The accumulation of memory cells associated with untreated MCMV infection suppressed 
the proportion of naïve CD8+ T-cells by 60%, whereas antiviral treatment was able to 
completely restore this effect. Furthermore, valaciclovir treatment of MCMV reduced the 
elevated viral load that followed influenza virus challenge demonstrating that anti-MCMV 
treatment can lead to improved immunity to other pathogens in old age. 
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1.1. INTRODUCTION TO HERPESVIRIDAE 
 
 
The order Herpesvirales is divided into 3 subfamilies, 17 genera and over 90 species of 
herpes viruses [3, 4]. 
 
 
 
The Alphaherpesvirinae subfamily includes three human pathogens: Herpes-simplex virus 1 
(HSV-1), Herpes-simplex virus 2 (HSV-2) and Varicella zoster virus (VZV). The alphaherpes- 
viruses primarily have tropism directed towards sites of mucosal epithelium and are 
associated with establishing latency in neurones [5]. In vitro, the alphaherpesvirinae spread 
rapidly and have a relatively short replicative cycle. 
 
 
 
The Betaherpesvirinae subfamily includes the genus Cytomegalovirus (CMV), Herpes 
lymphotropic virus 6 (HHV-6) [6] and Roseolovirus (HHV-7) [7]. CMVs are found in many 
mammalian species. This introduction will mainly concern human (HCMV) and murine 
cytomegalovirus  (MCMV).  HCMV  infection  is  normally  asymptomatic in  an 
immunocompetent  individual  due  to  robust  innate  and  adaptive  immune  responses 
however, severe disease manifestations may occur in immunocompromised patients [8-10]. 
Unlike the alphaherpesvirinae, CMVs have a slower replicative cycle and cause infected cells 
to become enlarged (cytomegaly) prior to cell death (cytopathic effect or CPE). CMVs can 
infect many cell types and are believed to persist in primarily a latent form in cells of the 
myeloid lineage [11]. The HHV-6 and HHV-7 viruses are the aetiological agents of roseola 
infantum [12]. 
3  
 
The subfamily Gammaherpesvirinae includes the two human pathogens Epstein-Barr virus 
(EBV) and Kaposi sarcoma-associated herpesvirus (KSHV). EBV infection is usually 
asymptomatic during childhood infection although primary EBV infection during adolescence 
is the most common cause of infectious mononucleosis. Moreover, EBV is the causative 
agent for a number of malignancies, e.g. nasopharyngeal carcinoma, Burkitt lymphoma and 
post-transplant lymphoproliferative disorder. Like EBV the KSHV is also oncogenic and can 
cause a sarcoma in immune-suppressed individuals [13]. 
 
 
 
Of the eight Herpesveridae that infect humans, each has its own unique profile of 
pathogenicity, tropism and sequelae. Acute infections with Herpesveridae are usually self- 
limiting due to successful immunological control by both the innate and adaptive immune 
systems. Herpesveridae viruses are never eradicated persisting for the lifetime of the host. 
To reduce the exposure to the immune system many of the Herpesveridae enter a state of 
latency and employ immune evasion mechanisms. Herpes viruses do undergo lytic 
reactivation from latency and deleterious changes to the immune system such as 
immunosuppression or the aging process are implicated in increased viral reactivation [14]. 
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1.2. CYTOMEGALOVIRUS 
 
 
1.2.1. STRAINS OF HCMV 
 
 
The cytomegaly of cells attributed to HCMV was first recognised in the mid-part of the 
twentieth century, since then several “wild-type” (wt) strains of HCMV have been isolated 
from clinical tissue [15]. Estimates suggest that up to 95% of the human population may be 
carriers of HCMV [16]. 
 
 
 
Toledo and Merlin are two common wt isolates of HCMV. The Toledo viral strain remains at a 
low passage however, it has acquired a number of mutations and up to 19 new open reading 
frames (ORFs) [17]. Polymorphisms among wt isolates can subtly alter the viral genome 
having an advantageous effect in regards to the viruses' fitness [18]. Larger alterations and 
genetic variability of wt HCMV isolates may facilitate superinfection and be responsible for 
the viruses high prevalence [19]. 
 
 
 
In addition to HCMV of wt origin, there are a larger number of laboratory-adapted viruses 
and mutant virus strains of HCMV [20]. For example the laboratory strain Towne and AD169 
have been routinely passaged in cell culture and as a result are considered less virulent due 
mutations they have acquired that restrict their tissue tropism. Comparisons between the 
genome of the isolate Towne and the laboratory strain AD169 highlighted a number of large 
genomic rearrangements in AD169 [21]. As a consequence the AD169 virus is missing very 
large sections of the genome including the ORFs RL5A [22], RL13 [23]and UL131A [24] which 
therefore makes immune studies of this particular virus non-representative of wt strains. 
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1.2.2. STRAINS OF MCMV 
 
 
CMVs are highly species specific and in small animal models, the most frequently used 
strains of CMV used are those capable of infecting mice (MCMV). Like HCMV, there are 
multiple MCMV strains and variants. Two of the most widely used MCMV strains are the 
widely laboratory passaged serotype Smith and the less frequently passaged isolate of K181. 
 
 
 
In contrast to studies of HCMV, the MCMV genome is more stable. The MCMV genome has 
lower rates of mutation in both in vitro or in vivo passaged isolates and therefore genome 
size is better conserved, with fewer major genomic rearrangements, large insertions or 
deletions [25, 26]. Akin to HCMV, the process of propagation of MCMV in vitro does reduce 
the virulence of the virus; however, MCMV can be isolated from the salivary gland during 
acute infection to prevent the loss of virulence. 
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1.2.3. STRUCTURE OF CMV 
 
 
Cytomegaloviruses have a classical herpesvirus structure. At its core is its large linear double 
stranded DNA genome contained within an icosahedral capsid. The capsid is in turn located 
within a mesh of matrix proteins and a tegument layer. An outer envelope and membrane 
encompasses the complete virion. 
 
 
 
The HCMV genome is approximately 236,000 bp in length. This is much larger than many 
viruses including other members of the Herpesviridae (e.g. EBV ≈170,000 bp). The HCMV 
genome usually encodes for approximately 170 ORFs, with rare isolates that encode up to 
250 ORFs [27, 28]. 
 
 
 
 
Sequence analysis of the MCMV genome of the Smith isolate was published in 1996 [29]. The 
Smith genome measures 230,278 bp. Encoded within this large genome are 170 ORFs, of 
which 78 share significant sequence homologies to the HCMV isolate AD169. MCMV genes 
denoted “M” e.g. M45, share direct homology to HCMV whereas non-homologous genes are 
denoted “m” e.g. m139. 
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1.3. THE TROPISM OF CMV 
 
 
Exposure to CMV in bodily secretions, such as saliva and breast milk, means that often the 
primary cell type to which the virus will be first exposed to is the mucosal epithelium [30]. 
CMV disseminates from the mucosal epithelium into the circulatory systems where it can 
infect multiple cell types. 
 
 
 
Lytic HCMV has been extracted from both pulmonary tissue and monocytes from the lungs 
[31-34]; and the sinusoidal [35] and hepatocytes of the liver [36]. CMVs have been detected 
in many large organs and for this reason during solid organ transplantation, an attempt is 
made to match the donor’s HCMV status to that of the patient to reduce the risk of primary 
infection post-transplant [37]. In addition, HCMV can infect the arteriole endothelium and 
the presence of HCMV in atherosclerotic plaques contributes to vascular disease [38, 39]. 
Latent HCMV is believed to primarily resides in very low copy numbers within cells of the 
myeloid origin including monocytes [40], macrophages [41] and dendritic cells (DCs) [40, 42]. 
 
 
 
In the wild MCMV is most likely spread through biting, scratching and the shedding of the 
virus is bodily secretions. In the laboratory, recombinant MCMV, designed to express green 
fluorescent protein (GFP), was used to track the dissemination of viral infection following 
intraperitoneal (i.p) inoculation. MCMV is carried from the site of inoculation into the 
mediastinal lymphatic system and from there into the bloodstream [43]. Six hours post- 
infection (p.i.) MCMV disseminates to the spleen where initially the marginal zones are 
targeted before the virus transmits into the red pulp (17 hours p.i.). Within 48 hours, MCMV 
has infected the spleen and liver causing cytomegaly. Lytic MCMV then becomes detectable 
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in many others organs during the primary infection but upon establishing a latent infection 
the virus resides in the fewer anatomical sites. The reservoirs of latent MCMV are the liver 
sinusoidal endothelial cells (LSECs) [35, 44] the lungs [34] and also within the non- 
haematopoietic cells of the lymph node [45]. 
9  
 
1.4. OVERVIEW OF THE CMV LIFE CYCLE 
 
 
The tethering of the CMV envelope to cell surface receptors is the most likely mechanism 
through which CMV attaches and gains entry to infect a cell [46]. An initial interaction 
between cell surface heparin sulphate and the HCMV glycoprotein complex gC-II stabilises 
the virus and the cell membrane [47-49]. In addition, cellular integrins, e.g. the β1 and αvβ3 
integrins, can also mediate adherence and function as entry receptors for HCMV, through 
binding of viral glycoproteins and mediating endocytosis of the viral particle [50-52]. The 
most often cited cellular receptor for HCMV entry is the epidermal growth factor receptor 
(EGFR) [53]. For infection of monocytes, the EGFR mediates HCMV entry [54] and post-entry 
into the cell HCMV migrates to the nucleus and inhibits downstream epidermal growth 
factor signalling to prevent further viral entry into the same cell [55]. MCMV infection also 
uses the EGFR to gain entry into cells as small molecule inhibitors of this receptor are 
effective in preventing MCMV establishing infection in vivo [56]. HCMV entry via membrane 
fusion is typically pH-independent [57] although pH maybe significant for infection of cells of 
epithelial and endothelial origin [58]. 
 
 
 
1.4.1. REPLICATION OF CMV 
 
 
Transcription of the CMV genome occurs within the nucleus of an infected cell. Transcription 
is segmented into three kinetic phases; firstly, Immediate Early (IE or α) gene expression, 
followed by Early (E or β) gene expression, and finally Late (L or γ) genes are expressed. 
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The IE genes are the first set of viral genes expressed. Transcription of IE genes is prior to de 
novo viral protein synthesis and requires host transcription factors. The IE gene products are 
transactivators that provide the necessary stimuli to induce E and L viral gene expression. 
For example, the HCMV IE viral tegument protein pp71 is one of the first gene products 
produced from latently infected cells. The pp71 ORF encodes a protein that functions to 
remove a cellular DAXX protein (anti-apoptotic) enabling cell cycle progression and viral 
replication [59-63]. Other IE gene products that induce E and L stages of replication are the 
gene products IE72 [64, 65] and IE19 [64]. These two products work as transcriptional co- 
activators alongside IE86 [66] to promote viral DNA replication [11, 67-70]. 
 
 
 
Post-IE gene synthesis and within the first 24 hours of HCMV infection of primary human 
foreskin fibroblasts, the E gene products are understood to be expressed. The E genes are 
primarily non-structural proteins that are involved in viral-DNA replication and maintenance 
of  the  genome e.g.  DNA-polymerase (UL54)  [71,  72]  and  the helicase-primase complex 
(UL70) [72, 73]. Without E gene expression further CMV replication could not occur. 
 
 
 
Subsequent to E gene expression, the L genes are synthesised. The L genes require the 
manifestation of E gene products i.e. the DNA-replication machinery, to enable their 
transcription. The L gene products tend to be structural proteins, and are involved in 
assembly of the complete virion [74]. 
 
 
 
Following gene synthesis and CMV genome replication within the nucleus of the infected cell 
the virus is processed into virions. Firstly, the viral genome inserts itself within the capsid. 
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The CMV capsid is an icosahedral protein structure organized into capsomeres, hexamers, 
pentamers and triplexes approximately 110 nm in diameter [75, 76]. 
 
 
 
The capsid translocates from the inner nuclear membrane into the perinuclear space and 
acquires a primary envelope, which fuses during budding into the outer nuclear membrane 
releasing the capsid into the cytoplasm. A final envelope is acquired through fusion with 
Golgi  derived  vesicles.  The  viral  envelope  encompasses  the  tegument  that  contains 
numerous proteins, glycoproteins, phospholipids, polyamines, and small RNAs [77, 78]. The 
CMV viral tegument region is approximately 50 nm thick. The tegument layer contains 
multiple viral proteins including immunogenic targets e.g. pp65 [79-81]. Egress of the virus 
particle occurs through the fusion between the cell membrane and the virion [82]. A single 
CMV infected cell has the potential to generate many viral progeny including two non-virion 
forms of CMV: the non-infectious enveloped particles (NIEPs) and dense bodies (DBs) [83, 
84]. NIEP lack the dsDNA whereas DBs lack a capsid. Both are more abundant than complete 
virions (produced in a ratio exceeding 20:1) [85]. 
 
 
 
1.4.2. CMV DURING LATENCY 
 
 
The lytic phase of CMV’s life cycle sees the production of de novo viral progeny whereas the 
period(s) of latency is defined as the persistence of the viral genome in the absence of lytic 
replication or evidence of gene expression. Under specific conditions, the latent CMV is 
capable of re-entering lytic replication. The pattern of lytic replication, latent infection and 
sporadic viral reactivation is likely to repeat a number of times throughout the lifetime of 
the host. 
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HCMV has the potential to infect many cell types however the exact sites of viral latency and 
the mechanisms from which the virus is able to reactivate is a source of contention. Latent 
HCMV does reside within undifferentiated myeloid cells and the reactivation of the virus and 
the progression of myeloid cell maturation are interconnected. In a recent study, by Chan et 
al  (2012),  it  was  shown  that  initiation  of   viral  reactivation  occurred  prior  to   the 
differentiation of the myeloid progenitor cell and this process caused the simultaneous 
production of virions and the differentiation of the monocyte [86]. Whereas, Reeves et al 
(2005) concludes that reactivation of infectious virus results from cellular chromatin 
remodelling during DC differentiation [87, 88]. Therefore, as HCMV resides in myeloid 
progenitor cells it is also likely that upon differentiation latent virus will be present in the 
daughter cells of the progenitors. 
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1.5. TRANSMISSION OF CMVS 
 
 
The definition of CMV seropositivity is the presence of anti-HCMV IgG or IgM 
immunoglobulins in the serum [89, 90]. HCMV seroprevalence is often described as 
ubiquitous  [32,  91],  with  seroprevalence  fluctuating  between  40-95%  of  the  global 
population  being  serologically  positive  [92].  The  high  prevalence  rate  is  partly  due  to 
multiple routes of dissemination that include both vertical and horizontal transmission. 
Studies that have analysed the prevalence of MCMV isolates among wild house mice (Mus 
domesticus) [93] and wild mice (Mus musculus) [94] both confirmed almost universal MCMV 
seroprevalence. 
 
 
 
Vertical transmission of HCMV from mother to foetus via the placenta occurs in humans. 
MCMV  does  not  transmit  between  a  mouse  and  its  offspring  due  to  the  structural 
differences in the placenta [95]. Animal models of vertical CMV transmission rely on the 
guinea pig model [96-98]. Contraction of maternal primary HCMV infection during pregnancy 
is a major concern due to the vertical transmission of the virus to the developing foetus. It is 
estimated that in excess of 5500 children in the USA are born each year with defects caused 
by congenital HCMV [16]. In utero HCMV can induce a variety of neurological complications 
including sensorineural and bilateral hearing loss [99], later development of speech and a 
reduced IQ [100], macrocephaly, seizures and premature death. Interestingly the 
transmission of latent virus to the foetus is less associated with congenital disease as a result 
only primary HCMV infection is screened for routinely during pregnancy [101]. 
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Horizontal transmission of CMV is typically associated with the shedding of virus in bodily 
fluids. Neonates may contract HCMV during breast-feeding as HCMV DNA is transmitted in 
both the cellular and whey component of breast milk [102-109]. In addition, HCMV has been 
isolated from over 60% of saliva and 37% of urine samples from healthy individuals [110]. As 
a direct consequence, the risk of HCMV exposure is elevated in areas of poor sanitation or in 
professions where exposure to bodily secretions is high, e.g. child-care workers [111]. 
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1.6. CMV PATHOGENESIS 
 
 
HCMV infection is not a serious pathogen in healthy individuals; this is because the immune 
system has adapted to suppress lytic replication. Primary HCMV infection is usually 
asymptomatic  and  therefore  records  of  acute  infection  inevitably  go  unreported.  Case 
reports of more severe HCMV disease in immunocompetent individuals do inevitably exist 
[112], however cases of symptomatic HCMV infections usually result in a self-limiting 
infectious mononucleosis [113, 114]. The immune response that limits HCMV infection is 
required to control viral reactivation and loss of immunological control can result in viraemia 
that affects multiple organs and systems. The most common clinical manifestations of HCMV 
disease  seen  in  immune  suppressed  patients  are  pneumonitis,  retinitis,  enteritis  and 
colonitis and disease of the gastroenteric tract which all have the potential to be fatal [115]. 
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1.7. CMV THERAPEUTIC OPTIONS 
 
 
1.7.1. ACYCLOGUANOSINE PRODRUGS 
 
 
Antiviral treatment of herpes infection was revolutionised in the 1970s with the introduction 
of Acycloguanosine prodrug compounds. Aciclovir was the first anti-herpes drug to be 
introduced that inhibited herpes-viral DNA replication. Acycloguanosines are used clinically 
to treat a broad range of infections, e.g. cold sores, shingles and HCMV reactivation. 
Acycloguanosine prodrugs may also have benefit in other conditions where Herpesviridae 
have been implicated, e.g. Bell’s palsy [116], schizophrenia [117] and in delaying the onset of 
Human immunodeficiency virus (HIV) acquired immunodeficiency disease (AIDS) [118]. 
 
 
 
 
 
 
 
 
Figure 1.1. The chemical structures of the purine base guanine (C5H5N5O) and the prodrug 
aciclovir (C8H11N5O3). Aciclovir resembles a nucleoside and once activated more closely 
resembles a guanine nucleotide that is selectively incorporated into the viral genome 
during transcription. 
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Acycloguanosine prodrugs exert an antiviral function due to their resemblance to the purine 
base guanine (Figure 1.1). The activation from the prodrug into an active form requires a 
series of three phosphorylation events to convert the guanine nucleoside analogue into a tri- 
phosphate molecule that mimics a guanine nucleotide (Figure 1.2). 
 
 
 
The first phosphorylation reaction is performed by a viral phosphatase thus creating a mono- 
phosphate acycloguanosine. Most Herpesviridae encode a thymidine kinase (TK) enzyme 
that provides the initial phosphorylation reaction to convert aciclovir into a mono-phosphate 
form.  CMVs  are  an  exception and  do  not  encode  a  TK, but  HCMV  and  MCMV  remain 
sensitive to acycloguanosine antivirals because of a protein kinase (PK) enzyme with a 
homologous function to the TK. The phosphotransferase enzyme UL97 of HCMV and M97 of 
MCMV  is capable of performing the same necessary primary phosphorylation as the HSV-TK 
[119]. 
 
 
 
The cellular kinase(s), (d)GMP and (d)NDP kinase, provides two further phosphorylation 
reactions to generate a guanine nucleotide analogue. The herpes virus’ DNA polymerase 
(M57 ORF of MCMV) then incorporates this analogue into the genome (Figure 1.2). 
Consequently, this leads to chain termination of the viral DNA due to the lack of a 3’-OH 
group on the sugar residue and a failure of viral genome replication. The antiviral does not 
kill virally infected cells it only prevents further viral replication. 
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Figure 1.2. Activation of the aciclovir (ACV) prodrug requires an initial phosphorylation 
event by a herpes virus encoded thymidine kinase (HSV-TK) or a CMV protein kinase (CMV- 
PK). Aciclovir-monophosphate is phosphorylated by cellular (d)GMP and (d)NDP kinase(s) 
creating aciclovir-triphosphate that selectively inhibits herpes virus DNA-polymerase. 
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Early acycloguanosine nucleoside prodrugs such as aciclovir have a short half-life in the body 
and a poor bioavailability. Therefore, aciclovir(s) are administered at a high dose. For 
example, doses exceeding 10 mg/kg daily of valaciclovir is given for the prevention and 
treatment of HCMV-disease post-allogeneic hematopoietic stem cell transplantation [120]. 
Valaciclovir (C13H20N6O4) is an esterified form of aciclovir converted into an active prodrug by 
a cellular valaciclovirase(s) (Figure 1.3) [121-124]. Newer acycloguanosine compounds such 
as ganciclovir are more potent derivatives acycloguanosines however; this class of antiviral 
has serious side effects in approximately 1% of patients. For example, ganciclovir is listed as 
being toxic, a mutagen and a carcinogen. Haematological side effects seen with ganciclovir 
treatment include neutropenia and thrombocytopenia [125]. Due to the toxicity associated 
with acycloguanosine prodrugs there has been a recent focus on developing new drugs to 
treat HCMV disease. These newer drugs e.g. Foscarnet, Cidofovir, Formivirsen [126] and 
Maribavir [127] are designed primarily to be administered for relatively short periods until 
the immune system is capable of controlling HCMV independently. 
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Figure 1.3. Conversion of valaciclovir into aciclovir. Valaciclovir has an improved 
bioavailability due to carrier-mediated intestinal absorption. Enzymatic conversion by a 
valaciclovirase is required for the conversion/activation in vivo [121]. 
 
 
 
 
 
 
In vitro propagation of HCMV in the presence of antiviral compounds has led to the 
emergence of antiviral resistant mutant strains [128]. Similarly, long-term antiviral therapy 
can lead to the emergence of drug resistant HCMV strains in vivo [129, 130]. In the pre- 
HAART (highly active antiretroviral therapies) era it was estimated that approximately 8% of 
AIDS patients would develop resistance to ganciclovir and become susceptible to HCMV 
disease after three months [131]; by six months estimates suggest 11% of patients and in 
excess of 25% will have a recrudescence of herpesvirus infection [132]. The clinical 
significance of antiviral resistance is that for successful long-term suppression of HCMV, a 
continuous dose of antiviral is required and cessation of therapy may result in disease. The 
selective pressure applied to HCMV during antiviral therapy may select for advantageous 
mutations to the phosphotransferase gene, UL97 [133]. These mutations often confer cross- 
resistance to other acycloguanosine antivirals [134, 135]. 
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1.7.2.  HCMV VACCINE DEVELOPMENT 
 
 
HCMV infection is asymptomatic in immunocompetent individuals; however, a vaccine that 
generates protective immunity to the virus would be beneficial in preventing HCMV disease 
manifestations  during   pregnancy  and   immunosuppression.  Anti-HCMV   vaccines  have 
entered clinical trials with moderate success. A particle vaccine expressing either the 
glycoprotein (gB) protein or a pp65/IE1 fusion protein was tested in a randomised, double- 
blind Phase-1 clinical trial in HCMV seronegative adults. The vaccine elicited T-lymphocyte 
responses (measured by IFNγ ELISPOT assays) and neutralising antibodies [136, 137]. A 
separate  Phase-1  trial  conducted  in  HCMV-seronegative  toddlers  administered  the  gB 
antigen with the MF59 adjuvant was highly immunogenic with higher immunoglobulin titres 
achieved than those who acquire HCMV naturally [138]. A different gB vaccine, again given 
with the MF59 adjuvant, was tested in a randomised placebo controlled trial of patients 
awaiting kidney/liver transplantation elicited strong humoral immunity and immunoglobulin 
titres that inversely correlated with the duration of viraemia [139]. These promising trials 
suggest that it may be possible to vaccinate and protect against HCMV. 
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1.8. THE IMMUNE RESPONSE TO CMV 
 
 
Acquisition of CMV infection becomes a life-long challenge to the immune system, as the 
virus is not eradicated from the host. To avoid detection by the immune system CMVs are 
able to revert from a lytic into latent states and employ a series of immune evasion 
mechanisms. Importantly prior CMV exposure does not provide protective immunity to 
secondary infection [140]. 
 
 
 
Loss of immunity can give rise to an increase in opportunistic HCMV infection [141, 142]. 
Cells of the innate system are usually the first to respond to infection and are not reliant 
upon prior sensitisation to non-self-antigens. The haematopoietic stem cells of the bone 
marrow are multipotent and differentiate to form the myeloid and lymphoid lineages of the 
immune system. The myeloid professional antigen-presenting cells (APCs), such as DCs and 
macrophages, provide  the  necessary stimuli  to  prime  and  maintain  lymphoid  immunity 
[143]. The adaptive immune response is initially less rapid, however upon resolution of acute 
infection a quiescent form of immunological memory is formed that rapidly responds to 
antigen re-exposure by proliferation and effector functioning [144]. 
 
 
 
The establishment of latent CMV infection, although asymptomatic, may be best phrased as 
a chronic infection due to dramatic changes seen in the T-lymphocytes populations of 
seropositive donors/animals [145-147]. A series of longitudinal epidemiological studies 
compared changes in immune parameters in  relation to  HCMV  seropositivity in 
octogenarians and nonagenarians. They concluded HCMV seropositive individuals had 
oligoclonal expansions of HCMV-specific CD8+  T-lymphocytes, an inverted CD4:CD8 T-cell 
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ratio, restricted T-cell receptor (TCR) usage and a low number of B-lymphocytes. The 
collective term for these changes was the Immune Risk Profile (IRP). Individuals with an IRP 
were characterised as being at an elevated risk of mortality at two, four and six years follow- 
up [148, 149]. Similarly, in a cross-sectional analysis of 70+  year old females in Baltimore 
USA, HCMV seropositivity directly impact upon mortality and in addition was found to 
accelerate the onset of frailty [150]. 
 
 
 
 
 
 
1.8.1. CD8+ T-LYMPHOCYTE RESPONSE TO CMV 
 
 
The CD8+ T-lymphocytes are form part of the adaptive immune response. They are cytotoxic 
and kill virally infected cells. The CD8+  T-cell response is initiated by a number of signals 
within the immunological synapse. First, direct antigenic stimulation is provided by 
engagement of the CD8+ T-cells own TCR binding to the APC presenting a cognate viral 
peptide loaded onto a major histocompatability complex (pMHC) (Figure 1.4). The antigenic 
peptides are prepared via proteasomal processing of viral proteins into shorter sequences 
that are loaded onto the MHC via the transporter for antigen presentation (TAP). The pMHC 
complex translocates from the ER to the outer membrane of the APC for detection by CD8+ 
T-cells with cognate TCR. TCR-binding of the pMHC causes the CD8 complex within the 
lymphocytes outer membrane to cluster around the TCR bringing the src family kinases e.g. 
Lck or Fyn, into close proximity of the CD3 ζ-side chain of the lymphocyte. The recruitment of 
Lck phosphorylates immuno-receptor tyrosine-based activation motifs (ITAMs) on the CD3 ζ- 
side chain. This induces a cascade of events including recruitment and activation of ZAP-70 
to the phosphorylated ITAM, and induction of downstream pathways such as upregulation 
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of transcription factors e.g. nuclear factor of activated T-cells (NFAT) and nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) which results in T-lymphocyte 
activation/proliferation [151, 152]. To augment the CD8+ T-cell proliferation a second co- 
stimulatory signal is provided; such as CD28 on the T-cell surface (constitutively expressed 
on naïve T cells) binding the B7-ligands (CD80 and CD86) on activated APCs which aids T-cell 
mitosis [153]. A third signal within the immunological synapses is provided by inflammatory 
cytokines e.g. interleukin-2 (IL-2), binding to its receptor (CD25) on the lymphocyte. These 
signals are required for the initiation of proliferation and cytotoxic function of the CD8+  T- 
cells (Figure 1.4). 
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Figure 1.4. CMV viral proteins are processed into short antigenic peptides by the 
constitutive proteasome or IFNγ inducible immunoproteasome. The peptide is then 
transloacted  from  the  endoplasmic  reticulum  (ER)  by  the  transporter  for  antigen 
processing (TAP) and presented by MHC-I on the cell surface to interact with CD8+ T-cells 
with a complementary TCR. Also within the immunological synapse, co-stimulation from 
CD28, OX40 and 41-BBL interactions and addition stimuli from proinflammatory cytokines 
aid CD8+ T-cell proliferation, cytokine release and cytotoxic activity. Nature Reviews in 
Immunology [154]. Licence number 2864720728549. 
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The entire HCMV proteome was previously screened for immunogenic MHC-I and MHC-II T- 
lymphocyte  epitopes  using  15mer  overlapping  peptides.  Sylwester  et  al  (2005) 
demonstrated that 60.9% of the 213 HCMV ORFs were immunogenic, with 38% of ORFs 
eliciting  both  CD4+   and  CD8+   T-lymphocyte  responses  (measured  by  CD69+   and  IFNγ 
production) and 12.2% of ORFs elicited only HCMV-specific memory CD8+  T-cell responses 
 
[155]. On average the CD8+ T-cell repertoire of an HCMV seropositive individual responds to 
 
21 ORFs with the five most frequently recognised by CD8+ T-cells being UL48, pp65, IE1, IE2 
and US32. The immunogenic ORFs spanned the entire kinetic profile of gene expression (IE, 
E, E-L or L), function (capsid, matrix, glycoprotein, DNA and immune evasions) localisation 
(virions  and  DBs),  and  was  irrespective  of  major  histocompatability  complex  (MHC) 
haplotype [156]. Furthermore, in the Sylwester et al (2005) study the average peripheral 
blood HCMV-specific immune response, per individual, was approximately 4.5% of the entire 
CD8+ T-cell pool in adults and 10% of the CD8+ T-cell memory compartment in older donors 
[155]. 
 
 
 
Staining of the peripheral blood mononuclear cells (PBMC) with MHC-I tetramer reagents 
showed that in elderly donors up to 40% of the entire lymphocyte pool may be directed 
against a single HCMV-epitope [145-147]. The expansion in HCMV-specific memory T- 
lymphocytes seen in the elderly reduces the heterogeneity of the overall cytotoxic CD8+  T- 
cell repertoire which has been demonstrated to be highly clonal [145, 147, 157, 158]. 
 
 
 
Ex vivo analysis of PBMC from elderly HCMV, seropositive donors display a skewed 
distribution of CD8+  T-lymphocyte memory populations. The phenotype can exist almost 
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exclusively of T-effector memory revertant CD45RA CD8+  T-cells (CD45RA+ CCR7-) with very 
few naïve (CD45RA+ CCR7+) CD8+ T-cells. Within the HCMV seropositive donor a large 
proportion  of  the  TEMRA  cells  are  HCMV-specific  and  under  the  correct  experimental 
conditioning  stimuli  e.g.  4-1BBL or  peptide  stimulation  the  cells  are  able  to  proliferate 
and/or produce multiple pro-inflammatory cytokines [146, 159]. 
 
 
 
Reactivation of HCMV-antigen could provide the necessary stimulus to generate the large 
peripheral HCMV-clonal expansions of CD8+ T-lymphocytes detected in the elderly. The high 
frequency of these cells and the corresponding decline in the naïve CD8+  T-cell repertoire 
could be detrimental to health. In HCMV seropositive donors, the accumulation of HCMV- 
specific  CD8+   T  cells  is  associated  with  six  fold  fewer  EBV-specific  CD8+   T-cells  in  the 
peripheral blood compared with seronegative donors [146]. It was proposed that HCMV is 
potentially detrimental in an immunocompetent host, through suppressing heterologous 
virus-specific  immunity  during  aging  and  consequently,  a  HCMV  seropositive  individual 
maybe more susceptible to infection(s) and may be predisposed to earlier mortality [148, 
149, 160]. 
 
 
 
 
There are many parallels between HCMV and MCMV infection including the high prevalence, 
dissemination, persistence and shedding from the host. Likewise, immunological models of 
HCMV infection have been developed in a number of laboratories that mimicked the large 
expansions of HCMV-specific CD8+ T-lymphocytes. The model of MCMV induced memory 
inflation was first developed in MCMV susceptible mice strains. Intravenous inoculation of 
BALB/c mice with the MCMV strain Smith resulted in an accumulation of pp89 and m164- 
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specific CD8+  T-cells that peaked at day 100 p.i. and were maintained at high frequencies 
[161]. For example, pp89 specific CD8+  T-cells have been estimated to contribute to 8% of 
the CD8+ T-cells from the spleen, 16% from the lungs, 16% from the liver and 24% from the 
salivary gland. Latent MCMV has been shown to reside within the spleen [162], lung [34], 
liver [35] and salivary gland [163] therefore it is unsurprising that a high frequency of MCMV- 
specific CTLs are found in these organs. In contrast, the percentage of pp89-specific cells was 
not enriched in the mesenteric lymph nodes or the salivary gland associated lymph nodes. 
Consequently, it appears that memory inflation is tissue specific and the homing or 
proliferation of these cells is independent of lymphoid organs and more closely associated 
with the sites of MCMV latency. 
 
 
 
Snyder et al (2008) further refined the MCMV model. They were amongst the first to show 
memory inflationary in the C57BL/6 mouse and detected diverse memory responses to over 
twenty viral proteins [164]. Immunogenic epitopes contained within the proteins encoded 
by the M45 and M57 ORFs elicit robust CD8+  T-cell proliferation during the acute phase of 
infection which later contracts to form a stable resting long-lived memory population [165]. 
Immunity towards the M38 and m139 epitopes displays kinetics that is atypical to the 
understanding of normal memory T-cell development. Initially proliferation of M38 and 
m139-specific CD8+ T-cells occurs during the primary infection, followed by a short 
contraction phase, however, there is then a gradual accumulation of virus-specific cytotoxic 
T-lymphocytes (CTLs) termed “memory inflation”. The lymphocytes that undergo memory 
inflation also present a highly differentiated membrane phenotype equivalent to the TEMRA 
phenotype. A  third  epitope that  also  develops memory inflation  is  processed from the 
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IE3/M122 ORF. CD8+ T-cell responses towards IE3 are not usually detected during the acute 
phase of infection but expanded to very high frequencies (>16% CD8+ T-cells) by 100 days p.i. 
[164]. These inflationary immune responses seen in the mouse [161, 165] are analogous to 
those immune responses seen in humans as they are detected in older age and have a 
distinctive highly differentiated membrane phenotype [146, 147]. 
 
 
 
The MCMV CD8+ T-lymphocytes which undergo memory inflation display lower levels of 
CD62L (L-selectin) than the non-inflationary M45 and M57 antigen-specific cells [165]. CD62L 
interacts with its receptor on the high endothelium venule (HEV) binding molecule CD62L (L- 
selectin) and expression on a lymphocyte ensures that the cell is preferentially retained 
within the lymph node at the correct anatomical site for antigen presentation. In addition 
the M38, m139 and IE3-specific CTLS have reduced expression of the cytokine receptors 
CD127 (IL-7Rα ) and CD122 (IL-15Rβ) [165]. Surface expression of these receptors is down 
regulated upon chronic stimulation and antigen exposure to prevent the cells from being 
exhausted and unable to proliferate [166-170]. Similarly, the inflationary subsets of cells 
have reduced levels of CD27 compared to the M45 and M57 subsets [165], expression of the 
CD27 molecule is regulated its interaction with CD70 on the APC and during chronic infection 
is believed to represent a transition of an effector cell into a long-lived memory cell [171, 
172]. CD28 expression is also modulated via interactions with its ligands (CD80/86) on the 
APC and successful activation promotes T-cell proliferation, the loss of this molecule occurs 
on the more highly differentiated lymphocyte subsets [173] and is unsurprisingly CD28 
expression is low on the M38, m139 and IE3 specific T-cells [165]. The inflationary cells were 
further characterised as having low expression of killer cell lectin-like receptor subfamily G 
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member (KLRG1) and programmed cell death (PD-1) [165]. KLRG1 is a receptor than binds E- 
cadherin and is located on the surface of both NK and T-lymphocytes. Elevated KLRG1 
expression can lead to inhibition of T-cell proliferation (inhibition of Akt signalling) and is 
more prominent with age and T-cell differentiation and therefore the high levels of KLRG1 
on inflationary T-cells show the cells as less capable of proliferation [174-176]. PD-1 is an 
inhibitory receptor expressed on T-cells. Levels of PD-1 are partially modulated by T-bet 
(transcription repressor) and loss of PD-1 is believed to help sustain virus-specific CD8+  T- 
cells from becoming exhausted therefore it is likely that the accumulating cells also have 
some functional impairment [177]. 
 
 
 
The inflationary MCMV-specific CD8+  T-cells proliferate rapidly during acute infection with 
the Ki67 (molecule expressed during mitosis) expressed on 100% of pp89-specific cells at day 
7 which was seen to fall to 22% by day 30, and as low as 7.5% by day 150 [161]. The M38, 
m139 or IE3-specific CD8+ T-cells when adoptively transferred, (from donor CD45.1 mice into 
immunologically naïve CD45.2 recipient mice) did not proliferate independently of latent 
MCMV infection and were almost completely lost from the recipient mice within 90 days 
[165]. When Snyder et al (2008) repeated the transfer of the same inflationary subset of T- 
cells, into MCMV infected mice the antigen-specific memory pool was maintained by the 
repopulation of cells with the same specificity from the recipient and not the donor [165]. In 
contrast, transfer of M45 or M57 (non-inflationary) specific CD8+ T-cells into MCMV immune 
mice were maintained at the same relative frequency in naïve mice, however upon transfer 
into MCMV immune mice the M45/M57 T-cell frequency decayed and was almost absent at 
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day 119 after adoptive transfer illustrating that the CTL populations are maintained via an 
additional signal(s) [165]. 
 
 
 
The work of Tanaka et al (2007) showed memory inflation (IE1-specific CD8+ T-cells) did not 
occur at 12 months following MCMV-infection in germ-free mice (GF). In addition, Tanaka 
did not detect an elevation in viral load or proinflammatory cytokines levels (IL-2, IL-7, IL-15, 
and IFNγ) within the lungs of GF mice compared to SPF mice. Re-colonisation of the GF gut 
with indigenous microbiota then enabled memory inflation of MCMV-specific CD8+ T-cells to 
occur [178]. From this the authors remarked that the wide variety of antigenic peptides 
derived from the microbiota were a likely source of cross-reactive epitopes of MCMV 
highlighting a role of antigen(s) and their presentation which influences whether memory 
inflation occurs. 
 
 
There are multiple lineages of CD4+ T-cells and in addition to directly suppressing MCMV 
replication [179] CD4+  T-cells can help to initiate cross-presentation of MHC-I antigens by 
professional APC such as conventional DCs (cDC) [180, 181]. Snyder et al (2009) investigated 
whether  the  mechanism  of  memory  inflation  would  occur  during  the  latent-phase  of 
 
infection in the absence of CD4-/- or MHC-II-/-. They showed that the loss of CD4+ T-cells 
impaired the generation and accumulation of IE3-specific CD8+ T-cells within the blood, 
spleen and lung [182]. It was also reported that the absence of CD4+ T-cells did not influence 
memory inflation of the m139 and M38-specific CD8+ T-cell response. Contrasting data from 
Walton et al (2011) showed that MHC-II-/- knock-out mice do not generate the normal 
frequencies of M45 and M57 T-cells (non-inflating) and memory inflation of the M38, m139 
32  
and IE3-specific CD8+  T-cells does not occur [183]. The additional role that CD4+  T-cells 
provide was not IL-21 mediated and is most probably mediated by CD40L interaction with 
infected APCs as CD40L-/-  mice also have reduced frequencies of IE3-specific T-cells in the 
blood (24 weeks p.i.) [182, 183]. 
 
 
 
Similar observations of impaired IE3-specific CD8+  T-cell responses were seen in  Batf3-/- 
(basic leucine zipper transcriptional factor ATF-like 3) knockout mice. Batf3 is a transcription 
factor required for cDC development, knockout mice have severe defects in the cross- 
presenting  of  viral  and  tumour  antigens  [184].  MCMV  infection  of  Batf3-/-   mice  have 
approximately 30% fewer IE3-specific CD8+ T-cells in comparison to mice with wt infection in 
 
both the lungs and spleen at 110 days post-MCMV infection [185]. In addition, the 
frequencies of M38 and m139-specific T-cells display “early” inflation kinetics, accumulating 
post-acute  infection,  and  retaining  an  effector  phenotype  (CD127lo    CD62L-    KLRG1hi); 
however, three months post-MCMV infection there was a partial reduction in the frequency 
of M38 and m139-specific CD8+ cells in Batf3-/- mice. Therefore, CD4+ T-cells may facilitate an 
interaction between virally infected cells that cross-present the IE3-antigen that initiates the 
expansion of IE3-specific CD8+ T-cells during latent infection. 
 
 
 
Presentation of pMHC to CD8+  T-cells requires the processing of viral proteins into shorter 
antigenic peptides by either the constitutive proteasome or the immunoproteasome. The 
presence of pro-inflammatory IFNγ is associated with an upregulation of MHC-I expression 
and the construction of the immunoproteasome in non-professional APCs [186]. Professional 
APCs express the immunoproteasome constitutively so it is unsurprising that MCMV is able 
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to modulate the immunoproteasome through inhibiting phosphorylation of STAT-2 and 
consequently inhibiting IFNγ-receptor signalling [187, 188]. The presence of the LMP7 (IFNγ 
inducible subunit of the immunoproteasome) is required for memory inflation as the 
frequency of M38 and m139-specific CD8+ T-cells is approximately double in wt compared to 
LMP7-/-  mice at 100 days post-MCMV infection [189]. Memory inflation of the IE3-specific 
 
cells was not examined in relation to a functional immunoproteasome however as the 
accumulation   of   cells   of   this   specificity   is   reliant   on   cross-presentation  [190]   and 
presentation from non-haematopoietic cells [45] IE3-presentation is also likely to utilise 
processing by the immunoproteasome. It was shown for IE1-specific T-cells to inflate in a 
BALB/c infected mouse that expression of the epitope is required from host MHC class-I 
molecules on non-professional infected cells presenting antigen as inflation did not occur in 
mice with mismatched MHC-I on the professional APCs [191]. 
 
 
 
Investigations that sought to inhibit lytic MCMV replication with acycloguanosine treatment 
have solely focused on treatment of a mutant MCMV strain (MCMV-Δm157-TK). There are a 
number of issues that arise through the using the MCMV-Δm157-TK mutant virus. The 
deletion of the m157 gene enables the virus to escape from NK-cell Ly49h-mediated 
cytotoxicity, which results in elevated acute MCMV titres in the lung and spleen. 
Consequently, the adaptive immune system responds to the higher viral loads with a larger 
CD8+ T-cell response (M45, M57 and m139 epitopes) and significantly elevated levels of 
proinflammatory cytokines (IFNγ, IFNα, IL12, IL-6 and IL-15) in the serum and in addition 
reduced numbers of circulatory DCs [192]. Therefore, the MCMV-Δm157 viruses do not elicit 
memory inflation  to  the same magnitude or kinetics as  a  wt MCMV. Furthermore, the 
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addition of the HSV-I TK to the MCMV-Δm157 mutant is believed to increase the virus’ 
sensitivity to acycloguanosines [193]. However, the insertion of the TK into the MCMV 
genome is unnecessary as Smith MCMV is highly susceptible to doses of antiviral as low as 1 
μM [194]. Consequently, the MCMV-Δm157-TK mutant virus is so far removed from the 
original that the immune response generated (+/- antiviral treatment) is not representative 
of MCMV infection. 
 
 
 
Both Walton et al (2011) and Snyder et al (2011) exposed MCMV-Δm157-TK infected mice to 
famciclovir treatment (2 mg/ml) and measured the corresponding CD8+  T-cell frequencies 
[183, 193]. Neither study reported any direct immunotoxicity towards the T-cells [195]. 
Snyder et al (2011) illustrated that antiviral treatment given seven days prior to MCMV- 
Δm157-TK infection resulted in the almost complete attrition of the IE3-specific immune 
response after 12 weeks of treatment [193]. Similarly, Walton et al (2011) demonstrated 
that famciclovir treatment of MHC-II-/- deficient mice infected with MCMV further reduced 
the frequency of IE-specific CTLs [183]. In addition, famciclovir treatment resulted in a larger 
proportion of both M45 and M38-tetramer specific cells to display a less differentiated 
surface phenotype (CD62L+  CD27+) [183]. Unfortunately, the phonotype of IE3 and m139- 
tetramer specific cells was not included in their analysis. 
 
 
 
In addition to antigen, cytokines directly modulate memory inflation. MCMV infection of IL- 
 
10-/-   knockout  mice  have  amplified  numbers  of  MCMV-specific  CD8+   T-cells  due  to  the 
removal of the suppressive effect of this anti-inflammatory cytokine [196]. Likewise, co- 
stimulation  via  the  TNF  superfamily  of  receptors  is  required  for  T-cell  responses.  The 
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absence of an interaction between 4-1BB and its receptor has two independent effects upon 
the MCMV-specific T-cell response in 4-1BB-/-  mice. The 4-1BB-/-  mice develop exaggerated 
acute MCMV-specific CD8+  T-cell responses however memory inflation does not occur for 
the M38 and m139-specific CD8+  T-cells (IE3-specific cells not tested) [197]. OX40 is 
transiently expressed by activated T-cells and functions to bypass the inhibitory signals 
provided by CTLA-4. Loss of OX40-/- interactions with its ligand OX40L (expressed on the APC) 
was  shown  to  impair  memory  inflation  of  M38  by  approximately  50%  at  day  90  p.i. 
suggesting memory inflation may require periodic costimulation from an infected cell [198]. 
In contrast loss of the costimulatory B7 ligands, CD80 and CD86, in B7.1/2-/- mice, was shown 
not to result in reduced numbers of M38, m139 and IE3-specific CD8+ T-cells [199]. 
 
 
Typically CMV-specific immune responses modelled in vivo have focused upon infections in 
immunologically naïve specific-pathogen free (SPF) animals to avoid cofounding effects on 
the experimental data. However, in the natural environment all animals become exposed to 
a large variety of pathogens throughout their lifetime and as a result would develop multiple 
immune responses. Having a history of pathogen exposure modulates the ability to mount 
de novo immune responses. For example, successive infection of C57BL/6 mice with 
Lymphocytic choriomeningitis virus (LCMV), Pichinde virus (PV), Vaccinia virus (VV), MCMV, 
and Vesicular stomatitis virus (VSV), caused the attrition of the pre-existing LCMV-specific 
CD8+   T-cells  with  each  subsequent  infection  [200].  The  decline  in  memory  CD8+   T-cell 
 
frequencies was attributed to the exposure of “heterologous antigen” and the attempts 
made by the immune system to accommodate the proliferation of the new lymphocyte 
response within a finite lymphoid population. The series of heterologous viral infections was 
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illustrated to cause the attrition of the absolute numbers and not just percentages of pre- 
existing memory T cells [201]. The mechanism through which this attrition may occur is 
through an increased sensitivity to type I interferons in memory T-cells. In experimental 
models interferon cytokines can selectively activate caspase-3 and caspase-8 and initiate 
apoptosis in sensitive memory T-cells but not antigen inexperienced lymphocytes [202-204]. 
Therefore, frequent viral (CMV) reactivation and the pro-inflammatory environment 
generated could both contribute to the loss of T-lymphocytes of other specificities and 
memory inflation of CMV-specific CTLs. 
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1.8.2. CD4+ T-LYMPHOCYTE RESPONSE TO CMV 
 
 
Ageing and lifelong HCMV infection sculpts both the naïve and memory CD8+ T-lymphocyte 
repertoires in older people. In contrast, age has been shown to be the strongest factor in the 
depletion of naïve (CD45RA+ CD27+) CD4+ T-lymphocytes from the peripheral blood of older 
donors [205]. However, healthy HCMV-seropositive individuals also develop an age- 
dependent decrease in naïve CD4+ T-lymphocytes and accumulation of memory CD4+ T- 
lymphocytes which is likely to start immediately p.i. as changes to CD4+ T-cell profile become 
evident in PBMC samples taken from children [9, 206]. Pourgheysari et al (2007) 
demonstrated memory inflation of CD4+ T-cells; as the frequency of HCMV-specific CD4+ T- 
cells more than doubled from on average 2.2% in younger donors (<50 years old) to 4.7% in 
older donors (>65 years old) [207]. 
 
 
 
 
In the study of Sylwester et al (2005) overlapping peptides were used to screen for HCMV 
immune responses; 44 ORFs generated HCMV-specific CD4+  T-lymphocyte responses [208]. 
The two most dominant CD4+ T-cell specificities were directed towards epitopes from the gB 
and pp65 proteins that were present in over 25% of the individuals they assayed. HCMV- 
specific immune responses constituted on average 4% of the entire CD4+ T-cell pool and over 
9% of the memory CD4+ T-cell compartment [208]. In another small study of memory CD4+ T- 
 
cell response to HCMV, the CD4+ specific T-cell response was dominated by small number of 
clonotypes [209]. Similarly, in  rhesus macaque models of CMV infection the  developing 
virus-specific CD4+ T-cells are clonal if the macaques are re-challenged with the same 
pathogen [210]. 
38  
Aging alone is thought to be the strongest factor for the decrease in the naïve (CD45RA+ 
CD27+)  CD4+   T-lymphocyte  population  observed  in  older  donors  [205]. However, HCMV 
causes a paradoxical increase in the CD4+ CD45RA+ CD27+ T-cell populations. The majority of 
these  cells  are  HCMV-specific  and  are  at  an  elevated  frequency  in  the  bone  marrow 
compared with the blood [205]. In healthy aged donors the phenotype of the overall CD4+ T- 
lymphocyte alters displaying elevated CD57+ expression, decreased levels of the co- 
stimulatory CD28 [205] and CD27 molecules [207], and disproportionately high levels of 
CD69 [211]. The CD4+  T-cell memory subset of cells from elderly donors produces less IL-2 
[207] but are not anergic as the cells can proliferate with IL-15 stimuli [212]. 
 
 
 
Animal models of CD4+ T-lymphocyte responses to MCMV have shown the cells to be 
essential in controlling acute infection. A number of MHC-II restricted CD4+ T-cell responses 
specific to MCMV have been mapped across the MCMV genome [213]. During the acute 
phase of infection, the MCMV-specific CD4+ T-cells proliferate and accumulate in the spleen 
and lungs. The MCMV-specific CD4+ T-cells were found to be polyfunctional producing 
proinflammatory cytokines such as IFNγ, TNFα and IL-2 [213] and regulatory cytokines such 
as IL-10 [214]. Furthermore, loss of the co-stimulatory ligands B7.1-/- and B7.2-/- impairs the 
expansion of MCMV-specific CD4+ T lymphocytes implies a role strong role of the APC in 
priming MCMV specific CD4+ responses [215]. 
 
 
 
The  HCMV-specific  CD4+   T-lymphocyte  response  has  been  characterised with  an 
accumulation of memory CD4+  T-cells and the decline in naïve CD4+  T-cells observed in the 
peripheral blood [214]. Moreover, in the C57BL/6 system a single MHC-II restricted CD4+ T- 
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cell epitope encoded by the m09 ORF was undetectable during the first 20 days p.i. but 
accumulates to 0.2% of the entire CD4+ T-cell response by day 50 and is maintained at that 
same relatively high frequency to day 100 during the latent infection [213]. The m09 ORF 
encodes  for  a  non-essential  glycoprotein  and  the  inflationary  CD4+   T-cell  kinetics  most 
closely resembles those observed by CD8+ T-cells towards the IE3 epitope in C57BL/6 mice. 
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1.8.3. B-LYMPHOCYTE RESPONSE 
 
 
CMV infection creates a number of immunogenic antigens that B-lymphocytes target. From 
an early stage of lymphocyte development through to plasma cell maturation B-cells express 
the surface molecule CD19. Activation of the B-cell receptor (BCR) and CD19 by CMV antigen 
leads to the proliferation of the cell and the generation of highly specific immunoglobulins. 
 
 
 
A number of epidemiological studies have highlighted a detrimental relationship between 
the magnitude of the HCMV-specific humoral response and survival in older populations 
[160, 216-219]. Data from the USA highlighted in an elderly population of Latino men those 
with the highest quartile of HCMV-specific IgG antibody titres had significantly elevated all- 
cause mortality (>1.4 times) over a  9-year period  compared to  those with  lower  three 
quartile titres of anti-HCMV IgG [218]. The IgG immunoglobulins have a short half-life (t1/2 of 
7-23 days) [220, 221] therefore, like the inflationary T-cell response, elevated antibody titres 
 
found in elderly HCMV seropositive individuals are most probably maintained by antigen re- 
exposure and subsequent B-cell proliferation (some studies have indicated a larger higher 
number of B-cells in PBMCs from elderly HCMV seropositive donors) [222]. 
 
 
 
The humoral immune response is best studied in animal models where B-cell deficient mice 
strains and adoptive therapy experiments have indicated the role of immunoglobulins in 
immune control of CMV. The transfer of hyper-immune serum, containing MCMV-specific 
immunoglobulins, into MCMV naïve C3H mice were found to be protective in over 90% of 
mice subsequently challenged with MCMV Smith. The hyper-immune serum resulted in low 
or absent viral titres during acute infection, but did not prevent MCMV establishing latent 
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infection as lytic virus was detected upon administration of anti-lymphocyte serum [223]. 
Likewise, the immunisation of newborn mice with immune serum reduced the immune 
pathology caused by MCMV infection [224]. Subsequently, immunoglobulins were confirmed 
to  reduce  virus  titres  in  both  the  salivary  glands  and  blood  of  infected  C57BL/6  mice, 
whereas the serum of B-cell deficient mice was not protective [225, 226]. The higher the 
affinity of the anti-MCMV IgG the greater the degree of protection against MCMV challenge 
[227]. Adoptive transfer of MCMV-experienced B-lymphocytes into RAG-/- mice lead to 
efficient control of MCMV in the absence of T-cell mediated immunity [8]. 
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1.8.1. NK-CELL MEDIATED RESPONSE 
 
 
Natural killer cells (NK-cells) are a principal component of the innate immune system. The 
NK-cell primary function is to recognise and kill virally infected cells. The NK-cell lineage is 
derived from a common lymphoid progenitor and in humans expresses the molecules CD16 
and CD56, and in C57BL/6 mice are identified by the expression of either the NK1.1 or NK1.2 
antigens on the cells surface. NK-cells seek out virally infected cells by sensing a reduction in 
MHC-I molecules (“missing-self”) and the upregulation of stress ligands, e.g. MHC class I 
polypeptide-related sequence A (MICA), on the surface of infected cells. A NK-cell deficiency 
[141, 228] or loss in NK-cell function [229, 230] has been associated with the increased 
incidence in HCMV disease. 
 
 
 
MCMV models have highlighted a balance between the virus and the corresponding NK-cell 
response. A number of experiments have screened multiple mouse strains to determine 
their genetic susceptibility to a lethal dose of MCMV [231]. Beige mice are the most 
vulnerable to MCMV doses whereas the same dose delivered via the same route of infection 
into a C57BL/6 mouse was shown to be asymptomatic [232]. The genetic difference between 
strains of mice susceptibility towards lethal doses of MCMV was mapped to the Cmv1 locus 
on chromosome 6. The Cmv1 gene encodes for the NK-cell gene complex, an MHC-I like 
molecule, called the Ly49h activating receptor. Insertion of the Ly49h encoding gene into 
susceptible beige mice - which lack this gene - confers resistance to MCMV [10, 233, 234]. 
The Ly49h receptor is bound to the outer membrane of the NK-cell, however it lacks an 
intracellular signalling domain, therefore, it requires the recruitment of the ITAMs DAP12 
and/or DAP10 [235-237]. The Ly49h-receptor on the NK-cell binds to the viral m157 protein, 
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an MHC-I like molecule, which activates and leads to the degranulation and release of 
cytotoxic granules such as perforin and granzyme, which work in combination to perforate 
the infected cell membrane and induce apoptosis (Figure 1.5). The Ly49h interaction with 
m157 occurs only in the mouse; however, interactions between Killer-cell Ig-like receptors 
(KIRs) on the NK-cells and HLA-C molecules have a similar effect with HCMV infection [238]. 
Wt isolates of MCMV often have acquired deletions or mutations in the m157 ORF causing 
the virus to evade the hosts NK-cell response [239]. The m157 gene has been retained by 
MCMV because of a secondary function: binding to the Ly49i receptor provides an inhibitory 
signal to the NK-cell [240]. 
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Figure 1.5 MCMV activation of NK-cells. Top) NK-cells from C57BL/6 mice express the 
DAP12-associated activating Ly49H receptor, which upon binding of the m157 protein 
initiates proliferation and cell-mediated cytotoxicity (perforin, granzyme and IFNγ) release 
from the NK-cells. Bottom) BALB/c mice do not express Ly49H and can express the 
inhibitory receptor (Ly49I) which upon binding m157 can impede the cytotoxic NK-cell 
response. Nature Reviews in Immunology [241]. Licence number 2864711358726. 
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1.9. IMMUNE EVASION MECHANISMS OF CMV 
 
 
Viruses employ mechanisms to evade detection by the immune system. CMVs, due to their 
co-evolution alongside their host, have developed numerous mechanisms to avoid detection 
by the innate and adaptive immune system. The immune evasion molecules of CMV are 
primarily expressed during the E-phase of replication. The evasion molecules are described 
most frequently as “immunoevasins” [154], “viral proteins interfering with antigen 
presentation” [242], or “viral regulators of antigen presentation” [243]. 
 
 
 
During both MCMV and HCMV infection the APCs are a key target of both acute infection 
and latent HCMV can reside in  myeloid cells [244, 245]. For CMVs to survive within an APC 
or any infected cell the virus makes use of techniques to reduce its exposure to both the 
innate and adaptive immune system (Table 1.1) [44, 243, 246]. 
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Table 1.1. Adapted from Lemmermann et al (2011) [247]: Table includes a list of HCMV and 
 
MCMV immunoevasins genes and the mechanism that aids immune evasion. 
 
 
Human Cytomegalovirus 
ORF Protein Phase Function 
US2 gp24 E Targets MHC-I ER-associated degradation in the proteasome 
 
US3 
 
gp23 
 
IE 
 
Binds to tapasin preventing peptide loading – retains MHC I 
 
complexes in the ER 
 
US6 
 
gp21 
 
E 
 
Inhibits peptide translocation into the ER – blocking of TAP- 
 
mediated peptide transport into the ER 
 
US10 
 
gp21 
 
E 
 
Induces degradation of HLA-G 
 
US11 
 
gp33 
 
E 
 
Targets MHC-I for proteosomal degradation 
 
UL82 
 
pp71 
 
L 
 
Retains MHC-I in a pre-Golgi compartment 
 
UL18 
 
gpUL18 
 
L 
 
MHC class I homolog (NK-cell immunoevasin) 
 
UL142 
 
gpUL142 
 
L 
 
Sequesters MICA ligands in Golgi (NK-cell immunoevasin) 
Murine Cytomegalovirus 
ORF Protein Phase Function 
m04 gp34 E Blocks pMHC expression on the cells surface 
 
m06 
 
gp48 
 
E 
 
Redirects pMHC to lysosomes for degradation 
 
m152 
 
gp40 
 
E 
 
Retains pMHC in the ER–Golgi intermediate compartment 
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The m04 immunoevasin protein encoded by MCMV is abundant in the ER and binds to the 
pMHC-I complex whilst it is still located in the ER. The m04 evasin remains bound to the 
pMHC and translocates with the pMHC-I complex from the ER to the infected cells surface 
where it remains attached and preventing complementary TCR interactions and impedes T- 
cell activation [248, 249]. The m04 protein has a dual function in allowing the pMHC complex 
to  translocate  to  the  cell  surface  prevents  NK-cell  activation  via  the  “missing-self” 
mechanism whilst also blocking pMHC presentation to the TCR. 
 
 
 
The  m06  immunoevasin  protein  binds  to  newly  synthesised  pMHC-I  in  the  Golgi  and 
combines with two cellular adapter proteins (AP-1A and AP-3A) before redirecting the 
complex for lysosomal degradation and hence the virally infected cell cannot be detected by 
the lymphocytes [250]. 
 
 
 
The m152 viral protein also strongly binds to the pMHC-I in the ER-Golgi compartment and 
prevents translocation of the complex to the cell surface [251]. More recently the m152 
protein has also been shown to down-regulate the surface expression of the NK-cell 
activating ligand RAE-1 making this evasin help the virus to evade both CD8+ T-cell and NK- 
cell mediated cytotoxicity [252]. 
 
 
 
HCMV also synthesises a number of its own MHC-I immunoevasin proteins. The US3 ORF 
encodes for a protein that binds to tapasin and prevents loading of peptide onto the MHC-I 
molecule [253]. Likewise US6 also functions through inhibiting peptide loading  onto the 
MHC-I through preventing the translocation of peptide into the ER via inhibition of TAP [254- 
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256]. The UL82 evasin retains the MHC-I molecule within the pre-Golgi compartment thus 
preventing peptide loading [257]. Two HCMV evasion proteins target the MHC-I molecule for 
degradation. The US11 ORF encodes for gp33 protein that targets MHC-I for degradation in 
the ER [258]. The ORFs US2 and gp24 also target degradation of MHC-I [259].The US10 
immunoevasin has a slightly different function in that regulates cell expression of the non- 
classical MHC molecule HLA-G [260]. 
 
 
The m155 ORF gene product of MCMV leads to evasion of Th1 CD4+ T-cell responses through 
mediating expression of CD40 on APCs thus preventing CD4+ T-cell activation/co-stimulation 
[261]. The UL18 and UL142 ORFs perform evasion of NK-mediated immunity. UL18 is a viral 
MHC-I homologue. The UL18 glycoprotein has α1 and α2 domains but lacks the α3 domain 
 
[262]; however this is sufficient to prevent NK-cell activation [263-266]. UL142 sequesters 
 
NK-cell activating ligands e.g. MICA and ULBP3 in the Golgi [155, 267-269]. 
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1.10. INFLUENZA A AND IMMUNOSENESCENCE 
 
 
1.10.1. INFLUENZA A PATHOGEN 
 
 
Influenza A viruses (IAV) belong to the family of Orthomyxoviridae viruses and are broadly 
characterised into subtypes according to their haemagglutinin (HA) and neuraminidase (NA) 
components. There are currently 16 known serotypes of HA and nine NA serotypes [270]. 
Individual strains of influenza virus are first designated according to their antigenic type (A or 
B) based on the nucleoprotein antigen (NP), the host of origin (if not human), geographic 
origin, strain number, year of isolation and for IAV their HA and NA subtype, e.g. 
A/Beijing/262/95 (H1N1). 
 
 
 
All  IAV  have  a  single  stranded,  segmented,  negative  sense  RNA  genome.  The  genome 
consists of eight segments and shares significant homology to Influenza B viruses whereas 
Influenza C viruses only have seven segments. The negative sense genome of IAV provides 
the template for the viruses own RNA-dependent RNA-polymerase to synthesise new 
messenger RNA (mRNA) and proteins. 
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1.10.2. EXPERIMENTAL MODELS OF INFLUENZA A 
 
 
The IAV infection requires adsorption of the virus into the cell via attachment of the virus to 
specific cell surface receptors [271]. It has been known since the 1940s that the viral HA 
binds to sialic acid (SA) on the cell surface to mediate viral entry [272, 273]. SA is a negatively 
charged 9-carbon sugar that forms glycosidic bonds with galactose and is involved in normal 
cellular adhesion events but is exploited by IAV to gain entry into cells [274]. IAV 
discriminately bind to SA as they require specific sugar chains e.g. human IAV prefer to bind 
α2,6 residues whereas avian IAV adhere with α2,3 linkages on SA [275, 276]. Although the 
IAV  have  a  preference,  the  viruses  are  capable  of  crossing  species  barriers  and  have 
therefore been modelled in many animal systems. 
 
 
 
Apes are rarely used to model human IAV infection because many primate species do not 
share  the  same  α2,6  SA  linkages  [274].  In  contrast,  pigs  are  more  prone  to  Influenza 
infection and are a natural vehicle of genetic re-assortment of human pandemic IAV [277]. 
Pigs express both the α2,6 and α2,3 SA residues making them susceptible to human and 
avian Influenza viruses [278]. Ferrets are an excellent experimental model of infection 
because they are susceptible to human IAV strains, exhibit “flu-like” symptoms and transmit 
the virus via aerosol [279-281]. Mice are also routinely challenged with Influenza viruses 
[282]. The BALB/c mouse has α2,6 and α2,3 SA receptors on cells of the lung and trachea 
making them suitable models for studies of Influenza pathogenesis [283, 284]. The C57BL/6 
mouse is also used to model IAV infection and many immune parameters of infection well 
documented [285, 286]. 
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1.10.3. IMMUNE RESPONSES TO INFLUENZA A 
 
 
IAVs are highly immunogenic pathogens and seasonal outbreaks contribute to ~500,000 
deaths annually [287]. The 1918 Spanish IAV pandemic arose due to antigen shift  and recent 
estimates suggests the outbreak resulted in 50 million deaths worldwide [288]. The more 
recent 2009 outbreak of Swine flu (H1N1) occurred due to triple re-assortment of avian, 
swine and human viruses and was fatal in almost 3% of individuals infected with the virus 
[289]. 
 
 
 
IAV infection primes the entire immune system. The immediate primary response which 
limits viral dissemination within the first 48 hours, is attributed to neutrophils [290], 
macrophages [291] and NK-cells [292] that occur prior to the development of the CTL 
response [293]. C57BL/6 mice generate a diverse number of IAV-specific CD8+  T-cells to 
multiple  IAV  antigens,  e.g.  the  nucleoprotein  (H2-Db   restricted:  NP366–374)  [294],  viral 
 
polymerase (H2-Db: PA224–233) [295] and the polymerase subunit 1 (H2-K
b: PB1703–711,) [296] 
which are well studied targets in murine models. The CD8+  T-cell response to the NP366–374 
epitope can dominate the acute infection and can constitute up to 80% of the IAV-specific T- 
cells yet contract to form smaller memory pools that persist to provide rapid responses to 
antigen re-exposure/challenge [297, 298]. 
 
 
 
CD4+ T-cells have both cytotoxic and regulatory roles during acute IAV infection. Upon Swine 
flu infection, CD4+ T-cells induce production of a wide variety of cytokines [299]. In vitro re- 
stimulation of IAV-specific Th1 CD4+ T-cells produce IL-2 that augments a more proficient 
cytotoxic response towards A/PR/8/34 (H1N1) infected cells. In contrast, co-culture of CTLs 
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with IL-4 secreting Th2 CD4+ T-helper cells was shown to have an antagonistic effect on CD8+ 
T-cell expansion [300]. In vivo, lymphocytes isolated from the mediastinal lymph node of 
C57BL/6 mice, inoculated with a nonfatal form of IAV, secreted IL-2, IL-10, and/or IFNγ. Peak 
cytotoxic CD4+ T-cells levels can be observed around 7 days p.i. whereas levels of the 
regulatory IL-10 secreting cells remain more constant during the first week of infection 
[301]. 
 
 
 
The transfer of hyper-immune serum provides protection in naïve mice from IAV challenge 
[302]. Immunoglobulins directed towards the HA antigen appear within the first week of 
illness and continue to increase for a number of weeks. Anti-HA antibodies neutralise IAV 
infection by preventing the virus adhering to SA. Anti-HA immunoglobulin titres tend to 
correlate with protection of illness therefore IAV vaccine strategies attempt to generate 
robust antibody titres and cellular responses. 
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1.11. HCMV AS A FACTOR OF IMMUNOSENESCENCE 
 
 
The  term  “Immunosenescence”  refers  to  the  decreased  ability  to  mount  an  effective 
adaptive immune response to pathogens and vaccinations that occurs with an increase in 
age. This process occurs naturally because of thymic involution and exhaustion of existing 
immunity [303-305] (Figure 1.6). For example influenza vaccination is highly effective in 
younger adults with protective antibody responses are generated in 70–90% of individuals; 
however, the same vaccine may only be effective in 17–53% of the elderly [306]. Currently 
attempts to restore immune function in the elderly with sex steroid ablation, growth factor 
treatment and cytokine replenishment have had only limited success [307]. 
 
 
 
Epidemiological data has correlated with immunological parameters to show that the 
presence of HCMV infection exacerbates immune senescence in the elderly [148]. The OCTO 
(>80 years old) and NONA (>90 years old) studies concluded that a HCMV seropositivity 
results in an accumulation of high differentiated CD8+ CD27- CD28- CD56+ CD57+ CD45RA+ T- 
cells, an inversion of the CD4:CD8 T-cell ratio [216, 217]. The presence of underlying HCMV 
seropositivity has been estimated to equate to an additional 'ageing effect' of 35 years on 
the  CD8+   T-cell  repertoire  [308].  As  a  separate  study  the  presence  of  HCMV-specific 
oligoclonal expansions was seen to result in reduced numbers of EBV-specific CD8+ T-cells in 
 
the blood of healthy adults [146]. Therefore, HCMV seropositive individuals maybe more 
susceptible to infections caused by other pathogens as a result of reduced numbers of CD8+ 
T-cells to infections other than HCMV. Consequently this may contribute to the significantly 
increased rates of mortality seen in epidemiological studies. Models of murine immune 
senescence showed pre-existing memory CD8+ T-cells are susceptible to attrition following a 
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series of heterologous infections [201, 309] and therefore trying to accommodate the 
accumulation of MCMV-specific cells may come at the expense of generating heterologous 
memory populations. 
 
 
 
The perception that the immune system is of a finite size and that the history of pathogen 
exposure can erode the ability to respond to infection is controversial because experimental 
evidence has also shown the adaptive immune system is capable of growing in size in 
response to repeated immunological challenge. Vezys et al (2009) utilised a prime-boost 
vaccination strategy to generate “enormous numbers of memory CD8 T cells specific for a 
single  antigen”  and  subsequently  monitored the number of pre-existing memory T-cells 
[310]. They noted an increased proliferation of CD8+ T-cells, in particular the non-lymphoid 
TEM subset within the lung, which did not develop at the expense of the initial memory pool. 
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Figure 1.6. Image represents naïve lymphocyte synthesis from the thymus from young and 
older individuals. Each coloured cell represents a unique TCR and therefore antigen 
specificity. During advancing age, the thymic medulla is gradually replaced by adipose 
tissue and the shrinkage of the thymus contributes to fewer naïve T-cell precursors in 
older individuals. Homeostatic proliferation can partially maintain naïve T-cell frequencies 
however; this leads to a restricted TCR-diversity. Consequently, older individuals are less 
well equipped to mount an immune response to a new pathogen. Nature Reviews in 
Immunology [311]. Licence number 2864710364858. 
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1.12. HYPOTHESIS  AND  AIMS:  MCMV  REACTIVATION  IS  A 
LIKELY CAUSE OF MEMORY INFLATION; THEREFORE, 
ANTIVIRAL INTERVENTION MAY PROVIDE AN 
OPPORTUNITY TO IMPROVE IMMUNE FUNCTION. 
Oligoclonal HCMV-specific CD8+  T-lymphocyte expansions towards immunodominant viral 
 
epitopes are readily detectable in the peripheral blood and accumulate with age [146, 147]. 
Likewise, memory inflation is characterised following MCMV infection [161, 165]. Both the 
inflationary HCMV [312] and MCMV [165] subsets of virus-specific CD8+  T-lymphocytes are 
relatively short-lived therefore their ability to accumulate is paradoxical. The accumulation 
of CMV-specific CD8+ T-lymphocytes occurs when viral titres are undetectable and therefore 
the large immune response is contrary to our understanding of how memory T-cells are 
maintained during a latent infection. 
 
 
 
The first aim of this thesis is to establish an MCMV model of memory inflation. Once this 
system is verified I will go on to determine the extent at which MCMV reactivation, during 
the latent phase of infection, has in maintaining the high frequency of virus-specific CD8+ T- 
cells. In order to examine if lytic replication is required for memory inflation MCMV infected 
mice will be administered the antiviral valaciclovir (for up to one year) to block stochastic 
lytic reactivation. Then the magnitude of the CD8+ T-cell response will be compared to 
untreated mice using a combination of peptide stimulation followed by measurement of 
intracellular IFN-γ production and also MHC-I tetramer staining. In addition, mice will be 
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infected with a mutant MCMV strain to examine whether a replication defective virus is 
capable of causing memory inflation. 
 
 
 
The second aim of this thesis is to examine whether a prior history of MCMV exposure 
affects the generation of a primary immune response to IAV challenge in an elderly 
population of animals. Furthermore, mice with latent MCMV infection will be administered 
valaciclovir  and  again  challenged  with  IAV  to  asses  if  antiviral  treatment  can  improve 
immune function compared mice with untreated memory inflation. 
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2. MATERIALS & METHODS 
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2.1. LIST OF MATERIALS 
 
 
   10% SDS solution, BIORAD 
 
   2-(N-morpholino)ethanesulfonic acid (MES), Sigma 
 
   3,3,5,5-tetramethylbenzidine substrate (TMB), Sigma 
 
   39% formaldehyde, Sigma 
 
   3-Amino-9-ethylcarbazole (AEC) tablet, Sigma 
 
   Acetic acid, Sigma 
  Acrylamide, Sigma 
  Aciclovir, Sigma 
   Adenosine-5’-triphosphate (ATP), Sigma), 
 
   Ammonium persulphate (APS), Sigma 
 
   Ampicillin, Invitrogen 
 
   Atipamezole, Tocris Bioscience 
 
   Bovine serum albumin (BSA), Sigma 
 
   Brefeldin A, Invitrogen 
 
   Calcium chloride, Sigma 
 
   Carboxymethylcellulose (CMC), Sigma 
 
   Chloramphenicol, Sigma 
 
   Coomassie brilliant blue, Sigma 
 
   Crystal violet, Sigma 
  d-Biotin Sigma 
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   Dimethyl sulfoxide (DMSO), Sigma 
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   Dithiothreitol (DTT), Sigma 
 
   Dulbecco’s modified essential media (DMEM), Sigma 
 
   Ethylenediaminetetraacetic acid (EDTA), Sigma 
 
   Extravidin peroxidise, Sigma 
 
   Foetal calf serum (FCS), Sigma 
 
   Gelatine, Sigma 
  Glucose, Sigma 
  Glycerol, Sigma 
   Heparin sodium (1000 I.U/ml), Wockhardt, 
 
   Hydrochloric acid, Sigma 
 
   Hydrogen peroxide, Sigma 
 
   Insulin-transferring-selenium, Sigma 
 
   Ionomycin calcium salt, Sigma 
 
   Iscove’s modified Dulbecco’s medium (IMDM), Sigma 
 
   Isopropyl-beta-D-thiogalactoside (IPTG), Invitrogen 
 
   Ketamine hydrochloride, Tocris Bioscience 
 
   L-arginine, Sigma 
 
   LB agar, Sigma   
LB broth, Sigma   
Leupeptin, Sigma 
   L-glutamine, Sigma 
 
   Manganese chloride, Sigma 
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   Medetomidine hydrochloride, Tocris Bioscience 
 
   Methanol, Sigma 
 
   Mouse serum, Sigma 
 
   N,N-dimethylformamide (DMF), Sigma 
 
   Nucleoprotein monoclonal antibody (MCA400), Serotec 
 
   Oxidised glutathione, Sigma 
 
   Paraformaldehyde, Sigma 
 
   Penicillin-streptomycin, Sigma 
 
   Pepstatin , Sigma 
 
   Phenol red, Sigma 
 
   Phenylmethanesulfonylfluoride (PMSF), Sigma 
  Phorbol 12-myristate 13 acetate (PMA), Sigma 
  Phosphate buffered saline (PBS) 
   Potassium acetate, Sigma 
 
   Potassium bicarbonate 
 
   Potassium chloride, Sigma 
 
   Primatone, Sigma 
 
   Reduced glutathione, Sigma 
 
   RMPI-1640 media, Sigma 
 
   Saline, Invitrogen 
 
   Saponin, Sigma 
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   S.O.C. medium, Invitrogen 
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   Secondary anti-mouse IgG (H+L) HRP conjugated antibody, Promega 
 
   Sodium acetate, Sigma 
 
   Sodium azide, Sigma 
 
   Sodium bicarbonate, Sigma 
 
   Sodium carbonate, Sigma 
 
   Sodium chloride, Sigma 
 
   Sodium dodecyl sulphate (SDS), Sigma 
 
   Sodium MOPS, Sigma 
 
   Streptavidin-APC, Invitrogen 
 
   Tetramethylethylenediamine (TEMED), Sigma 
 
   Tris, Sigma 
 
   Triton X-100, Sigma 
  Trypan blue, Sigma 
  Tween, Sigma 
   Urea, Sigma 
 
   Valacyclovir hydrochloride, GlaxoSmithKline 
 
   β-meracaptoethanol, Sigma 
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2.2. LIST OF BUFFERS 
 
 
   0.3% crystal violet solution: 0.3% (w/v) crystal violet dissolved in 10% (v/v) methanol in 
 
H2O 
 
   0.5% (w/v) saponin: diluted in PBS 
 
   15% running gel: 115 ml H2O, 125 ml 1 M Tris pH 8.8, 5 ml 10% SDS; mixed with 5 ml of 
 
30% acrylamide, 160 µl of 10% APS and 6 µl of TEMED 
 
   4% (v/v) formaldehyde: 39% formaldehyde diluted in PBS 
  4% (w/v) paraformaldehyde: diluted in PBS 
   Antisedan: 2 ml atipamezole, 8 ml saline 
 
   BIORAD solution: 1 part 10% SDS solution to 4 parts H2O 
 
   Bir A buffer: 100 mM Tris, 20 mM sodium chloride, 5 mM magnesium chloride, 0.1 
mM PMSF 
   Carboxymethylcellulose overlay (CMC overlay): one part 5% CMC, two parts MM 
  Coomassie brilliant blue stain 
   D10 media (500 ml DMEM, 10% (v/v) FCS, 1% v/v penicillin-streptomycin, 1% v/v L- 
 
glutamine, 1% v/v sodium pyruvate, 1% v/v sodium bicarbonate 
 
   Destain buffer: 10% acetic acid, 50% methanol 
 
   ELISA coating buffer: 0.2 M sodium bicarbonate, 0.2 M sodium carbonate 
 
   ELISA dilution buffer: 1% (w/v) BSA, 0.05% (v/v) Tween20, PBS 
  ELISA wash buffer: 0.05% (v/v) Tween20, PBS 
   F-media: 140 mM sodium chloride, 8 mM potassium chloride, 7 mM calcium chloride, 
 
0.5 mM magnesium chloride, 1.7 mM glucose, 0.3 mM chloramphenicol, 0.25 mM 
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phenol red and 2 g gelatine 
 
   Growth media (GM): DMEM, penicillin-streptomycin, L-glutamine, 10% (v/v) FCS 
 
   IMDM  media:  500ml  Iscove’s  modified  Dulbecco’s  medium,  1.5  ml  10%  (w/v) 
primatone. 2.5 ml FCS, 0.5 ml insulin-transferring-selenium, 5 ml penicillin- 
streptomycin, 0.5 ml 25 μM β-meracaptoethanol 
   Lavage buffer: 50 ml PBS and 50 μl EDTA 
  LB agar: 1.5% (w/v) in distilled H2O 
   LB media: 2% LB broth (w/v) in distilled H2O 
 
   MACS buffer: PBS and 1% BSA 
 
   Maintenance media (MM): DMEM, penicillin-streptomycin, L-glutamine, 2% (v/v) FCS 
  MonoQ buffer A: 20 mM Tris 
   MonoQ buffer B: 20 mM Tris, 500 mM sodium chloride 
 
   Red-cell  lysis  buffer:  800  ml  H20,  89.9  g  ammonium  chloride,  10.0  g  potassium 
bicarbonate, 370.0 mg tetrasodium EDTA, pH 7.3 
   Refolding  buffer:  100  mM  Tris,  400  mM  L-arginine,  2  mM  EDTA,  5  mM  reduced 
glutathione, 0.5 mM oxidised glutathione, 0.1 mM PMSF 
   Resuspension buffer: 50 mM Tris, 100 mM sodium chloride, 1 mM EDTA, 1 mM DTT 
  Sedative solution:0.5 ml medetomidine, 0.38 ml ketamine 4.12 ml H2O 
   S75 buffer: 20 mM Tris and 50 mM sodium chloride 
 
   Stacking gel: 136 ml H2O, 23 ml 1 M Tris pH 6.8, 2 ml SDS was mixed with 670 µl of 
 
30% acrylamide and 60 µl of 10% APS and 6 µl of TEMED 
 
   TFB1 buffer: 30 mM potassium acetate, 100 mM potassium chloride, 10 mM calcium 
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chloride, 50 mM manganese chloride, 15% v/v glycerol, pH 5.8 
 
   TFB2  buffer:  10  mM  sodium  MOPS,  25  mM  calcium  chloride,  10  mM  potassium 
chloride, 15% v/v glycerol, pH 6.5 
   Triton wash: 50 mM Tris, 100 mM sodium chloride, 0.5% Triton X-100, 1 mM EDTA, 1 
mM DTT, 0.1% sodium azide 
   Tween buffer: 0.05% v/v Tween in H2O 
 
   Urea solubilisation buffer: 8 M Urea, 50 mM MES, 0.1 mM EDTA, 0.1 mM DTT 
 
   Valacyclovir antiviral: 500 mg valaciclovir tablet crushed and diluted in 500 ml distilled 
 
H2O 
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Table 2.1. List of the fluorescent conjugated anti-mouse antibodies used in subsequent 
tetramer and ICS staining experiments. 
Anti-mouse lymphocyte surface antibodies 
 
 
Target Antigen Clone Fluorochrome Company 
CD3 500A2 FITC eBioscience 
 
CD4 
 
GK1.5, L3T4 
 
AF-700 
 
eBioscience 
 
CD4 
 
GK1.5, L3T4 
 
PE 
 
eBioscience 
 
CD8 
 
Ly-2, 53-6.7 
 
Pacific Blue 
 
eBioscience 
 
CD8 
 
Ly-2, 53-6.7 
 
APC 
 
eBioscience 
 
CD27 
 
LG.3A10 
 
PerCp/Cy5.5 
 
BioLegend 
 
CD44 
 
IM7, Ly-24 
 
APC-Cy7 
 
eBioscience 
 
CD62L 
 
Ly-22, MEL-14 
 
PE-Cy7 
 
eBioscience 
 
CD122 
 
TM-b1 
 
FITC 
 
eBioscience 
 
CD127 
 
A7R34 
 
PE 
 
eBioscience 
Anti-mouse intracellular antibodies 
Target Cytokine Clone Fluorochrome Company 
IFNγ XMG1.2 FITC eBioscience 
 
TNFα 
 
MP6-XT22 
 
PE 
 
eBioscience 
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2.3. MCMV CULTURE 
 
 
2.3.1. MOUSE EMBRYO FIBROBLASTS 
 
 
Mouse embryo fibroblasts (MEFs) are the most widely used permissive cell type for 
propagating MCMV and for accurate titration of the number of lytic virus particles in a given 
volume. To generate MEFs female BALB/c mice were mated to generate pregnancy. At 
embryonic day 14, the pregnant mice were euthanised by cervical dislocation, pinned onto a 
dissection board and sprayed with 70% ethanol. Under aseptic conditions, within a laminar 
flow cabinet, an incision was made dissecting the lower abdomen exposing the uterine horn 
and embryos. The embryonic sacs were removed and placed into a Petri dish containing 
sterile PBS. Any placental or uterine horn tissue was discarded and the embryos transferred 
into a second Petri dish containing fresh PBS. 
 
 
 
The embryos were placed into the barrel of a 20 ml syringe, and homogenised by returning 
the plunger, dissociating the embryo into 10 ml TE. The homogenate was then incubated at 
37 °C, 95% air/5% CO2 for a maximum of 10 minutes. 
 
 
 
 
The homogenate was then passed through a fine metal sieve into a Petri dish containing 2 ml 
of FCS. The sieving removes large cellular debris but ensures the passage of fibroblast cells. 
 
 
 
The MEF homogenate was transferred into a falcon tube containing 10 ml of GM and 
centrifuged  at  720  g  for  10  minutes  at  room  temperature  (RT).  The  supernatant  was 
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aspirated; the pellet resuspended in 10 ml of GM and used to seed 150 cm2  tissue culture 
flasks with, on average, one embryo seeding up to three 150 cm2 flasks. 
 
 
 
The  MEF  suspension  was  then  incubated  (37  °C,  95%  air/  5%  CO2)  until  a  confluent 
monolayer of cells was formed (approximately one week). At which point it is essential to 
passage the cells to prevent cell death, maintain cell viability and increase MEF cell numbers 
for further assays. 
 
 
 
 
 
 
2.3.2. PASSAGE OF MEF CELLS 
 
 
Upon the MEFs reaching confluence the spent growth medium was discarded, and the 
monolayer was washed with 10 ml of sterile PBS to remove trypsin inhibitors in the serum. 
The PBS rinse was then discarded and 3 ml of TE added to the flask. After approximately 
three minutes, the cells start to detach from the flask and at this point serum-containing GM 
was added to inhibit the trypsin-reaction. The medium was then agitated to dislodge the 
monolayer and create a MEF suspension. 
 
 
 
The MEF suspension was spun at 700 g for 10 minutes at RT to create a cell pellet and the 
supernatant removed. The MEF cell pellet was then resuspended in MM and transferred to 
the appropriate sized culture flask or enumerated. 
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2.3.3. TRYPAN BLUE CELL COUNTING 
 
 
To check cell viability and enumerate the numbers MEFs/lymphocytes, 20 μl of cell 
suspension was diluted 1:1 with 0.4% trypan blue stain and loaded onto a counting chamber 
of a Neubauer haemocytometer (FastRead Counting Slides, Immune Systems). The number 
of viable cells (the intact membrane excludes the blue dye whereas dead cells are stained 
blue) were counted in four 1 mm2  squares; this was repeated a further four times and an 
average calculated. To determine the concentration of the cells per ml the following formula 
was used: 
 
 
 
c = [(n/4)*2]*104 
 
 
 
 
Where                           c = concentration (cells/ml) 
 
n = average number of cells per 1 mm2 
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2.4. MCMV VIRUS STRAINS 
 
 
2.4.1. MCMV SMITH 
 
 
The Smith strain of MCMV (ATCC) was obtained from Dr C. Sweet (School of Biosciences, 
University of Birmingham, UK). A working stock of Smith was propagated using MEFs and an 
infectious stock of less frequently cultured virus was used for in vivo inoculations. 
 
 
 
2.4.2. MCMV tsm5 
 
 
The temperature-sensitive mutant virus 5 (tsm5) was generated in the laboratory of Dr C. 
Sweet by N-methyl-N'-nitro-N-nitrosoguanidine mutagenesis of the K181-Birmingham strain. 
The tsm5 virus has restricted growth at temperatures exceeding 39 °C in MEFs and at 37 °C 
in macrophages and does not produce detectable infectious virus in vivo [313-315]. Working 
stocks of tsm5 were propagated in vitro using MEF cells. 
 
 
 
 
 
 
2.4.3. MCMV PROPAGATION AND HARVESTING 
 
 
MEFs were seeded into 150 cm2 tissue culture flasks, containing 25 ml of GM, and incubated 
(37 °C, 95% air/ 5% CO2) until 80-90% confluent. The GM was then replaced and 200 μl of 
working stock virus (either Smith or tsm5) was added along with 5 ml of MM. The flasks were 
returned to the incubator for one hour, before a further 15 ml of MM was added. The flasks 
were then incubated (37 °C, 95% air/ 5% CO2) until the MEF monolayer showed 100% CPE. 
The  supernatant  from  the  MCMV  infected  flasks  was  harvested  and  transferred  to  a 
72  
 
centrifuge tube. This was centrifuged at 850 g for 10 minutes at RT to sediment the MEF 
 
debris. 
 
 
 
 
The supernatant was aspirated, transferred into a sterile high-speed centrifuge tube 
(NALGENE) for ultracentrifugation at 29,000 g for 30 minutes (4 °C) to sediment the virus. 
The supernatant was discarded and the viral pellet resuspended in 8 ml of MM. The viral 
stock was then divided into 1 ml aliquots and immediately frozen at -80 °C. 
 
 
 
 
 
 
2.4.1. MCMV TITRATION BY PLAQUE ASSAY 
 
 
MCMV infected MEFs are killed by the replicating virus, the dead cells detach from the 
monolayer leaving behind a visible plaque. The addition of the CMC overlay provides an 
impermeable barrier that traps and prevents the released viruses killing non-adjacent cells. 
 
 
 
MEF cells from the second passage of cell culture were enumerated using the trypan blue 
method. The concentration of cells was adjusted with GM to 1x106 cells/ml. A volume of 0.5 
ml MEF suspension was seeded into individual wells of flat-bottomed 24-well plates 
(Corning), for 24 hours (37 °C, 95% air/ 5% CO2) until approximately 80-90% confluent. 
 
 
 
Titration of MCMV stocks was performed in triplicate using separate aliquots of virus. Viral 
stocks were serially diluted in MM (1:10) across a dilution range (x10-1 to x10-5) (Figure 2.1). 
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The media in the wells was replaced with 200 μl of the appropriate viral dilution and the 
plates returned to the incubator for one hour. After one hour 1 ml of semi-solid CMC overlay 
was added to each well and the plates returned to the incubator for five days. 
 
 
 
To visualise the MCMV plaques 0.5 ml of 4% formaldehyde fixative was added to each well 
for 10 minutes. The overlay fixative was then removed and replaced with a further 0.5 ml of 
4% fixative for 30 minutes, followed by 0.5 ml of 0.3% crystal violet staining solution. The 
stain was left for one hour before gently washing the wells with running tap water. Plates 
were allowed to air dry and plaques counted using a light microscope. 
 
 
 
 
 
 
 
1 2 3 4 5 6 
 
A Uninfected 1 x10-1 1 x10-2 1 x10-3 1 x10-4 1 x10-5 
 
B Uninfected 1 x10-1 1 x10-2 1 x10-3 1 x10-4 1 x10-5 
 
C Uninfected 1 x10-1 1 x10-2 1 x10-3 1 x10-4 1 x10-5 
 
D Uninfected 1 x10-1 1 x10-2 1 x10-3 1 x10-4 1 x10-5 
 
E Uninfected 1 x10-1 1 x10-2 1 x10-3 1 x10-4 1 x10-5 
 
F Uninfected 1 x10-1 1 x10-2 1 x10-3 1 x10-4 1 x10-5 
 
Figure 2.1. Plate scheme showing the titration of MCMV on MEF. Row 1 uninfected 
fibroblasts. Row 2 virus dilution of 1 x10-1. Row 3: 1 x10-2. Row 4: 1 x10-3. Row 5: 1 x10-4. 
Row 6: 1 x10-5. 
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To calculate the number of average plaque forming units (PFU) the number of plaques per 
well was counted from a suitable dilution range. The average number of plaques was 
corrected for the dilution factor to quantify the MCMV titre as log10 PFU/ml. 
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2.5. INFLUENZA A VIRUS 
 
 
2.5.1. INFLUENZA A VIRUS 
 
 
The IAV strain A/PuertoRico/8/34-A/England/939/69 (H3N2) clone 7a was previously 
generated in the laboratory of Dr C. Sweet through re-assortment of A/Puerto Rico/8/34 
(H1N1) and the A/England/939/69 (H3N2) strains. 
 
 
 
2.5.2. INFLUENZA A VIRUS CULTURE 
 
 
Twenty-four fertilised white hens’ eggs were placed into a specialised Marshall Egg incubator 
 
(37 °C) in a humid atmosphere. 
 
 
 
 
After 10 days, a light source was used to “torch” the eggs making visible the position of the 
air sac, embryo and its vasculature. Marks were made indicating the air sac and a suitable 
position over the allantoic cavity. Using a blunted needle the shell was weakened at the 
marks before two punctures were made in the shell, first over the air sac followed by one 
over the allantoic cavity. 
 
 
 
An  aliquot  containing  the  IAV  clone  7a  was  removed  from  -80  °C  and  diluted  in 
approximately 10 ml RMPI-1640. 
 
 
 
200 μl of the dilute virus was injected into the allantoic cavity of each egg. The needle was 
placed parallel to the shell to prevent piercing the yolk sac. The holes in the shell were then 
repaired using melted wax to make an airtight repair. 
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The influenza-infected eggs were then returned to incubator for a further three days to 
encourage IAV replication. On the fourth day, the eggs were placed at 4 °C overnight as a 
humane method of killing the embryo. 
 
 
 
The following day the shell over the air sac was carefully removed using scissors ensuring the 
chorioallantoic  membrane  remained  intact.  Then  using  sterilised  pipettes,  the 
chorioallantoic membrane was broken and the allantoic fluid was removed from each egg 
(approximately 5-8 ml/egg) and pooled. The IAV stock was then divided into 1 ml aliquots 
and frozen at -80 °C. 
 
 
 
One aliquot was immediately used to confirm that IAV was successfully propagated in the 
eggs by haemagglutination assay. 
 
 
 
 
 
 
2.5.3. HAEMAGGLUTINATION ASSAY 
 
 
Whole blood (6 ml) was isolated from a healthy human donor and centrifuged at 700 g for 
 
10 minutes at RT. The supernatant and white cell layers were removed and discarded using a 
Pasteur pipette and the erythrocytes washed in dilute F-media. The centrifugation and wash 
step was repeated until the supernatant appeared clear. The red blood cells were then 
diluted in F medium to create a 1% w/v suspension. 
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Into each well of a W.H.O plate 200 μl of F-media was added. A serial two-fold dilution series 
of IAV stock was performed in F-media by adding 200 μl of virus to the first well, mixing and 
transferring 200 μl to the next well. This was repeated along the row. 200 μl of the red blood 
suspension was then added to each well. Plates were incubated for 30-45 minutes at RT. The 
presence of the IAV binds to the SA on the erythrocytes, causes haemagglutination, and 
prevents the cells from sedimenting in the well. 
 
 
 
 
 
 
2.5.4. TITRATION OF INFLUENZA A VIRAL STOCKS 
 
 
To calculate the IAV titre 78 fertilised white hens’ eggs were placed into the Marshall Egg 
incubator for 10 days at 37 °C. As before, the eggs were “torched” and the shell pierced in 
the air sac and allantoic cavity. 
 
 
 
Two aliquots of the IAV were defrosted from -80 °C and diluted (1:10) to the highest dilution 
factor of 1 x10-9 in RMPI-1640 containing antibiotics. Three series of viral dilutions were 
created, two from aliquot A (A1  and A2) to compare the variability within the same aliquot 
and one from aliquot B to compare the difference in titre between individual aliquots of IAV. 
 
 
 
As before 200 μl of each virus dilution was injected into the allantoic cavity of each of four 
eggs per dilution and the holes were sealed with melted wax. The infected eggs were then 
returned to the incubator and after three days incubation the eggs were placed at 4 °C 
overnight. 
78  
 
To determine the IAV dose needed to infect 50% of eggs (EID50), 200 μl of the allantoic fluid 
from each egg was placed into an individual well of a WHO plate. 200 μl of red blood cell 
suspension was added and incubated for 30 minutes at RT. Each well was scored for the 
presence or absence of haemagglutination. This score was then applied to Weil’s Table to 
determine the IAV titre. 
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2.5.5. MOVING AVERAGES AND WEIL’S TABLES 
 
 
To calculate the EID50/ml of clone 7a the following formula was used: 
Log10 EID50 = log *do + log R ** (f+1) 
* do = highest dilution used for the derivation of “f” in Weil’s Tables 
 
**R = dilution factor 
 
 
 
 
Table 2.2. The R and f-values for each aliquot taken from Weil’s Tables. 
 
 
 Ampoule Highest Dilution R-values  f-value 
A1  x10
-8
 0, 1, 3, 4 0.500  
 
A2 
  
x10-9 
 
0, 0, 2, 4 
 
1.000 
 
 
B 
  
x10-8 
 
0, 1, 2, 4 
 
0.750 
 
 
 
 
Where **R = dilution factor, therefore log R is 1 
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Ampoule A1 
 
Log10 EID50 = log *do + log R ** (f+1) 
Log10 EID50 = -8 + 1 (0.500+1) 
Log10 EID50 = -8 + 1.5 
 
Log10 EID50 = -6.5 
 
 
 
 
This is an estimate of the dilution of virus needed to infect 50% of the eggs.  The reciprocal 
of this number is the infectious dose per unit volume. 
 
 
 
Infectious dose = 1 x106.5 EID50/ 0.2ml 
 
Infectious dose =  1x 107.2 EID50/ml 
 
 
 
 
Ampoule A2 
 
Log10 EID50 = -9 + 1 (1.000+1) 
Log10 EID50 = -9 + 2 
Log10 EID50 = -7 
 
 
 
 
Infectious dose = 1 x107 EID50/ 0.2ml 
 
Infectious dose =  1 x107.7 EID50/ml 
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Ampoule B 
 
Log10 EID50 = -8 + 1 (0.750+1) 
Log10 EID50 = -8 + 1.75 
Log10 EID50 = -6.25 
 
 
 
 
Infectious dose EID50 = 1 x10
6.25 EID50/ 0.2ml 
 
Infectious dose EID50 = 1 x10
6.95 EID50/ml 
 
 
 
 
The geometric mean titre was then calculated to allow a calculation for the amount required 
to infect the mice. 
 
 
 
Mean Titre = (EID50 A1 + EID50 A2 + EID50 B) / n 
 
Mean Titre = (7.199 + 7.699 + 6.949) / 3 
 
Geometric Mean Titre =  1 x107.28 EID50/ml 
 
The antilog (7.282) is 1.92x107 
 
 
 
 
Therefore, 1x106 EID50 is present in 52.2µl 
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2.6. MICRO-PLAQUE REDUCTION ASSAY 
 
 
The  method  for  the  micro-plaque  reduction  assay  (μPRA)  was  modified  from  a  similar 
method used previously by Pavic et al (1997) [316] and Kruppenbacher et al (2001) [317]. In 
those assays, the degree of CPE, caused by HSV-1 in the presence of acycloguanosine 
prodrugs, was scored subjectively to estimate the percentage viability/CPE. This μPRA 
determined the actual number of plaques formed in the presence/absence of drug and is 
therefore quantitative. 
 
 
 
Aciclovir was dissolved in DMSO at 7 mg/ml. Valaciclovir hydrochloride was prepared by 
grinding a 500 mg tablet in a pestle and mortar with PBS and filter sterilised through a 0.2 
μm syringe filter (Millipore). 
 
 
 
Primary MEFs were isolated from 14 day pregnant BALB/c mice, cultured, and enumerated 
as described previously. MEF cells from a second passage were adjusted to 5x105  cells/ml 
and 100 μl added per well (flat bottomed 96 well plates) to create a cell density of 5x104 
cells per well. 
 
 
 
50 μl of the appropriate concentration of aciclovir (plate 1) or valaciclovir (plate 2) was 
added to create a dilution series with final antiviral concentrations ranging from 0 to 125 
μM. Finally, 50 μl of MCMV Smith was added to all wells at an MOI≈0.01. Also included were 
a DMSO control and uninfected wells. 
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Plates were incubated for four days (37 °C, 95% air/ 5% CO2) during which infected cells die 
to form plaques. 
 
 
 
Following the four day incubation, the plates were removed from the incubator and 50 μl of 
 
4% fixative was added to each well. The plate was incubated for 10 minutes at RT to fix the 
cell membrane. The fixative and media was then flicked off into bleach. A further 100 μl of 
fixative added for 30 minutes prior to staining. 0.5 ml of 0.3% crystal violet staining solution 
was then applied for one hour before gently washing under running water. Plates were 
allowed to air dry. 
 
 
 
The number of plaques was then counted at x10 magnification using a light microscope. The 
mean number of plaques per well was then calculated (n=8). This figure was then normalised 
to the highest number of plaques observed in the absence of aciclovir or valaciclovir. 
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2.7. TETRAMER SYNTHESIS 
 
 
2.7.1. GENERATION OF COMPETENT E. COLI 
 
 
A stock of Escherichia coli (E. coli) strain BL21 (DE3)pLys was briefly thawed from -80 °C. Using 
a wire loop a small volume was streaked onto an agar plate (2% LB broth and 1.5% LB agar). 
This plate was incubated at 37 °C overnight and a single colony was used to inoculate 5 ml of 
LB media that was placed into a 37 °C shaking incubator and monitored until the bacterial 
culture had grown to the optical density (OD550 nm) of 0.5. The 5 ml culture was then 
centrifuged at 2,000 g for 15 minutes at 4 °C. The supernatant was decanted and the pellet 
resuspended in 80 ml of cold TFB1 buffer. The TFB1 culture was then centrifuged at 4000 g 
for 10 minutes at 4 °C and the pellet resuspended in 8 ml of cold TFB2 buffer. The E. coli 
culture was then divided into pre-chilled eppendorfs and snap frozen in liquid nitrogen. 
These BL21 are now artificially competent and are able to take up extracellular DNA from the 
environment. 
 
 
 
 
 
 
2.7.2. MHC-I AND Β2M PLASMIDS 
The pET-24a plasmid encodes an antibiotic resistance gene in addition to a Lac operon 
sequence. The Lac operon can be selectively activated to induce protein expression with the 
addition of IPTG (Invitrogen). In three separate plasmids, the murine MHC-I proteins H2-Db 
and  H2-Kb   and  human  β2-microglobulin  (β2M)  were  cloned  downstream  of  the  IPTG 
response element. The H2-Db and H2-Kb plasmids were obtained as a gift from Prof P. 
Klenerman and Dr A. Gallimore. 
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2.7.3. TRANSFORMATION OF BL21 WITH PLASMID DNA 
 
 
An aliquot of competent BL21 E. coli was defrosted on ice. 2 μl of the appropriate plasmid 
DNA (H2-Db, H2-Kb or β2M) was added to the BL21 cells and incubated on ice for one hour, 
after which the BL21 cells were subjected to heat shock: 42 °C for 45 seconds followed by 4 
°C for one minute. The process of subjecting the bacteria to the cycling of temperatures 
between hot and cold encourages the uptake of the plasmid DNA into the bacteria. In 
addition, 200 μl of S.O.C. medium was then added. The transformed BL21 were then placed 
into the orbital shaker, and incubated at 37 °C for one hour, to expand the cultures. The 
culture was then spread evenly onto an agar plate containing the antibiotic ampicillin. Only 
successfully transformed bacteria that express the gene for antibiotic resistance would grow 
when incubated overnight at 37 °C. 
 
 
 
 
 
 
2.7.4. EXPRESSION OF MHC-I/Β2M 
 
 
The growth of bacterial colonies in the presence of the antibiotic agar is evidence of a 
successful transformation procedure. A single transformed BL21 colony was then selected 
using a wire loop to inoculate 25 ml LB media containing 1 mg/ml ampicillin and incubated 
overnight at 37 °C in the orbital shaker to generate a small subculture. 
 
 
 
The following day 5 ml of the overnight subculture was used to inoculate a larger one litre 
conical flask containing LB media and ampicillin. The large culture was then incubated in an 
orbital shaker at 37 °C until the OD600 nm reached 0.4-0.5; at this point protein expression was 
induced by adding 0.5 ml of 1 M IPTG and incubated for a further four hours. The addition of 
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IPTG activates the Lac operon, enabling transcription of the cloned MHC-I/β2M genes and 
subsequent translation into the required protein. The cultures were then divided into plastic 
containers designed to be centrifuged at high-speeds. The cells were then harvested by 
ultra-centrifugation at 18,000 g for 15 minutes at 4 °C. The supernatant was discarded and 
the transformed bacteria resuspended in 40 ml cold PBS. The MHC-I heavy chain or β2M 
proteins remain suspended in inclusion bodies within the E. coli. 
 
 
 
 
 
 
2.7.5. PURIFICATION FROM INCLUSION BODIES 
 
 
Sonication is required to isolate and purify the inclusion bodies from bacteria. The bacterial 
suspension was transferred into a glass beaker and placed on ice. The cold suspension is 
placed under the flat probe of the sonicator (Qsonica Q500) and pulsed five times for 45 
seconds, with a 15 second gap in between pulses to prevent the solution overheating. 
 
 
 
The solution was transferred to an ultracentrifugation tube and spun at 18,000 g for 15 
minutes at 4 °C. The supernatant was discarded and the pellet resuspended in 6 ml of Triton 
wash. The suspension was transferred into a mechanical glass homogeniser and used to 
break open the bacterial membrane. The suspension was transferred back into an 
ultracentrifugation tube and spun again at 18,000 g for 15 minutes at 4 °C The 
homogenisation process was repeated two more times with Triton wash and twice with 4 ml 
of resuspension buffer. 
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The protein suspension was pelleted, the resuspension buffer discarded and the pellet 
resuspended into 10 ml of Urea solubilisation buffer. The protein was incubated at 4 °C 
overnight  on  an  orbital  shaker  to  encourage  solubilisation.  The  following  morning  the 
solution was again pelleted using the ultracentrifuge, spun for 15 minutes at 18,000 g at 4 
°C, to sediment the insoluble material. The supernatant contains the solubilised MHC-I/β2M 
 
that was then transferred into aliquots and frozen at -80 °C. 
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To check for successful protein expression and the purity of the expressed proteins an SDS- 
page was performed (Figure 2.2). 
 
 
 
 
 
 
 
 
Figure 2.2. SDS page expression of H2-Kb protein from E. coli inclusion bodies. Synthesised 
by E. coli pre-IPTG induction (middle lane), post-IPTG induction, and urea solubilisation 
(right lane). 
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2.7.6. REFOLDING OF MHC-I WITH MCMV CD8+ T-CELL PEPTIDES 
 
 
To create a refolded MHC-I monomer, 500 ml refolding buffer was chilled to 4-8 °C and 
stirred constantly with a magnetic stirrer. Into each individual refolding buffer, 1 mg of 
MCMV peptide was added (Table 2.3). 
 
 
 
Table 2.3. Immunogenic MCMV viral epitopes used for tetramer synthesis. 
 
 
Protein Epitope Sequence MHC-I 
M38 316-323 SSPPMFRV H2-Kb 
 
m139 
 
419-426 
 
TVYGFCLL 
 
H2-Kb 
 
IE3 
 
416-423 
 
RALEYKNL 
 
H2-Kb 
 
M57 
 
816-824 
 
SCLEFWQRV 
 
H2-Kb 
 
M45 
 
985-993 
 
HGIRNASFI 
 
H2-Db 
 
 
 
 
A 10 mg stock of human β2M protein was thawed and transferred into 5 ml of 5 M urea, into 
which 20 ml of the refold buffer was added very slowly using a Pasteur pipette. The dilute 
β2M was then transferred back into the larger 500 ml refolding buffer very slowly to avoid 
the protein precipitating. 
 
 
 
Approximately 5 mg of MHC-I heavy chain (either H2-Kb or H2-Db) was then used to pulse the 
refold buffer using the same technique as for β2M. Pulsing was typically performed four 
times allowing a minimum of eight hours between the additions of the heavy chain. 
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2.7.7. BUFFER EXCHANGING OF MONOMER 
 
 
The 500 ml of refold buffer in addition to containing the successfully refolded monomer 
molecule contained a combination of unbound viral peptide, β2M, MHC-I heavy chain and 
aggregated proteins. To isolate the refolded monomer the refold buffer was transferred into 
an ultrafiltration Amicon stirred cell (Millipore) containing a nitrocellulose membrane (pore 
size 25 nm). The buffer was concentrated to approximately 4 ml as per manufacturer 
instructions. 
 
 
 
At this stage, the monomer is in a buffer that contains high concentrations of salt and urea 
that are removed prior to biotinylation and purification by liquid chromatography. 
 
 
 
To buffer exchange the monomer suspension, PD10 desalting columns (GE Healthcare) were 
used as per manufacturer instructions with cold Bir A buffer and the monomer solution 
adjusted to 7 ml using an Amicon centricon filter device (Millipore). 
 
 
 
To the 7 ml sample, 35 μl of 100 mM d-Biotin, 350 μl of 100 mM ATP, 7 μl of 1 mg/ml 
leupeptin and pepstatin and 3 µl of the Bir A enzyme were added. This was incubated 
overnight at RT in the dark. 
 
 
 
 
 
 
2.7.8. PURIFICATION OF MONOMER BY FPLC AND HPLC 
 
 
Refolds were judged successful if the monomers purified at the correct size using liquid 
chromatography. The refolded monomer contains the murine MHC-I bound with the viral 
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peptide, human β2M and a biotin tag. The refolded molecule has a molecular weight of 
 
approximately 35 kDa. 
 
 
 
 
Initial purification is performed by size exclusion chromatography. The biotinylated 
monomers were loaded onto an Äkta purifier (GE health care) for purification by fast-protein 
liquid chromatography (FPLC) using a Superdex™ 75 column (S75) and the S75 buffer (Figure 
2.3). This fraction was then further purified by anion exchange chromatography. The 
monomer was loaded onto the MonoQ™ column of the Äkta purifier. Buffer A is first added 
to equilibrate the column followed by increasing volumes of Buffer B that contains salt to 
elute the monomer (Figure 2.4). 
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Monomer 
 
 
 
 
 
 
 
Biotin 
 
 
 
Aggregates β2M 
 
 
 
 
 
 
Figure 2.3. Size exclusion of m139-monomer. Protein aggregates elute in fractions A2-A5, 
followed by the refolded pMHC-I β2M monomer complex in A5-A7. Finally, free β2M and 
biotin are removed from the column (Fraction A11+). 
 
 
 
Monomer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  2.4.  Anion exchange  of  m139-monomer. The  green  line  shows  increasing NaCl 
concentration with the highly pure monomer eluted into fraction A3. 
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2.7.9. MONOMER CONJUGATION 
 
 
The biotinylated monomers were conjugated into tetramers using Streptavidin-APC. The 
biotin molecule on the α3 chain of the H2-Kb/H2-Db acts as an acceptor for avadin binding. 
To achieve equimolar ratios of Streptavidin-APC and monomer, the protein concentrations 
of the monomers were calculated using either a Biuret or Bradford assay. Monomer stocks 
were kept in 20-100 µl aliquots and the protein concentration recorded (mg/ml). 
 
 
 
For every 1 mg of monomer 87 µg of Streptavidin-APC was added. The Streptavidin-APC was 
added over 10 intervals. Adding the Streptavidin-APC gradually maximises monomer 
conjugation and tetramer formation. The conjugated monomers were kept at 4 °C in the 
dark until use. 
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2.8. SDS PAGE 
 
 
To analyse the purity of inclusion body preparations or proteins following HPLC purification 
samples were run on a non-reducing sodium dodecyl sulphate (SDS) page. 
 
 
 
A stock of polyacrylamide running gel was loaded into the 75 mm glass plates of a BIORAD 
specialised gel caster. A stacking gel was added to the top of the polyacrylamide running gel 
and a loading comb was added. The SDS gel was allowed to set and then placed into the 
BIORAD electrophoresis module and filled with SDS buffer. 
 
 
 
Small volumes of samples were denatured on a heating block for 10 minutes at 95 °C. 
Samples were loaded into the wells of the gel and 90 volts applied across the gel. Gels were 
stained with Coomassie dye and incubated overnight at RT and excess stain removed using 
the destain buffer. 
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2.9. BRADFORD ASSAY 
 
 
To determine the protein concentration of the inclusion body preparations and the purified 
monomers a standard Bradford assay was used. 
 
 
 
BSA was diluted two-fold in PBS from 1 mg/ml to 0.03 mg/ml to generate a standard curve. 5 
 
µl of the known BSA standards were added in duplicate into a flat-bottomed 96-well plate 
(IWAKI) and into each well 200 µl of dilute BIORAD solution was added. The plates were read 
using a microplate reader (Model 680, BIORAD) at OD595 nm to produce the standard curve of 
optical density against protein concentration. Samples were analysed in duplicate as were 
PBS blanks. 
 
 
 
Protein concentrations were calculated according to the absorbance from the known 
standard curve (linear regression) and the following equation: 
 
 
 
y = ax - b 
 
Where                           y = protein concentration (mg/ml) 
 
a = sample OD595 nm 
 
x = gradient of standard curve 
 
b = y-axis intercept of standard curve 
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2.10. BIOTINYLATION ELISA 
 
 
To asses if the HPLC purified monomer has been successfully biotinylated an enzyme-linked 
immunosorbent assay (ELISA) was performed. 
 
 
 
Into a flat-bottomed 96-well PolySorp™ ELISA plate (NUNC) 10 µl of the appropriate sample 
was added to the corresponding well, into which 90 µl of PBS was added. A minimum of two 
negative controls were included for each assay, 100 µl of PBS. 
 
 
 
The plate was then incubated for one hour at 37 °C. 200 µl of dilute Tween buffer was added 
to each well, flicked off, and the plate patted dry on tissue. This wash step was repeated a 
further two times. 
 
 
 
Extravidin peroxidase was diluted 1:1100, of which 100 µl was added to each well and the 
plate incubated at RT in the dark for 15 minutes. The ELISA plate washed three times as 
before with dilute Tween buffer. Finally, 100 µl of TMB substrate was added to each well. 
This assay is not quantitative and only requires the biotinylated fractions to become blue. 
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2.11. MOUSE MODEL 
 
 
2.11.1. MICE 
 
 
SPF immunocompetent female C57BL/6 mice were obtained from Harlan and kept at the 
Biomedical Services Unit at the University of Birmingham. Food and water was available ad 
libitum. All experiments were carried out in accordance with Home Office project licence PPL 
40/2998 and personal licence PIL 40/9427. 
 
 
 
 
2.11.2. MCMV INOCULATIONS 
 
 
A dose of 1x106  PFU of MCMV strain Smith was administered via intraperitoneal injection 
 
(i.p). 
 
Mutant MCMV strain temperature sensitive mutant 5 (tsm5) was administered i.p at a dose 
of 1x104 PFU. 
 
 
 
All infected animals were housed in negative pressure film isolators to prevent the spread of 
 
MCMV infection to other experimental colonies. 
 
 
 
 
2.11.3. INFLUENZA A INOCULATIONS 
 
Mice were anaesthetised with 0.1 ml of Sedative solution. 1x106 EID50 of IAV strain A/Puerto 
Rico/8/34-A/England/939/69 clone 7a (H3N2) was administered drop wise by intranasal 
inoculation  (i.n.).  To  reverse  the  sedative,  mice  were  given  a  subcutaneous  recovery 
injection of 0.2 ml Antisedan solution. 
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2.11.4. ANTIVIRAL TREATMENT 
 
 
The  antiviral  valaciclovir  was  administered  orally.  To  prepare  the  antiviral  500  mg 
Valaciclovir hydrochloride (GSK) tablets were crushed using a pestle and mortar and 
resuspended in 500 ml of distilled H2O. The valaciclovir suspension at 1 mg/ml was placed 
into the drinking bottles and replaced up to twice weekly. 
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2.12. ANIMAL DISSECTIONS 
 
 
2.12.1. ASEPTIC ISOLATION OF MAJOR ORGANS 
 
 
Mice were sacrificed by approved Schedule 1 methods and dissected immediately. The 
spleen, kidneys, liver, lungs and salivary glands were taken from all animals, washed in cold 2 
ml sterile PBS, frozen immediately and stored at -80 °C. 
 
 
 
 
 
 
2.12.2. SPLENIC LYMPHOCYTES 
 
 
Spleens were placed into a Petri dish containing 10 ml of RPMI-1640 medium. The spleen 
was macerated between two frosted microscope slides. The homogenate was then 
transferred into a 15 ml tube, the debris allowed to settle, and the supernatant transferred 
into another 15 ml tube and centrifuged at 700 g for 10 minutes to generate a cell pellet. 
 
 
 
The supernatant was removed and pellet resuspended in 4 ml of cold red-cell lysis buffer 
and incubated for five minutes at RT. 10 ml of RPMI-1640 was added to dilute the lysis buffer 
and the cell suspension was spun at 700 g for 10 minutes at RT to generate a lymphocyte 
pellet. 
 
 
 
The lymphocytes were then resuspended in 10 ml of RPMI-1640 and counted using the 
Trypan blue method. The lymphocyte suspension was adjusted to a working concentration 
of 5x106 splenocytes per ml. 
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2.12.3. ISOLATING  LYMPHOCYTES  FROM  CAUDAL  MEDIASTINAL 
LYMPH-NODES 
Caudal mediastinal lymph nodes (CMLN) were placed into 5 ml of sterile PBS. The membrane 
 
of the lymph node was mechanically disrupted using a 1 ml syringe. The lymph node 
suspension was transferred into a 15 ml tube and centrifuged at 700 g for 10 minutes at RT. 
The numbers of lymphocytes were counted using the Trypan blue method and resuspended 
in 200 μl of MACS buffer. 
 
 
 
2.12.4. BRONCHIOLAR LAVAGE OF PULMONARY LYMPHOCYTES 
 
 
Two  incisions  were  made  in  the dissected  mice  to  enable bronchiolar lavage. The  first 
incision was made in the diaphragm and a second at the top of the trachea. 1 ml of lavage 
buffer was drawn up into the barrel of 2 ml syringe through a 23 gauge needle (25 mm) 
fitted with 23 gauge tubing (80 mm). The tube was then placed into the trachea of the 
mouse and the 1 ml of lavage fluid flushed into the lungs and drawn back up into the 
syringe. The  lavage fluid  containing  lymphocytes was  then  centrifuged at  700  g  for  10 
minutes at RT and the lymphocyte pellet resuspended in 200 μl of MACS buffer. 
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2.13. FLOW CYTOMETRY: DETECTION OF VIRUS-SPECIFIC CD8+ 
 
 
T-LYMPHOCYTES 
 
 
2.13.1. TETRAMER STAINING 
 
 
To detect virus-specific CD8+  T-lymphocytes by flow cytometry MHC-I tetramers were used 
To standardise the tetramer staining procedure, where possible 1x106  splenocytes were 
used per staining reaction. Splenocytes were first washed, centrifuged (700 g for 10 minutes 
at 4 °C) and resuspended in 200 µl of MACS buffer. 1-2 µl of the appropriate APC-conjugated 
tetramer was  added  and  incubated for 30  minutes at  37 °C  in  the dark. The  unbound 
tetramer was then removed by adding 4 ml of MACS buffer and the cells were centrifuged as 
before and resuspended in 200 µl of MACS buffer. 
 
 
 
To provide detailed information on the cell’s phenotype, surface molecules on the 
lymphocytes were stained with antibodies to CD4, CD8a, CD27, CD44, CD62L, CD122 and 
CD127 (See Table 2.1). Antibodies were incubated with the cells for 15-30 minutes at 4 °C in 
the dark. Again, any unbound antibody was removed and the splenocytes resuspended in a 
final volume of 200 μl MACS buffer. Lymphocytes were then ready for flow cytometric 
analysis, events were acquired on a LSR-II and data analysed using FACSDiva software. 
 
 
 
 
 
 
2.13.2. INTRACELLULAR CYTOKINE STAINING (ICS) 
 
 
Splenocytes were rested overnight in RPMI (37 °C, 95% air/5% CO2) and the following 
morning 1x106 lymphocytes were placed into the wells of a 96-well plate in a volume of 200 
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µl. The corresponding MCMV peptide was added at 1 µg/ml. The splenocytes were then 
returned to the incubator for one hour prior to the addition of 5 µM brefeldin A (prevents 
cytokine secretion from the Golgi). Following the addition of brefeldin A the cells were 
incubated for a further five hours. A negative unstimulated control and a positive PMA- 
ionomycin stimulated control were also included in each experiment. 
 
 
 
Following stimulation lymphocytes were washed, centrifuged (700 g for 10 minutes at 4 °C), 
resuspended in 200 µl of MACS buffer. The splenocytes were then labelled on their surface 
with the anti-CD4 and anti-CD8 monoclonal antibodies for 15-30 minutes at 4 °C. The 
unbound antibody was removed with MACS buffer and the cells fixed with 100 µl of 4% 
paraformaldehyde. The cells were then incubated for 30 minutes in the dark before washing 
off  the  fixative.  The  membranes of  the  splenocytes  were  then  permeabilised  with  the 
addition of 0.5% saponin. Intracellular cytokines were fluorescently labelled with IFNγ and 
TNFα antibodies. The intracellular antibodies were incubated for 30 minutes at RT in the 
dark. Unbound antibodies were removed; the cells resuspended in 200 µl MACS and 
transferred into FACS tubes. Samples acquired on a LSR-II and data analysed using FACSDiva 
software. 
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2.14. TITRATION OF LYTIC MCMV EX VIVO BY EXPLANT 
CULTURE 
MCMV infects multiple sites and cell types within an animal thus the liver, lungs, kidney, 
heart and salivary glands of infected mice were harvested to detect lytic MCMV within these 
tissues. 
 
 
 
MEFs were adjusted to 1x105 cells/ml in D10 media. 1 ml of cells was added to each well of a 
 
24-well plate and incubated at overnight (37 °C, 95% air/5% CO2) whereby cells reached 
approximately 70% confluency. 
 
 
 
Tissue samples were homogenised in 1 ml D10 media in 5 ml FALCON tubes. In between 
each sample, the probe was cleaned by submerging it into bleach once, 70% ethanol three 
times and PBS three times, and any fibrous tissue was removed with tweezers. Samples were 
serially diluted (1:10) across a dilution range (1x10-1 to 1x10-3) and kept on ice. 
 
 
 
The D10 media was aspirated from each well and washed immediately with 1 ml of PBS 
(warmed to 37 °C). The PBS was removed and 200 μl of homogenate dilution added to the 
cells (duplicate). The plates incubated for one hour (or for centrifugal enhancement spun at 
1,000 g for 30 minutes at 37 °C). The homogenate was removed and 1 ml of CMC overlay 
 
was added and the plates incubated further for six days (37 °C, 95% air/ 5% CO2). 
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The plates were removed from the incubator and the overlay was flicked off the wells into 
bleach.  1  ml  of  4%  fixative  solution  was  added  to  each  well  and  the  plates  were  left 
overnight at RT. The following day fixative was flicked off and the plates rinsed gently under 
running water from the tap. Wells were stained for 10 minutes with 500 μl of 0.3% crystal 
violet solution. The stain was then flicked off and the plates rinsed under water and allowed 
to air dry. 
 
 
 
The number of PFU per organ was calculated by multiplying the mean number of plaques 
per organ by the dilution factor and correcting for volume (PFU/organ). 
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2.15. DETERMINING MCMV TITRE BY REAL-TIME 
QUANTITATIVE PCR 
Tissue was removed and washed in 2 ml of sterile PBS and immediately frozen at -80 °C. 
Samples were thawed at room temperature and whole organ or 0.268 g (+/- 0.016 g) of liver 
was homogenised using a mechanical probe (Pro 200, Monroe, USA) in 2 ml of sterile RPMI. 
The homogenate was then centrifuged at 720 g for 10 min at 4 °C. The supernatant was then 
harvested and then spun as before to remove residual cellular debris. The supernatant was 
then divided into three 700 μl aliquots and stored at -80 °C. 
 
 
 
An individual aliquot was thawed and spun at 13k g for 10 minutes to generate a pellet. The 
supernatant was discarded and the DNA extracted from the cells was performed as per 
manufactures instructions (QIAgen: Blood and Tissue Kit). 
 
 
 
Primers were designed to amplify sections of the m29.1 gene: 
Fwd: 3’- GAAATGCACACGGAAAAAAAGC 
Rev: 3’- ATCGTATGAGTAGTGGGCGTTTCT 
 
 
 
 
The reference gene used was for the murine GAPDH: 
 
Fwd: 3’- AAGAGAGGCCCTATCCCAACTC 
 
Rev: 3’- TAGGCCCCTCCTGTTATTATGG 
 
 
 
 
The corresponding TaqMan probes were: 
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m29.1: FAM-TACCCGAATGGCTTTATGCCATTGCC-TAMRA 
GAPDH: GAPDH: YY-TCTCCCTCACAATTTCCATCCCAGACC-BHQ1 
The assay was designed to run in multiplex on the ABI Prism 7500 FAST series. Each reaction 
was performed in duplicate and contained 3 μl of DNA, 450 nM of m29.1 primers, 25 nM of 
GAPDH primers, 187.5 nM of probes and 10 μl of Universal Master Mix II (Applied 
Biosciences). 
 
 
 
The thermo-cycle conditions were as follows: 50 °C for 2 minutes, 95 °C for 10 minutes, and 
 
40 cycles of 95 °C for 15 seconds and 60 °C for 1 minute. Data was analysed on the 7500 ABI 
Prism Fast software and the relative number of MCMV genomes to GAPDH was calculated 
using the 2-∆Ct method. 
 
 
 
Where2-∆Ct = Ct(m29.1) – [Ct(GAPDH)+1] 
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2.16. SEMI-QUANTITATIVE MCMV IgG ELISA 
 
 
To  obtain  plasma,  cardiac  bleeds  were  required.  First  mice  were  administered  0.2  ml 
Sedative solution by i.p. injection to anaesthetise the animal. Cardiac bleeds were then 
performed before the mice recovered using a 26 gauge needle (25 mm) attached to a 1ml 
syringe. The blood obtained was placed into sterile Eppendorf tubes containing 5 µl of 
heparin sodium. Plasma was separated from whole blood by centrifugation, 1500 g for five 
minutes at RT. 
 
 
 
Plasma from a minimum of five MCMV infected mice was pooled and a standard curve 
generated in the ELISA dilution buffer (1:100, 1:200, 1:400, 1:800 and 1:1600). 
 
 
 
MCMV lysate was produced by harvesting MCMV from the culture media of MCMV-infected 
MEFs. The culture media was transferred from the flask to a centrifuge tube and centrifuged 
at 850 g for 10 minutes at RT. The supernatant was then sonicated five times in a sonicating 
water bath. A mock lysate was produced by sonicating uninfected MEFs. The protein 
concentration of the MCMV lysate and mock lysate was confirmed by Bradford assay. 
 
 
 
The MCMV lysate was diluted in ELISA coating buffer 1:600 whereas the mock lysate was 
diluted 1:800 to achieve a final protein concentration of 3 μg/ml. 50 μl of the appropriate 
lysate was added to the corresponding well of a 96-well ELISA plate. This plate was then 
covered and incubated at 4 °C overnight. 
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The following day the serum samples were diluted 1:600 in the ELISA dilution buffer and the 
plated was washed three times with 200 μl of ELISA wash buffer. Each time the wash buffer 
was flicked off into bleach and any remaining fluid was removed by tapping the plate onto 
tissue. 
 
 
 
100 μl of the appropriate standard dilution was added to the wells of the 96-well plate. Two 
 
100 μl PBS blanks were also included on the plate. 100 μl of the appropriate serum sample 
dilution was added in duplicate to the plate. The plate was incubated for one hour at RT, and 
then washed three times (as above) with ELISA wash buffer. 
 
 
 
The secondary anti-mouse IgG (H+L) HRP conjugated antibody was diluted 1:2500 and 100 μl 
added to each well. The plate was again incubated for one hour at RT and washed three 
times (as above) with ELISA wash buffer. 
 
 
 
100 μl of TMB solution was then added directly to the wells and the plate incubated for 10 
minutes at RT in the dark. Immediately, 100 μl of 1 M hydrochloric acid was then added to 
stop the reaction. The plates were read using a microplate reader at OD450 nm. 
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2.17. DETERMINING INFLUENZA A VIRAL TITRES 
 
 
Madin Darby canine kidney (MDCK) cells were grown to confluency in 150 cm2 tissue culture 
flasks in 20 ml of IMDM. Once confluent MDCKs were washed in PBS, trypsinised and 
resuspended at 7x105 cells per ml. 
 
 
 
Lungs from IAV infected mice were homogenised in 1 ml of IMDM and centrifuged at 700 g 
for 10 minutes at RT. The supernatant was collected and diluted two fold over the, range 
1:2-1:32. The IAV stock virus was also diluted in IMDM (1:2000, 1:6000 and 1:18000). 
 
 
 
 
200 μl of MDCK cells and 200 μl of lung homogenate or IAV stock virus were added 
immediately to the appropriate wells of a 24-well plate. The plates were incubated (37 °C, 
95% air/5% CO2) for five hours after which 300 μl of 2% w/v CMC was added to each well 
 
and the plates returned to the incubator for a further 48 hours. 
 
 
 
 
The existing media was removed and the wells washed with 600 μl of PBS. The cells were 
fixed with 400 μl of 4% formaldehyde for 30 minutes. 250 μl of 0.5% TritionX-100 was then 
added for 30 minutes to permeabilise the cells. 
 
 
 
Cells were washed twice with 200 μl of PBS. Into each well 200 μl of 10% FCS/PBS was then 
added for 90 minutes. The buffer was then removed and the cells washed again with PBS. 
Then  200  μl  of  primary  mouse  anti-Influenza  A  nucleoprotein  monoclonal  antibody 
(MCA400) was added to each well and incubated for 90 minutes. 
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The supernatant was then discarded and the wells washed five times with PBS. 200 μl of the 
secondary antibody (anti-mouse IgG HRP diluted 1:2500 in 10% FCS/PBS) was then added. 
Plates were then incubated for 90 minutes in the dark. 
 
 
 
One AEC tablet was dissolved in DMF. Once dissolved 47.5 ml of acetate buffer was added 
slowly to the DMF with constant stirring. Once mixed 25 μl of 30% hydrogen peroxide was 
also added to create a developing solution. 
 
 
 
The supernatant from the plates was then discarded and the wells washed five times with 
PBS. Then 300 μl of the developing solution was added to each well and the plates incubated 
in the dark for 30 minutes to one hour. IAV infected cells turned a reddish-pinkish colour. 
Each well was then washed in 200 μl of sterile water, before the numbers of plaques were 
counted. 
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3. RESULT  1:     PROLONGED  (12  MONTHS)  VALACICLOVIR 
TREATMENT REDUCES THE MCMV-SPECIFIC IMMUNE 
RESPONSE COMPARED TO UNTREATED MCMV-INFECTED 
MICE 
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3.1. DETERMINING THE IMPACT MCMV INFECTION HAS ON 
CD8+ T-CELL PHENOTYPE 
MCMV causes memory inflation within the murine immune system and those lymphocytes 
display a highly differentiated T-cell phenotype [165]. 
 
 
 
Murine T-lymphocytes express a combination of molecules on their cell surface to aid 
adhesion including: CD62L [318] and CD44 (hyaluronan receptor) [319]. The CD62L molecule 
mediates lymphocyte rolling on inflamed endothelium and enables lymphocytes to 
attachment  to  the  lymphatic  high  endothelium  venule  [320-322].  In  contrast  CD44 
interaction with its ligand causes adherence of the T-cell at an inflammatory site [323, 324] 
and, furthermore, loss of CD44 facilitates lymph node homing [325, 326]. The antigen- 
inexperienced subset of lymphocytes, i.e. naïve CD8+  T-cells, express the combination of 
CD44- CD62L+ (TN) (Figure 3.1 F). Naïve lymphocytes preferentially migrate and remain within 
 
the T-cell zones of the lymph node awaiting presentation of foreign antigens by professional 
APCs. The central memory (TCM) subset expresses both CD44
+  and CD62L+  molecules on its 
cell membrane. The central memory population of lymphocytes forms following resolution 
of acute infection and relocate to the lymph node in anticipation of re-exposure to antigen. 
The third main subset distinguished by CD44 and CD62L co-expression are the effector 
memory (TEM) populations of lymphocytes. TEM lymphocytes express CD44 but not CD62L on 
their surface. The lack of CD62L indicates these cells are not located in the lymph node, and 
high expression of CD44 shows the cells to be attracted to sites of inflammation/activity. 
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Those lymphocytes which do not express both CD44 and CD62L were classified as double- 
negatives (TDN) and are the least frequent T-cell subset found in the spleen [327]. 
 
 
 
In prior experimental models of MCMV infection the inflationary memory MCMV-specific 
CD8+ T-cells exclusively have a TEM phenotype [165]. In addition to low level CD62L and high 
CD44 expression the M38, m139 and IE3 antigen-specific T-cells have a highly differentiated 
phenotype. This is characterised by low levels of expression of CD27 and low levels of the 
cytokine receptors CD122 and CD127. In addition, the inflationary T-cells have high levels of 
NKG2D and KLRG1 with reduced expression of PD-1 [165] which were not measured in this 
study. 
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Figure 3.1. Phenotype of CD8+ T-cells based on CD44 and CD62L co expression. A) C57BL/6 
mice infected with 1 x106 PFU MCMV Smith and mice periodically sacrificed at one, five, 16 
and 52 weeks p.i. B-G) FACS plots demonstrating the gating set of memory CD8+  T-cells. 
Single cells (B), lymphocytes (C), live lymphocytes (D), CD8+ T-cells (E). Co-expression CD44 
and CD62L (F-G) naïve (TN: CD8
+ CD44- CD62L+), central memory (TCM: CD8
+ CD44+ CD62L+), 
effector memory (TEM: CD8
+  CD44+  CD62L-) and double negative (TDN: CD8
+  CD44-  CD62L-) 
phenotype. 
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A group of six to eight week old female C57BL/6 mice were inoculated i.p with 1x106  PFU 
 
Smith strain of MCMV and the spleens removed at weeks one, five, 16 and 52 p.i. (Figure 3.1 
 
A). The lymphocytes were stained with antibodies for CD8, CD44 and CD62L. The cells were 
analysed and the CD8+  T-cell population classified into the four memory subsets based on 
the cell surface distribution of CD44 and CD62L (Figure 3.1 B-G). 
 
 
 
Prior to MCMV infection (week 0) the most prominent CD8+ subset in the SPF animals were 
TN CD8
+ T-cells contributing towards 82% of the CD8+ T-cell pool. In addition, only 15% of the 
CD8+ T-lymphocytes displayed a memory phenotype (TCM + TEM). The remaining 2.5% of CD8
+ 
T-cells were double negative for CD44 and CD62L (Figure 3.2, Table 3.1). 
 
 
 
Immediately following inoculation the hierarchy of the memory subsets changed because of 
the proliferation of lymphocytes needed to control the MCMV infection. One week post- 
inoculation saw the primary expansion of TEM  CD8
+  T-cells from 5% to over 30% of CD8+  T- 
lymphocytes. A corresponding decline in naïve CD8+  T-cells was observed (82% to 54%) 
 
during  the  first  week  of  infection.  Subsequent  to  controlling  primary  infection,  the 
proportion of TEM  contracted to 15% of the CD8
+  T-cell pool at week five. In contrast, the 
proportion of TN CD8
+ T-cells rebounded, between week one and five p.i., to almost pre- 
inoculation levels. At this stage the mice were approximately only 11-13 weeks old therefore 
the recovery in TN can be still attributed to thymopoiesis [328]. 
 
 
 
 
Memory inflation of the TEM population occurs at a rapid rate between week 16 and 52 post 
 
Smith infection. The TEM cells at week 52 accumulated within the spleen and the population 
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exceeded 50% of the entire CD8+ T-cell population. Corresponding to the increase in TEM, the 
frequency of TN  CD8
+  T-cells declined to 25% causing an inversion of the TN  to TEM  ratio 
(Figure 3.2, Table 3.1). Loss of naïve T-cells either through aging or through infection is 
implicated in senescence of the adaptive immune response [329-331]. 
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Figure 3.2. MCMV infection drives the expansion of TEM CD8
+ T-cells. Frequency of TN, TCM, 
TEM and TDN CD8
+ T-cells sampled from the spleen of Smith infected mice at zero, one, five, 
16 and 52 weeks p.i. Mean +/- SEM (n=4). 
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Table 3.1. Proportion of TN, TCM, TEM and TDN CD8
+ T-cells pre and post-MCMV infection. 
 
Mean +/- SEM. 
 
 
Memory Subset (% CD8) (n=4) 
Week 0 1 5 16 52 
TN 82.1 +/- 1.7 54.3 +/- 6.0 73.0 +/- 3.8 66.6 +/- 4.2 25.5 +/- 11.1 
 
TCM 
 
10.7 +/- 0.8 
 
10.8 +/- 1.7 
 
10.2 +/- 1.2 
 
10.6 +/- 0.7 
 
18.6 +/- 3.9 
 
TEM 
 
4.8 +/- 0.9 
 
32.7 +/- 7.9 
 
15.2 +/- 4.1 
 
21.2 +/- 4.8 
 
54.2 +/- 13.1 
 
TDN 
 
2.5 +/- 0.3 
 
02.2 +/- 1.5 
 
1.6 +/- 0.2 
 
1.6 +/- 0.3 
 
1.6 +/- 0.31 
 
 
 
 
 
 
 
Having shown the expansion of TEM in MCMV infected mice it was important to compare the 
frequency of  each memory subset  to  that  seen in  an  aged-matched MCMV  uninfected 
mouse due to the spontaneous generation of clonal T-cells [332, 333]. Here the frequency of 
TN CD8
+ T-cells at 12 months old in the uninfected animals was 53% of the entire CD8+ T-cell 
pool (Figure 3.3, Table 3.2). In MCMV infected animals the proportion of TN  CD8
+  T-cells is 
 
halved to approximately 25% (***p<0.001). The proportion of TCM T-cells did not vary 
between MCMV infected and uninfected animals. MCMV infection causes the selective 
accumulation of the TEM  population of CD8
+  T-cells (from 27% to 54% ***p<0.001). The 
proportions of TCM and TDN phenotype CD8
+ T-cells did not vary between MCMV infected and 
 
uninfected animals. 
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Figure 3.3. MCMV infection expands the TEM  CD8
+ T-cell pool. Frequency of memory CD8+ 
 
T-cells in the spleen 52 weeks p.i. compared to uninfected aged matched litter mates. 
Mean +/- SEM (n=4). Data analysed by 2way-ANOVA plus Bonferroni post-test 
(***p<0.001). 
 
 
 
Table 3.2. Memory CD8+ T-cells in uninfected mice and MCMV infected 52 weeks p.i. Mean 
 
+/- SEM. 
 
 
Memory Subset (% CD8) 
 
 
 Uninfected (n=4) MCMV Infected (n=4) 
TN 
 
TCM 
53.10 +/- 4.56 
 
18.13 +/- 0.57 
25.52 +/- 5.53 
 
18.62 +/- 1.94 
 
TEM 
 
TDN 
 
27.22 +/- 4.66 
 
1.55 +/- 0.16 
 
54.21 +/- 6.54 
 
1.65 +/- 0.18 
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3.1.1. MCMV  BECOMES  UNDETECTABLE  IN  CHRONICALLY  INFECTED 
MICE 
Herpesvirus infections are synonymous with establishing latent infection and intermittent 
 
lytic reactivation from latency [164, 165]. My hypothesis suggested that the well- 
documented   expansion   of   MCMV-specific   CD8+    T-cells   is   due   to   intermittent   lytic 
reactivation and antigen stimulation of the naïve lymphocyte pool during the latent-phase of 
infection. The accumulation of TEM CD8
+ T-cells proved to be a good surrogate marker of the 
accumulation of virus-specific CTLs (Figure 3.2 & 3.3). Therefore, the MCMV viral titre was 
assessed by quantitative PCR (qPCR) over the course of  infection in the salivary  gland. 
Primers were designed to amplify a short sequence of the viral gene m29.1 and the cellular 
GAPDH gene to determine a relative quantification of viral genomes per cell [334]. 
 
 
 
The presence of MCMV gene m29.1 relative to GAPDH was calculated from DNA extracted 
from salivary gland tissue at weeks one, five, 16 and 52 p.i. Viral titres were highest at week 
one p.i. (ΔCt 10) (Figure 3.4). At week five p.i., MCMV DNA was present in only 75% of 
salivary glands sampled and by week 16 latent MCMV genomes was only evident in one 
animal. At week 52 p.i., the virus was completely undetectable by qPCR in the salivary gland 
in all mice. The absence of detectable virus in the salivary gland does not exclude that viral 
reactivation and possible T-cell priming is occurring at other anatomical sites within the 
animal. 
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Figure 3.4. MCMV infection becomes undetectable during latent infection. MCMV viral 
loads in salivary glands as determined by qPCR at one, five, 16 and 52 weeks p.i. Data 
presented as delta Ct (ΔCt) comparing signal for the m29.1 gene vs. GAPDH. 
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DETECTION OF MCMV-SPECIFIC CD8+  T-CELL RESPONSES 
BY ICS 
In a second experiment, six-eight week old female C57BL/6 mice were inoculated i.p with 
 
1x106 PFU Smith strain of MCMV. The infected mice were periodically sacrificed by cervical 
dislocation. Lymphocytes were isolated from the spleens and the proportion of virus-specific 
cells measured by peptide stimulation and ICS. Samples were made during the acute phases 
of infection at seven (n=2) and 14 days (n=2) p.i. and again at the later stages of infection at 
36 (n=2) and 116 (n=3) days post-MCMV infection by which time memory inflation would 
occur (Figure 3.5 A). 
 
 
 
The gating was designed to determine the percentage of MCMV-specific CD8+ T-lymphocytes 
in the spleen. Splenocytes were stained using a combination of monoclonal antibodies 
directed to cell surface antigens such as CD8 and the intracellular cytokines. Lymphocyte 
populations selected from the other cell types within the spleen using a combination of 
inclusive gates. The CD8+ T-cells were selected and the cytotoxic lymphocytes producing IFNγ 
were determined in response to peptide stimulation (Figure 3.5 B). 
122  
 
3.1.2. MONITORING ACUTE AND LATENT MCMV-SPECIFIC 
CD8+ T-CELL RESPONSES BY ICS 
Antigen-experienced memory CD8+ T-lymphocytes can be detected by the synthesis of pro- 
 
inflammatory cytokines such as IFNγ or TNFα following ex vivo peptide stimulation and ICS. 
Here ICS for IFNγ-specific CD8+ T-lymphocytes proved to be a highly sensitive method of 
detecting the antigen-specific CTLs without the need for MHC-I tetramers. 
 
 
 
After i.p inoculation, MCMV disseminates from the peritoneal cavity, through professional 
APCs to the mediastinal lymphatics and is then widely disseminated throughout the body 
[43]. The hierarchy of CD8+ T-cell immunity has previously been determined for 
immunodominant T-cell epitopes from the M38, M45, M57, m139 and IE3 viral proteins in 
both acute and latent phases of MCMV infection in C57BL/6 mice [164, 165]. For example, 
seven days p.i. Munks et al (2006) observed large frequencies (5-14%) of CD8+ T-cells 
synthesising  IFNγ  in  response  to  each  of  the  M38,  M45,  M57  and  m139  viral  peptide 
antigens [164]. In contrast Snyder et al (2008) identified fewer than 1% of M45-specific CD8+ 
T-cells at the same time following MCMV (MW97.01) infection [165]. It has been calculated 
that the growth rate of MCMV-specific CD8+  T-cells in the spleen has an average doubling 
time of 12 hours and corresponds to the peak immune response between days six and seven 
p.i. [335]. 
 
 
 
In the present study, following i.p MCMV Smith infection, the M38 epitope was initially the 
most immunogenic with 4.8% of the entire CD8+ T-cell pool specific for this epitope at day 7 
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p.i. In addition to robust immune responses to M38 approximately 3% of the CD8+  T-cells 
produced IFNγ in response to m139 or M45 stimulation whereas 2% of CD8+  T-cells were 
directed towards IE3 and M57 (Figure 3.5 C). The differences in initial immunodominance 
between this model and those observed by Munks et al (2006) and Snyder et al (2008) are 
most likely a reflection of the strain differences: both Munks and Snyder infected mice i.p 
with MW97.01 (BAC derived virus) whereas here the non-manipulated Smith strain was used 
[164, 165]. 
 
 
 
Both Munks et al (2006) and Snyder et al (2008) observed a very low frequency of IE3- 
specific CD8+ T-cells (<1%) during acute infection and saw memory inflation of the T-cell 
response towards this epitope during the chronic phase of infection [164, 165]. Here, 
unexpectedly CTLs with specificity for the IE3 antigen (2.4%) detected at day 7 and this 
finding was consistent in all future experiments (Figure 3.5 C). An explanation why IE3- 
specific lymphocytes were detected so early in the course of infection may be due to slight 
genetic variations between viral strains or the cross-presentation of similar antigens [336]. 
 
 
 
It is widely accepted that between days seven and 14 post-MCMV infection there is a 
contraction in frequency of virus-specific CD8+ T-cells. This contraction is thought to occur at 
a near constant rate to form a small pool of cytotoxic memory T-cells. The proportion of 
M38, M45 and m139-specific CD8+ T-cells demonstrated a rapid rate of decay from the peak 
immune response between day seven and 14, e.g. m139-specific CD8+ T-cells decreased by 
over 50% (contracting from 3.4% to 1.5%). The rapid decay of CD8+ T-cells observed between 
day seven and 14 fits an exponential model whereby initially the frequency of lymphocytes 
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decreases at a constant rate (approximately every 16 hours) until it reaches a plateau phase 
which becomes the central memory pool [335]. In slight contrast to this exponential model 
the frequency of M57 and IE3 CTLs increased slightly between day seven and 14, e.g. M57- 
specific CD8+ T-cells increased from 2.2% to 2.8%. However, these increases were not 
statistically  significant  and  at  day  14  the  M57  and  IE3  CTLs  did  undergo  their  own 
contraction phase. The frequency of virus-specific T-cells was again determined for the five 
viral antigens at day 36 p.i. where further contraction in the T-cell frequency was observed. 
At day 36, the acute infection would be expected to be resolved and therefore an attrition of 
the primary cytotoxic immune response was expected (Figure 5.3 C). 
 
 
 
Memory inflation was observed for all five epitopes assayed at day 116 p.i. The viral epitope 
that  raised  the  greatest  inflation  from  day  36  was  IE3  (Figure  3.5  C).  The  IE3  CTLs 
accumulated in frequency from 1.2% to 5.0% of the entire CD8+ T-cell pool at day 116. The 
IE3  protein  is  homologous  to  IE1  of  HCMV  and  also  a  common  target  for  CD8+   T-cell 
 
responses in HCMV infected individuals [145]. The immunodominant immune response 
directed towards the m139 viral antigen also contributed to 5% of the CTL pool. The m139 
gene product belongs to the US22 family, which is conserved in HCMV strains. The m139 
forms part of a complex with m140 and m141 and co-localises in the cis-Golgi within the 
infected cell’s cytoplasm [337]. The US22 complex is an early gene product and is essential 
for viral replication in macrophages [338]. The frequency of M38-specific cells inflated to 
almost  the  same  magnitude  as  the  acute  immune  response  [165].  M38  and  its  family 
member m38.5 are possible immune evasion genes therefore, the immune response to this 
particular antigen is potentially very important in preventing viral escape. 
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Memory inflation was previously described as a unique characteristic to some but not all of 
the known immunodominant MCMV CD8+ T-cell epitopes [164, 165]. For example, Snyder et 
al (2008) detailed that the frequency of M45 and M57 specific CTLs remained below 1% for 
the course of MCMV infection forming long-lived stable central memory populations [165] 
whereas here there was an accumulation of those cells with the same antigen specificity. In 
addition to this experiment, all subsequent experiments detected relatively high frequencies 
(≈5%) of M45 and M57 MCMV-specific CD8+ T-cells during the latent phase of infection 
(Figure 3.5 C). 
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Figure 3.5. Memory inflation: an accumulation of MCMV-specific CD8+ T-cells. A) C57BL/6 
mice infected with 1x106 PFU MCMV Smith. Mice sampled at seven, 14, 36 and 116 days 
p.i. B) Representative gating of IFNγ producing CD8+ T-cells. C) Average frequency of IFNγ 
producing CD8+ T-cells as a percentage of CD8+ T-cells (n=2-3 mice per time point). 
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INHIBITION OF MCMV REPLICATION BY NUCLEOSIDE 
ANALOGUES IN AN IN VITRO SYSTEM 
The acycloguanosine antivirals are nucleoside analogues designed to inhibit the replication 
 
of herpes viruses. In vitro procedures by Pavic et al (1997) [316] and Kruppenbacher et al 
(1994) [317] determined the effectiveness of acycloguanosine drugs at inhibiting CPE caused 
by HSV-1 in vitro. In the present study, the method of micro-plaque reduction assay (μPRA) 
was modified to compare the capacity of aciclovir and valaciclovir, two similar nucleoside 
analogues, in preventing MCMV replication in permissive MEF primary cells following four- 
days of co-culture. 
  
 
 
 A n ti vir al  Co n centr ation  (μM)  
 
Antiviral Uninfected MEF 0.00 0.13 0.50 1.25 
 
Aciclovir 
 
 
 
 
 
 
 
 
 
 
 
 
Valaciclovir 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Micro-plaque reduction assay: MEFs were co-cultured in media containing either aciclovir or valaciclovir (0-125μM) and 
infected with the Smith strain of MCMV (MOI≈0.01). The mean number of PFU was determined after four days. Representative images 
taken at x100 magnification. 
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The Smith virus proved capable of infecting and replicating within MEFs causing CPE and viral 
plaque formation (Figure 3.6). The average number of plaques per well was plotted against 
the range of antiviral concentrations (Figure 3.7 A). In the absence of aciclovir or valaciclovir 
the virus created an average of 25 or 30 viral PFU per well respectively. Increasing the 
concentration of antiviral produced an almost linear decrease in the mean number of 
PFU/well. 
 
 
 
At high concentrations of antiviral, e.g. 125 µM, both aciclovir and valaciclovir totally 
inhibited the CPE of the MEF monolayer. As a result, zero plaques were detected within any 
of the eight replicate wells. Further dilution of aciclovir concentration from 125 µM to 2.50 
µM also completely abrogated plague formation. It was not until 1.25 μM that viral plaques 
were detected in the monolayer cultured with aciclovir. Furthermore, valaciclovir was equal 
to, if not slightly superior to aciclovir; in inhibiting MCMV replication within MEF as plaque 
formation did not occur until 0.50 µM (Figure 3.7). 
 
 
 
The average number of plaques per well was normalised to the highest number of plaques 
observed at 0 μM concentration of antiviral(s) (Figure 3.7 B). Normalisation of the mean 
PFU/well reduced the variability between the two assays. Both aciclovir and valaciclovir 
were equally efficacious and showed similar kinetics in their inhibition of plaque formation 
within the MEF monolayer. 
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Figure 3.7. Nucleoside analogues inhibit plaque formation in MCMV infected fibroblasts. 
Micro-plaque reduction assay: MEFs were co-cultured in media containing aciclovir or 
valaciclovir (zero to 125 μM) and infected with the MCMV Smith strain at an MOI≈0.01. 
The mean number of PFU was determined at each antiviral concentration following four 
days incubation. X-axis antiviral concentration (μM), Y-axis shows mean PFU/well (A), y- 
axis shows normalised PFU/well (%) (B). 
130  
 
3.1.3. ESTIMATION OF THE EC50  OF ACICLOVIR AND VALACICLOVIR IN 
VITRO 
The Smith strain of MCMV displayed a similar level of sensitivity to both acycloguanosines in 
the micro-plaque reduction assay (μPRA). To calculate half the maximal inhibitory 
concentration (EC50), dose response curves for aciclovir and valaciclovir were generated 
(Figure 3.8). The EC50 of aciclovir was estimated to be 0.52 µM and similarly valaciclovir 0.51 
µM. 
 
 
 
 
EC50 Aciclovir EC50 Valaciclovir 
y = mx + c y = mx + c 
y = 80.17x + 8.96 y = 79.13x + 9.32 
x =  0.52 µM x =  0.51 µM 
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Figure 3.8. Nucleoside-analogue dose-response. Top: aciclovir and Bottom: valaciclovir 
dose-response curves. X-axis antiviral concentration (μM) vs. Y-axis normalised PFU/well. 
Linear line of best applied, line equation and R2 also shown. 
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3.2. SHORT TERM VALACICLOVIR TREATMENT PARTIALLY 
REDUCES THE MCMV-SPECIFIC IMMUNE RESPONSE 
I hypothesised that to reduce the MCMV-specific immune response valaciclovir treatment 
given for a period that extends beyond the half-life of the inflationary T-cells would inhibit 
any stochastic DNA-replication and prevent the repopulation of the virus-specific/effector 
memory CD8+  T-cells. Therefore, six-eight week old female C57BL/6 mice were inoculated 
with 1 x106 PFU of MCMV Smith (n=20). Mice were examined at one year p.i. to determine 
 
MCMV-specific memory inflation (n=4). Subsequently half of the mice were given valaciclovir 
for three months (90 days, n=4) or six months (180 days, n=4) and the frequency of MCMV- 
specific CD8+ T-cells compared to untreated mice (Figure 3.9 A). 
 
 
 
The valaciclovir treatment consisted of the antiviral being orally available ad libitum in the 
drinking water. The  antiviral  suspension  was  changed up to  twice weekly. The  average 
volume of drinking water consumed by the cage of animals was recorded and the average 
fluid intake consumed by each mouse per day was determined; this figure was then 
converted into an equivalent dose for a 75 kg individual (Figure 3.9 B). The average daily 
volume of drinking water consumed per day per mouse was 3.66 ml. The drinking water 
contained 1 mg/ml valaciclovir in suspension. Therefore, each mouse consumed on average 
3.66 mg of valaciclovir per day. The average mass of a one year old mouse was measured to 
 
be 30 g therefore the equivalent dose in a 75 kg human would be 9.10 g/day equivalent to 
doses used in transplant patients [339, 340]. The dose of antivirals given to the mice was 
estimated to excessive of that needed to supress MCMV infection in vivo. 
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Figure 3.9. Valaciclovir treatment of MCMV infection in elderly mice. A) C57BL/6 mice 
were infected i.p with 1 x106  PFU MCMV Smith. After 12 months the mice were divided 
into either the untreated arm or the oral valaciclovir (1 mg/ml) treated arm for a total of 
three or six months. The MCMV-specific CD8+  T-cell response was determined at 12, 15 
and 18 months p.i. B) Left axis average daily fluid intake by the mice fed oral valaciclovir in 
their drinking water (ml/d). Right axis equivalent valaciclovir dose for an adult (75 kg/d). 
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3.2.1. MEASURING  THE  EFFECT  OF  3  AND  6  MONTHS  ANTIVIRAL 
LONGITUDINAL MCMV-SPECIFIC IMMUNE RESPONSE 
The inflationary MCMV-specific CD8+  T-lymphocytes (M38, m139 and IE3) were shown via 
 
adoptive transfer into SPF animals to have a half-life of approximately 45-60 days [165]. 
Therefore, to repopulate the inflationary memory pool lymphocytes from the TN  and TCM 
CD8+  T-cell reserves are believed to be activated through MCMV reactivation and antigen 
presentation [341]. To inhibit the formation of new antigen-dependent inflationary CD8+ T- 
 
cells valaciclovir was initially administered one year p.i. for three or six months (double-to- 
four times the expected half-life of the short-lived effector cells). Initially antiviral treatment 
only caused small fluctuations in the frequency of MCMV-specific cells (determined by ICS); 
however, six months of valaciclovir did cause partial attrition of all MCMV-specific CD8+  T- 
cell responses measured. 
 
 
 
Taking the frequency of M38-specific CTLs as an example, at 12 months p.i. 3.71% of CD8+ T- 
cells produced IFNγ in response to ex vivo stimulation. M38-specific memory inflation 
continued to occur, rising to 5.51% (at 15 months p.i.) and 8.07% (18 months) in the 
untreated mice. Whereas, with the addition of antiviral therapy memory inflation was 
lessened; at 15 months to 3.57% and only 4.92% by 18 months p.i. (Figure 3.10 C, Table 3.3). 
In summary, following six months of antiviral treatment the M38-specific immune response 
was 40% smaller compared with animals that did not receive any treatment. 
 
 
 
The proportions of the m139-specific CTLs showed similar, although not identical, kinetics to 
 
M38-specific cells. Short-term (three months) treatment was ineffective at reducing the 
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MCMV-specific response. For example, memory inflation continued for m139-IFNy specific 
cells between more than doubled between 15 (6.64%) and 18 months (14.13%) p.i. 
Comparing this frequency to the mice that received 6 months of valaciclovir, fewer than 9% 
of CD8+ T-cells were m139-specific at 18 months p.i. (Figure 3.10 D, Table 3.3). 
 
 
 
In the spleens of valaciclovir treated mice IE3-specific CD8+  T-cells accumulated to become 
the most immunodominant T-cell population reaching 10.48% of CD8+ T-cells at 18 months 
p.i. (Figure 3.10 E, Table 3.3). The IE3-response in MCMV untreated mice was approximately 
10% higher than that in the valaciclovir treated mice (Figure 3.10 E, Table 3.3). It was 
surprising that the three inflationary T-cell populations all responded differently to the same 
period of treatment. Without further investigation the reason(s) why the IE3-response was 
least affected by six months antiviral treatment may correspond to the delayed kinetics in 
which these cells accumulate compared to the M38 and m139 antigen-specific T-cells [165]. 
The IE3 antigen is thought not to generate T-cell proliferation during the acute immune 
response and consequently may be expressed at higher levels during latency. The IE3 gene 
has been characterised as being an immediate-early viral product essential in reactivation 
from latency, therefore antigens expressed prior to DNA-replication such as the IE ORFs may 
be least affected by treatment due to the presence of pre-existing translated products made 
prior to the antiviral exerting an effect. 
 
 
 
The frequency of M45 and M57-specific CD8+ T-cells fluctuated less than m139 and IE3- 
specific T-cells (Figure 3.10 A+B). The M45 and M57-specific CD8+ T-cells were previously 
demonstrated to have higher expression of CD27, CD122 and CD127 on their cell surface 
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than the inflationary subsets of MCMV-specific cells [165]. The CD27 co-stimulatory receptor 
is usually down-regulated on the CTL surface upon its interaction with its CD70 ligand on the 
APC and likewise the presence of cell surface cytokine receptors suggests the cell is still very 
capable of replicating via homeostatic proliferation; they were also shown to have a half-life 
of approximately 120 days following adoptive transfer into naïve animals [165]. Therefore, 
antiviral treatment administered for greater than three months could reduce the proportion 
of the most highly differentiated M45 and M57-specific CD8+ T-cells which are maintained by 
sporadic TCR stimulation and not self-proliferation [165]. Following six months of valaciclovir 
treatment, the frequency of M45 CTLs was reduced from 8.5% to 5.2% and M57 CTLs from 
7.9%  to  4.7%  of  CD8+    T-cells  suggesting  the  “non-inflationary”  T-cells  require  viral 
 
reactivation (Figure 3.10 A+B, Table 3.3). 
 
 
 
 
Although none of the reductions in CTL frequencies was statistically significant by non- 
parametric analysis, the data is suggestive that the maintenance of high frequencies of 
MCMV-specific CD8+ T-cells is sensitive to current pharmacological therapies. The magnitude 
of the MCMV-specific CD8+  T-cells was not ablated by treatment, which suggests either 
 
homeostatic mechanisms are partially compensating or the virus is able to survive in niches 
in the presence of the antiviral. 
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Figure 3.10. Valaciclovir treated mice have reduced frequencies of MCMV-specific CD8+ 
IFNγ+ T-cells. Frequency of M45 (A), M57 (B), M38 (C), m139 (D) and IE3-specific (E) CD8+ T- 
cells in MCMV untreated (black squares) and antiviral treated (grey squares) mice. Mean 
+/- SEM (n=3-4). 
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Table 3.3. Frequency of MCMV-specific CTLs determined by ICS at 12, 15 and 18 months 
post-infection +/- three or six months valaciclovir treatment. Mean +/- SEM. 
 
 I FNγ  (%  
CD8) 
  MCMV untreated  MCMV treated 
Epitopes 12 months 15 months  18 months 15 months 18 months 
M38 3.71 +/- 0.99 5.51 +/- 0.95  8.07 +/- 1.92 3.57 +/- 1.93 4.92 +/- 0.82 
 
M45 
 
3.96 +/- 0.89 
 
5.27 +/- 0.61 
  
8.50 +/- 2.39 
 
5.11 +/- 0.94 
 
5.24 +/- 0.73 
 
M57 
 
5.74 +/- 0.91 
 
5.36 +/- 0.31 
  
7.86 +/- 1.78 
 
5.55 +/- 0.73 
 
4.72 +/- 0.50 
 
m139 
 
6.51 +/- 1.70 
 
6.64 +/- 0.65 
 
14.13 +/- 4.11 
 
6.24 +/- 2.57 
 
8.89 +/- 2.10 
 
IE3 
 
8.90 +/- 0.79 
 
7.57 +/- 0.21 
 
11.88 +/- 2.40 
 
8.51 +/- 1.21 
 
10.48 +/- 2.49 
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3.2.2. MCMV TREATED MICE HAVE FEWER CD8+ CD62L- T-CELLS 
 
 
MCMV infection and the associated memory inflation causes the massive expansion of TEM 
which do not express CD62L [165]. Using CD62L as an indirect marker of T-cell activation 
three subsets of CD8+ T-cells can be determined: they are the CD62L-, CD62Llo and CD62Lhi T- 
cells (Figure 3.11 A + B). 
 
 
 
18 months post-MCMV infection, untreated MCMV infection resulted in an accumulation of 
over 70% of CD8+ T-cells having no expression of CD62L on the cell surface whereas six 
months treatment the frequency of CD8+ CD62L-T-cells was reduced to below 40% (*P<0.05) 
(Figure 3.11 B). There was no difference in the frequency of CD62Llo expressing CD8+ T-cells 
between the MCMV untreated (8.2%) and MCMV treated (7.5%) groups of mice (Figure 3.11 
B). Corresponding to the accumulation of CD62L- cells in untreated mice the CD62Lhi 
population constituted only 15% of CD8+ T-cells in untreated mice whereas over 52% of CD8+ 
T-cells in the treated group were CD62Lhi (*p<0.05) (Figure 3.11 B). These data demonstrate 
that  MCMV  causes  a  high-level  of  T-cell  stimulation  in  latently  infected  mice  that  is 
reversible through antiviral treatment. Importantly, the CD62Lhi subset is the least 
differentiated subset of CD8+ T-cells that includes the naïve lymphocytes that are partly 
responsible for de novo immunity. 
 
 
 
To  assess  if  valaciclovir  treatment  was  directly  responsible  for  the  increased  CD62L 
expression on CD8+ T-cells was determined the effect of high doses of antiviral directly upon 
splenocytes ex vivo (Figure 3.11 C). Lymphocytes were isolated from the spleen of a single 
MCMV infected mouse. The cells were cultured for 24 hours in media containing valaciclovir 
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exceeding the EC50  required to suppress MCMV replication in MEFs (Figure 3.6 + 3.7). The 
percentage of CD8+  CD62L-  T-cells was determined in the absence of antiviral where only 
10.5% of cells retained the expression of CD62L. Those splenocytes cultured with valaciclovir 
(0-100 μM) did not gain further expression of CD62L (Figure 3.11 C). The antiviral is unlikely 
to indirectly raise CD62L expression however to confirm this antiviral treatment should also 
have been administered to uninfected mice in vivo. 
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Figure 3.11. MCMV untreated mice have elevated frequencies of CD8+  CD62L-  T-cells. A) 
Gating of CD62L-, CD62Llo  and CD62Lhi  CD8+  T-cells. B) Frequency of CD62L-, CD62Llo  and 
CD62Lhi CD8+ T-cells six months post-antiviral treatment. Mean +/- SEM (n=3-4). Data 
analysed by 2way-ANOVA (*p<0.05). C) Mean CD62L+ CD8+ T-cells isolated from the spleen. 
Splenocytes (1 x106) were cultured for 24 hours in media containing valaciclovir (0-100µM) 
and percentage of CD62L- cells recorded. 
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3.3. MONTHS VALACICLOVIR TREATMENT DOES NOT 
REDUCE MCMV-SPECIFIC IgG 
Elevated anti-HCMV-specific IgG titres have been correlated to increased rates of vaccine 
failure  and  mortality  in  elderly  individuals.  Therefore,  it  was  sought  to  determine  if 
prolonged valaciclovir treatment would suppress the generation of anti-MCMV-specific IgG. 
 
 
 
ELISA determined humoral immunity for anti-MCMV-specific IgG. The standard curve 
generated to show non-specific binding of pooled serum from uninfected mice and MCMV 
infected mice to a mock-infected lysate. Anti-MCMV-specific IgG binding was determined by 
showing the OD450 nm  of pooled MCMV-infected sera binding to an MCMV-infected lysate 
(Figure 3.12 A). Antiviral treatment did not significantly reduce the anti-MCMV-specific IgG 
titre at either three or six months of antiviral treatment in comparison to untreated mice 
(Figure 3.12 B). 
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Figure 3.12. Valaciclovir treatment does not reduce the anti-MCMV specific IgG titre. A) 
Binding of uninfected sera to mock (open circles) and MCMV lysate (black circles) and 
binding of MCMV-infected sera to mock (open squares) and MCMV lysate (black squares). 
B) MCMV-specific IgG titre from uninfected animals, MCMV infected mice and following 
three and six months treatment. Mean +/- SEM (n=3-4). 
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3.4. PROLONGED    TREATMENT    (12    MONTHS)    CAN 
SIGNIFICANTLY REDUCE THE MCMV-SPECIFIC CD8+  T- 
CELL RESPONSE 
In a third experimental setting, animals were infected with MCMV and six months p.i. the 
mice were separated into untreated (MCMV untreated) or the antiviral therapy (MCMV 
treated) groups. Treatment was administered for 12 months and the magnitude of the 
MCMV-specific CD8+ T-cell response was recorded 18 months after the initial inoculation 
(Figure 3.13 A). 
 
 
 
12 months of antiviral treatment did not affect the cellularity of the spleen. The average 
number of cells was determined between the MCMV untreated and Valaciclovir treated 
groups of animals 18 months post infection. The data shows a relatively small increase in the 
number of lymphocytes that is not statistically significant. On average the spleens from the 
MCMV untreated mice contained 16.9x106 cells compared to 21.4x106 in the MCMV treated 
group (Figure 3.13 B). This concludes that antiviral treatment does not affect the cellularity 
of the spleen. 
 
 
 
The frequency of MCMV-specific CD8+ T-cells was determined by ICS and compared between 
the two groups at 18-month p.i. (+/- 12 months treatment). In all instances, the frequency of 
antigen-specific lymphocytes was lower in the treated than the untreated mice. The M38 
and M45 IFNγ+ producing CD8+ T-cells comprised around 5% of CD8+ T-cells in the untreated 
mice and by comparison were reduced to approximately 1% in the treated mice (a relative 
145  
 
reduction of 80%) (Figure 3.13 C). The most significant reductions were observed in relation 
to the frequency of IE3 CTLs. In untreated mice 8.4% of CD8+ T-cells were IE3-specific 
compared to only 2% in the valaciclovir treated mice (a relative reduction of 83%) (Figure 
3.13 C). 
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Figure 3.13. Prolonged valaciclovir treatment does not affect cellularity and leads to large 
reductions in MCMV-specific CTLs. A) Mice infected i.p. 1x106 PFU Smith. After six months 
animals divided into untreated (MCMV untreated n=7) or received valaciclovir (MCMV 
treated n=8). B) Number of splenocytes 18 months p.i. Mean +/- SEM. Data analysed by 
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Mann-Whitney U test. C) Frequency CD8+ IFNγ+ splenocytes 18 months p.i. Mean +/- SEM. 
Data analysed by 2-way ANOVA. 
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3.5. RESULTS CHAPTER 1: CONCLUSIONS 
 
 
Memory inflation is a phenomena observed in CMV infected animals. Both aging and HCMV 
infection  cause  an  expansion  of  oligoclonal  T-cells  in  the peripheral  blood.  The  HCMV- 
specific CD8+  T-cell surface phenotype is primarily highly differentiated (CD45RO-  CD57+ 
CCR7- CD27- CD28- CD95+ CTLA4+) [156, 342] likewise the cells that accumulate during MCMV 
 
infection are also highly differentiated (CD44+ CD27- CD62L- CD122- CD127- KLRG1+ NKG2D+) 
[165]. Here, in the first experiment, MCMV Smith infected C57BL/6 mice developed an 
accumulation of CD8+  CD44+  CD62L-  T-cells (TEM) which were tracked to show the dynamic 
effect MCMV has upon memory T-cell subsets (Figure 3.2). Primary MCMV inoculation 
corresponded to the generation of TEM and consequently the proportion of TN lymphocytes 
decreased. Coinciding with the resolution of infection (week 5) the TN population managed 
to repopulate itself with naïve T-cell output maintained up to 16 weeks after infection. 
However, between week 16 and 52 the accumulation of TEM lymphocytes occurred at such a 
rapid rate that there was an inversion between the TN and TEM populations. Crucially others 
have shown that murine naïve CD8+ T-cells (CD38+ TREC+) are maintained through thymic 
output and not through peripheral T-cell division [328] therefore the reduced frequency of 
naïve T-cells observed can be attributed to underlying MCMV infection. At 52 weeks p.i. the 
MCMV untreated mice had 50% fewer TN  than uninfected mice (Figure 3.3) and therefore 
would be expected to have a reduced capacity to respond to other infections. 
 
 
 
The expansion of virus specific (CD8+ IFNγ+) T-cells was then determined in a separate 
experiment (Figure 3.5). Ex vivo peptide stimulation and the synthesis of proinflammatory 
cytokines  by  the  CTLs  enabled  the  immune  response  to  be  monitored  during  primary 
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infection  and  the  latent/chronic  phase  of  infection  where  memory  inflation  occurs  for 
known specific viral epitopes. The ICS protocol proved to be highly successful with virus 
specific immune responses detected towards immunodominant epitopes of M38, M45, M57, 
m139 and IE3 throughout the course of infection. Peak primary immune responses were 
measured at days seven and 14, for the five antigens, with contraction of the immune 
response between day 14 and 36 p.i. Memory inflation of epitope-specific CD8+ IFNγ+ T-cells 
occurred between day 36 and day 116. The accumulation of M45 and M57 specific cells is in 
contrast to what is observed in other previously published models of MCMV also induced 
memory inflation [165, 196]. The most likely mechanism that explains the high frequency of 
M45 and M57 virus-specific T-cells is because of strain variations or via cross-presentation of 
microbial/dietary antigens which are likely to vary between institutions and are known to 
modulate CD8+ T-cell immunity to MCMV [178, 343]. 
 
 
 
I was unable to quantify viral reactivation as the MCMV genome was undetectable from 16 
weeks p.i. in the salivary gland (Figure 3.4) and were unfortunate that the reaction was not 
sensitive enough to detect latent MCMV in other tissues. 
 
 
 
The acycloguanosine class of antivirals have a broad spectrum of activity. To initiate activity 
acycloguanosines require phosphorylation first mediated by a viral TK and then by two 
cellular kinase enzymes. MCMV does not encode a typical TK yet is remains sensitive to 
acycloguanosine via M97 mediated phosphorylation of the antiviral [194, 344]. The efficacy 
of aciclovir and valaciclovir towards MCMV strain Smith was assessed in vitro using the 
μPRA. Lytic replication and plaque formation was completely inhibited with both antivirals at 
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concentrations exceeding 1.25 µM (Figure 3.7). The EC50 of aciclovir and valaciclovir towards 
the Smith strain of MCMV was calculated to be approximately 0.5 µM (Figure 3.8), 
demonstrating MCMV to have an equivalent level of sensitivity to acycloguanosines as both 
HSV-I and HSV-2 [345]. Due to this similarity in antiviral efficacy valaciclovir was selected as 
the optimal candidate to suppress MCMV replication in vivo due to improved bioavailability 
[346]. Oral valaciclovir has an in vivo half-life of approximately two hours [346] therefore to 
constantly suppress lytic MCMV infection a 1 mg/ml valaciclovir hydrochloride suspension 
was available ad libitum in the animal’s drinking water to ensure a sustained dose. Due to 
the stability of valaciclovir in solution the antiviral containing drinking water was changed up 
to twice weekly [347]. On average the 30 g mice consumed approximately 4 mg of antiviral 
per day which equates to an almost equivalent dose of 10 g/day for a 75 kg adult (Figure 3.9) 
and is therefore comparable to the high doses administered to suppress HCMV reaction 
post-transplantation [339]. 
 
 
 
An improvement to these studies would be to quantify the in vivo dose of valaciclovir or its 
metabolites in the serum. Following oral acycloguanosine treatment a valaciclovirase, e.g. 
biphenyl hydrolase-like protein, cleaves the ester bond from valaciclovir to convert the drug 
into aciclovir [121-124]. During the first-round of metabolism aciclovir is converted into 9- 
[(carboxymethoxy) methyl]guanine (CMMG) by an alcohol dehydrogenase and aldehyde 
dehydrogenase with CMMG converted into 8-hydroxy-aciclovir (8-OH-ACV) by a further 
oxidation mediated by an aldehyde oxidase enzyme [348-350]. Aciclovir and its metabolites 
CMMG  and  8-OH-ACV  can  be  accurately  measured  using  liquid  chromatography/mass 
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spectrometry and this data would be useful in conjunction with accurate viral load data to 
assess at what in vivo concentration lytic MCMV reactivation can be completely suppressed. 
 
 
 
Having shown C57BL/6 mice infected with MCMV Smith developed memory inflation (TEM or 
CD8+ IFNγ+ T-cells) and that valaciclovir inhibited lytic MCMV replication in vitro the antiviral 
treatment  was  given  to  suppress  sporadic  MCMV  reactivation  in  vivo.  Aciclovir  has 
previously been used to suppress MCMV titres in Swiss-Webster mice [344] where the drug 
was shown to have a high affinity for the MCMV DNA-polymerase and lead to ablation of 
MCMV titres in all tissues (except the salivary gland) [344]. Rarely is the MCMV-specific 
immune response monitored for more than 12 months due to the costs associated with 
keeping the animals. Consequently, this model is amongst the first to mimic the early 
acquisition of CMV, to assess the how the T-cell response to the virus changes into aged 
population of animals and to compare the effect of valaciclovir treatment on the CTL 
response. The old age of these animals is unlikely to be achieved by wild mice due to 
predation, disease, consequently the 18-month-old mice in this experiment can be 
considered elderly, and the memory inflation observed in the mice could serve as an 
indication of treating HCMV clonal expansions in elderly humans. 
 
 
 
Initially, three months of valaciclovir treatment proved to be an insufficient period to affect 
the frequency of virus-specific CD8+ T-cells (Figure 3.10 A-E) which was similar to the findings 
of Snyder et al (2011) [193]. When treatment was given for a total of six months the 
frequency of CD8+ IFNγ+ T-cells were partially reduced in the region of 10-30% (depending on 
the epitope) in in the MCMV treated mice compared with the untreated mice (Figure 3.10 A- 
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E). Yet when the antiviral was administered for 12 months highly significant reductions were 
observed for three of the five CD8+ IFNγ+ T-cell responses recorded (with the M57 and m139- 
specific measurements thought to have failed due to a technical matter). The M38, M45 and 
IE3 CTL response were all 80% or more greater in the untreated mice compared with the 
mice that received that antiviral treatment (Figure 3.3 C). This effect was not due to a 
reduction in absolute lymphocyte numbers (Figure 3.13 B). It appears likely that almost all 
MCMV CD8+ T-cell responses are sensitive to antiviral treatment. 
 
 
 
It was suggested that memory inflation is not dependent on the source of antigen and the 
kinetics in which it they are expressed, however it is interesting to discuss the source of the 
three immunodominant CD8+  T-cell responses. One year post MCMV infection the most 
frequent CD8+ T-cell response was directed was towards the IE3 epitope. Almost 9% of the 
 
entire CD8+  T-cell population was specific for this immediate early protein antigen. IE3 is 
homologous to IE1 that encodes for an inflationary epitope in HCMV HLA-A2 individuals 
[147]. IE3 is a transactivator of subsequent gene synthesis and critical in the reactivation of 
latent MCMV. Therefore, it is unsurprising that an IE3 gene product is a target of such large 
MCMV-specific immune responses. The second most immunodominant immune response 
was directed towards the m139 epitope (6%). The m139 gene is a member of the US22 
family, which is well conserved in HCMV strains. The m139 protein forms part of complex 
with m140 and m141 proteins [337] and co-localises in the cis-Golgi within the infected cell 
cytoplasm. The US22 complex is an early gene product and is essential for viral replication in 
macrophages [338]. m139 is required for lytic replication within macrophages therefore it is 
an ideal target for CD8+ T-cells. The M38 epitope did not inflate to the same extremes as has 
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been observed in other studies (>3.5% rather than 10%) [165]. M38 and its family member 
m38.5 are believed to be viral immune evasion genes. The m38.5 protein is expressed as an 
early gene product and prevents Bax-mediated apoptosis, however the evasion molecule 
does not protect against Bak-induced cell death [351]. M38 is a likely candidate for an 
inflationary immune response because MCMV infected leukocytes that express M38 evade 
intrinsic cell death mechanisms which results in increased viral dissemination [352]. 
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4. RESULTS 2:    ANTIVIRAL TREATMENT REJUVENATES THE 
IMMUNE SYSTEM OF MCMV INFECTED MICE AND LEADS 
TO IMPROVED IMMUNITY TO INFLUENZA CHALLENGE 
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4.1. DOES PRIOR MCMV INFECTION +/- ANTIVIRAL 
TREATMENT AFFECT DE NOVO IMMUNE RESPONSES TO 
INFLUENZA IN ELDERLY MICE? 
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4.2.  THE FREQUENCY OF MCMV-SPECIFIC CD8+ T-CELLS IS 
SIGNIFICANTLY REDUCED WITH 12 MONTHS OF 
ANTIVIRAL TREATMENT 
The MCMV-specific immune response to the five immunodominant CD8+  T-cell epitopes 
 
(M38, M45, M57,  m139  and  IE3)  were  measured in  the  spleens  of  the  elderly  MCMV 
infected mice by ICS (IFNγ and TNFα) 18 months post-MCMV and 10 days after the IAV 
infection. 
 
 
 
The data from previous chapter showed the prolonged course of antiviral treatment could 
cause over 80% attrition in the MCMV-specific CD8+ T-cell response. Therefore, 12 months of 
antiviral treatment was again administered to MCMV infected animals (Figure 4.1). The 
proportion of MCMV-specific CD8+ T-lymphocytes responding to peptide stimulation was 
again consistently lower in the valaciclovir treated group (MCMV+AV) compared with the 
untreated mice (MCMV-AV). For example, the frequency of CD8+ IFNγ+ T-cells maintained in 
MCMV-AV mice to the inflationary epitopes M38 and m139 exceeded 5% and 7% of the CD8+ 
T-cells but was reduced to 1.5% and 2% following sustained valaciclovir treatment. The 
MCMV-specific CD8+  T-cells whose population was most significantly reduced in frequency 
were those cells with specificity for the IE3 immunodominant epitope that has constantly 
elicited the largest immune response in the chronically infected mice. Here, in MCMV-AV 
mice over 12% of CD8+  T-cells produced IFNγ in response to IE3-stimuli compared to less 
than 1% in those mice which received antiviral treatment (**p<0.01) (Figure 4.2 B). This is a 
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relative decrease of 95% in the frequency of IE3-specific CD8+  T-cells and shows that pre- 
existing memory inflation of IE3-specific CD8+ T-cells is sensitive to blocking viral replication. 
 
 
 
Furthermore, immune responses directed against the “non-inflationary” antigens from the 
M45  and  M57  proteins  also  to  rely  on  MCMV  reactivation  to  maintain  their  relative 
frequency in the memory pool. For example, 3% and 5% of CD8+  T-cells in the MCMV-AV 
mice produced IFNγ in response to M45 and M57 peptide stimulation respectively. However, 
this frequency was reduced to below 2% for both epitopes in the MCMV+AV group of mice 
(Figure 4.2 B, Table 4.1). Snyder et al (2008) showed, via adoptive transfer of M45 and M57 
antigen specific cells, that they had a longer life-span than the short-lived effectors [165] and 
here the antiviral seems to have been given for a sufficient length of time to suppress the 
M45 and M57 antigen-specific T-cells much lower dependence on antigen stimulation. 
 
 
 
The MCMV-specific CD8+ T-cells associated with memory inflation are polyfunctional and 
produce IFNγ, TNFα, IL-2, and visible CD107a degranulation [161, 196]. Here, the untreated 
MCMV-AV mice showed a very strong a positive correlation (R2>0.98) between those virus- 
specific cells which produced both IFNγ and TNFα whereas the CTL response in the antiviral 
treated mice had a similar albeit slightly less strong correlation (R2>0.82) (Figure 4.3, Table 
4.1). 
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Figure 4.2.       Valaciclovir treated mice have significantly reduced frequencies of MCMV- 
specific CD8+ T-cells. A) Representative ICS FACS plots. Frequency of IFNγ (B) and TNFα (C) 
specific CD8+ T-cells 18 months p.i. +/- 12 months antiviral treatment. Mean +/- SEM (n=3). 
Data analysed by 2-way ANOVA plus Bonferroni post-test (**p<0.01). 
160  
TN
F 
(%
 C
D
8)
 
TN
F 
(%
 C
D
8)
 
 
A 
20 MCMV-AV 
B 
4 MCMV+AV 
 
 
15 R
2 = 0.9802 3 R2 = 0.8239 
 
 
 
10 2 
 
 
 
5 1 
 
 
 
0 
0 5 10 15 20 
 
IFN  (% CD8) 
0 
0 1 2 3 4 
 
IFN  (% CD8) 
 
Figure 4.3.       MCMV-specific CD8+  T-cells remain polyfunctional. The mean frequency of 
the M38, M45, M57, m139 and IE3 specific CD8+ T-cells producing IFNγ and TNFα following 
ex vivo peptide stimulation in MCMV-AV (A) and MCMV+AV (B) mice 18 months post- 
MCMV infection. 
 
 
 
 
Table 4.1. Frequency of IFNγ and TNFα MCMV-specific CD8+ T-cells 18 months post-MCMV 
 
infection +/- six months valaciclovir treatment. Mean +/- SEM. 
 
 
 MCMV-AV (n=3)  MCMV+AV (n=3)  
 I FNγ  (%  CD8 )   T NFα  (%  CD8)   I FNγ  (%  CD8 )   T NFα  (%  CD8)  
M38 
 
M45 
 
M57 
m139 
IE3 
5.40 +/- 4.06 
 
5.53 0+/- 7.29 
 
3.88 +/- 3.36 
 
7.53 +/- 0.55 
 
12.68 +/ 2.23 
4.77 +/- 3.29 
 
5.29 +/- 3.70 
 
4.01 +/- 2.98 
 
6.59 +/- 0.66 
 
13.18 +/- 2.84 
1.63 +/- 1.39 
 
1.76 +/- 1.37 
 
0.65 +/- 0.37 
 
2.11 +/- 1.05 
 
0.64 +/- 0.48 
1.58 +/- 0.85 
 
1.70 +/- 1.00 
 
0.84 +/- 0.48 
 
1.99 +/- 1.41 
 
-0.19+/- 0.50 
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4.3.  THE IE3-SPECIFIC CD8+  T-CELL POPULATION IS MOST 
AFFECTED BY ANTIVIRAL TREATMENT AND SHOWS 
UNUSUAL KINETICS IN RATE OF DECAY 
Long-term antiviral-treatment of the latent MCMV-infection successfully reduced the 
frequency of in IFNγ/TNFα-producing MCMV-specific cells CD8+ T-cells as detected by ex vivo 
peptide stimulation. To confirm that the observed decrease in functional response 
corresponded to an actual decrease in virus specific cells, IE3 and m139-specific MHC-I 
tetramers  were  used  (Figure  4.4).  The  IE3-specific  CTLs  were  the  best  candidates  for 
tetramer staining due to the 95% reduction in IFNγ-producing cells observed in the spleens 
in those MCMV infected mice that received the high dose antiviral for 12 months (Figure 
4.2). 
 
 
 
 
Memory inflation of IE3-specific cells was evident as 14% of the entire splenic CD8+  T-cell 
pool stained positive for the MHC-I tetramer in MCMV-AV mice (Figure 4.4 A+B). In 
comparison the frequency of IE3-specific cells in MCMV+AV group was below 1% of CD8+ T- 
cell pool (Figure 4.4 A + B). Again, this equates to a relative reduction of IE3-specific CTLs of 
approximately 90% thus confirming the previous ICS data (Figure 4.2) showing valaciclovir 
treatment to be effective treatment of memory inflation. 
 
 
 
Furthermore, analysis was continued to compare the phenotype of IE3-tetramer specific 
CD8+ T-cells from the spleens of MCMV infected and those with antiviral treatment. Overall 
the phenotype of the IE3-tetramer specific CD8+  T-cells detected in the spleens from the 
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MCMV+AV group was less differentiated than those mice which were untreated (Figure 4.4 
 
C). MCMV-AV mice tended to have a reduced proportion of IE3-specific cells that expressed 
CD27, CD62L, CD122 and CD127. Significant differences were determined in the level of 
CD62L between the two groups. For example, expression of CD62L was approximately 
twenty-times  less  common  on  the  IE3-specific  T-cells  from  the  MCMV-AV  than  the 
MCMV+AV group (Figure 4.4 C *p<0.05). The reduced CD62L expression observed on the 
IE3-specific cells and high expression of CD44 show that these cells are almost entirely of an 
TEM subset in the MCMV-AV groups whereas an elevated proportion of IE3-specific T-cells in 
MCMV+AV also held a TCM phenotype. The mean percentage expression of CD122 was also 
elevated in MCMV+AV treated mice (4.8%) in comparison to the untreated mice where 
expression of CD122 was almost absent (0.2%) (*p<0.05). The CD122 antibody labels the 
gamma-chain of the IL-15Rβ, its ligand (IL-15) provides a proliferative signal to the 
lymphocyte [354]. 
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Figure 4.4.       Valaciclovir inhibits memory inflation of IE3-tetramer specific CD8+  T-cells. A) Representative FACS plot of the IE3- 
tetramer specific CD8+  T-cells in the MCMV-AV and MCMV+AV treated mice. B) Frequency of IE3 and 139-tetramer specific CD8+  T- 
lymphocytes in the 18 months post-MCMV challenge. C) Expression of CD27, CD44, CD62L, CD122 and CD127 on the IE3-tetramer 
specific CD8+ T-cells. Mean +/- SEM Data analysed by 2-way ANOVA plus Bonferroni post-test (*p<0.05). 
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Figure 3.11 C showed MCMV untreated mice have an increased proportion of activated CD8+ 
CD62L- T-lymphocytes in comparison to mice treated with valaciclovir for six months. 12 
month antiviral treatment redistributed the overall memory status of the CD8+ T- 
lymphocytes in valaciclovir treated mice to resemble an uninfected animal (Figure 4.5 A). 
 
 
 
MCMV-AV  mice  displayed  significantly  reduced  frequencies  of  TN   (15%  *p<0.05)  and 
elevated frequencies of TEM CD8
+ T-cells (68.2% **p<0.01) 18 months p.i. which could be due 
to uncontrolled viral reactivation and T-lymphocyte priming. In stark comparison the CD8+ T- 
cells from the MCMV+AV group was much less differentiated with approximately 40% of 
cells having a TN  phenotype and 35% with a TEM phenotype. The antiviral treatment 
rejuvenated the distribution of memory subsets making it impossible to distinguish between 
the MCMV+AV and the MCMV-neg mice (Figure 4.5 B, Table 4.2). Furthermore, the TCM 
population consisted of 20% of CD8+ T-cells in the MCMV+AV and MCMV-neg mice but only 
12% in the MCMV-AV group and although this was not a significant decrease it partially 
 
supports the hypothesis that frequent reactivation periods skew the T-cell pool via a 
transition from least differentiated into highest differentiated T-cells. 
 
 
 
MCMV infection also generates a diverse and polyfunctional CD4+  T-cell response [213]. 
Using the same co-expression of CD44 and CD62L on the CD4+  T-cell pool the MCMV-AV 
mice were observed to have the lowest frequency of naïve CD4+ T-cells (4%) and the highest 
frequency of effector CD4+  T-cells (83%). The proportion of TN  CD4
+  T-cells did not 
significantly vary between the three groups of mice, however, the frequency of TEM was 
significantly reduced to 57% of CD4+ T-cells in the MCMV+AV treated group compared with 
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the MCMV-AV animals (***p<0.001) (Figure 4.5 C, Table 4.2). These observations suggest 
that the antiviral does not retain all lymphocytes in a naïve state but does prevent the an 
accumulation of the MCMV-specific CD4+ T-cells. 
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Figure 4.5.       Valaciclovir restores the memory status of splenic T-cells. A) Representative 
gating and T-cell memory subsets. Percentage memory subset of CD8+ (B) and CD4+ (C) T- 
cells from the spleens of elderly mice 18 months post-MCMV. Mean +/- SEM (n=3-4). Data 
analysed by 2-way ANOVA plus Bonferroni post-test (*p<0.05, **p<0.01 and ***p<0.001). 
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Table 4.2. Frequency of CD8+  and CD4+  memory T-cells from the spleen of 18 month old 
 
MCMV-neg, MCMV-AV and MCMV+AV treated mice. Mean +/- SEM. 
 
% CD8+ T-cells 
 
 
 MCMV– neg (n=4) MCMV-AV (n=3) MCMV+AV (n=3) 
TN 36.93 +/- 7.511 15.29 +/- 7.50 42.53 +/- 7.18 
 
TCM 
 
21.87 +/- 1.856 
 
12.19 +/- 3.26 
 
19.28 +/- 1.34 
 
TEM 
 
36.34 +/- 7.397 
 
68.19 +/- 11.00 
 
35.19 +/- 5.51 
 
TDN 
 
4.86 +/- 0.827 
 
4.34 +/- 0.93 
 
% CD4+ T-cells 
 
3.00 +/- 0.97 
TN 6.80 +/- 2.14 4.23 +/- 1.82 12.92 +/- 1.37 
 
TCM 
 
17.90 +/- 6.27 
 
10.14 +/- 4.65 
 
23.32 +/- 4.68 
 
TEM 
 
73.23 +/- 7.60 
 
83.34 +/- 7.01 
 
57.32 +/- 2.29 
 
TDN 
 
2.07 +/- 0.73 
 
2.29 +/- 1.28 
 
6.44 +/- 5.18 
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4.4. SURVIVAL    AND    WEIGHT    LOSS    ARE    NON- 
IMMUNOLOGICAL PARAMETERS AFFECTED BY A 
HISTORY OF MCMV-INFECTION AND TREATMENT 
Both elderly humans and mice are often more susceptible to IAV infection therefore the 
history of MCMV infection (+/-treatment) was examined in the context of the subsequent 
generation of an immune response to IAV. 
 
 
 
The IAV clone 7a used to challenge the mice is a combination of two IAVs rearranged to form 
a less virulent virus suitable for non-lethal infection in mice. However, due the old age of 
these mice all animals demonstrated adverse side effects to the procedure such as inactivity 
and a hunched posture. In two of the eight MCMV-AV mice, acute infection was so severe it 
was lethal. No mice that were MCMV–neg or MCMV+AV treated died upon exposure to IAV. 
Moreover, the MCMV-AV mice displayed the worst clinical symptoms with one mouse 
developing severe ataxia prior to its death on day four. Comparison of the Kaplan-Meier 
curves by log rank test show this difference in survival between the three groups of mice to 
be insignificant (p=0.135), however, this study was not powered sufficiently to determine if 
prior MCMV infection contributes to an increased risk of death to IAV (Figure 4.6 A). 
 
 
 
 
Experiments which have compared weight loss differences between adult and aged mice in 
response to IAV infection (A/PuertoRico/8/34) showed elderly mice to be more sensitive to 
rapid weight loss [355]. During the 10 day period post-IAV challenge, all mice lost a large 
proportion of their body mass and no animals fully regained the mass lost during the acute 
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infection. The MCMV-AV group lost the greatest percentage of their original body mass 
during acute IAV infection. The average body mass of these MCMV-AV mice decreased from 
30.3 g to 23.2 g, equivalent to 23.3% reduction of their initial body mass (Figure 4.6 B). 
Surprisingly, the MCMV-neg group also lost body mass with similar kinetics to the MCMV-AV 
group, i.e. a decrease from 31.7 g to 25.0 g (21.2%). In contrast, the MCMV+AV treated mice 
displayed biphasic kinetics. During the first five days, post-challenge, the MCMV+AV treated 
group lost mass with the same kinetics as the mice in the other two groups. Yet, between 
days five and 10 a plateau phase was achieved where no further body mass was lost in the 
MCMV+AV  group  of  animals.  Therefore,  over  the  entire  10  day  period  the  MCMV+AV 
treated mice saw only a modest decline of 14.30% from their original body mass (Figure 4.6 
B). The maintenance of body mass between day five and day 10 in the MCMV+AV mice 
 
would coincide with the induction of an IAV-specific adaptive immune response. 
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Figure 4.6.       Antiviral treatment provides protection to IAV challenge. A) Kaplan-Meier 
survival curves following acute IAV infection in MCMV-neg (open circle), MCMV-AV (black 
square) and MCMV+AV (grey square) treated mice. B) The mean percentage decrease in 
animal body mass measured during IAV infection. 
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4.5. THE  MAGNITUDE  OF  NP-SPECIFIC  CD8+    T-CELL 
RESPONSES WERE COMPARABLE IN BAL, CMLN AND 
SPLEEN DESPITE MCMV INFECTION OR TREATMENT 
In view of the relative clinical protection against IAV challenge that was afforded by long 
term antiviral therapy the magnitude and quality of the IAV-specific immune response was 
determined using the NP366-374 MHC-I tetramer. The frequency of tetramer-binding cells was 
measured in the bronchoalveolar lavage fluid (BAL), the caudal mediastinal lymph node 
(CMLN) and the spleen in order to study the adaptive immunity in local tissue, the draining 
lymph node and systemic tissue. 
 
 
 
 
The magnitude of the NP-specific immune response was greatest in BAL fluid where it 
represented on average 6% of the CD8+  T-cell pool and this relative frequency was 
comparable between all groups. In addition, NP-specific tetramer staining was seen on 1-2% 
of CD8+  T-cells in both the CMLN and spleen and this value was again similar in all groups 
(Figure 4.7 A+B). Additionally, the number of NP-specific CTLs in the BAL and CMLN were 
obtained from the flow-cytometer and there were no significant difference in the absolute 
size of the response in the three groups of mice (Figure 4.8 A + B, Table 4.3). This is in 
contrast to the recent data presented by Cicin-Sain et al (2012) who noted much reduced 
frequencies of influenza NP-specific cells in the blood of eight month old BALB/c which were 
administered MCMV five months previously and then challenged with a low dose (EID50 300) 
of IAV [356]. 
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Figure 4.7. NP-tetramer specific CD8+ T-cells in BAL, CMLN and spleen. A) 
Representative NP-tetramer staining in the BAL fluid, CMLN and spleen 10 days post-clone 
7a infection. B) Frequency of NP-specific CD8+ T-cells. Mean +/- SEM (n=4-6). 
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Figure 4.8. Numbers  of  NP-specific  CTLS  are  not  significantly  altered  by  MCMV  or 
 
treatment. Number of lymphocytes in BAL (A) and CMLN (B). Mean +/- SEM (n=3-6). 
 
 
 
 
Table 4.3. Number of NP T-cells in BAL and CMLN. Mean +/- SEM. 
 
 
Number NP-tetramer positive cells 
 
 
 BAL CMLN 
MCMV-neg (n=5) 
MCMV-AV (n=6) 
MCMV+AV (n=3-4) 
1220.6 +/- 1659.3 
 
847.0 +/- 622.7 
 
856.7 +/- 862.2 
277.8 +/- 244.7 
 
503.8 +/- 374.3 
 
197.3 +/- 190.1 
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4.6. THE NP-SPECIFIC CD8+  T-CELL IMMUNE RESPONSE WAS 
MOST ALTERED IN THE CMLN IN THE MCMV+AV GROUP 
The memory status and phenotype of NP-tetramer positive cells was determined in the BAL, 
CMLN and spleen (Figure 4.9). In all three groups of mice the NP-tetramer positive 
lymphocytes from the BAL almost exclusively displayed a TEM phenotype (>90%) (Figure 4.9 
A). To ensure that these cells are retained within the bronchoalveolar airspace, over 93% of 
 
all the NP-specific cells up-regulated expression of the CD44 adhesion molecule and down- 
regulated CD62L on their cell surface (Figure 4.10 B). Overall, the phenotype of the antigen- 
specific T-cells in the BAL appeared independent of MCMV seropositivity and antiviral 
treatment with exception of CD127 expression. CD127 was expressed significantly higher by 
the NP-specific cells in the BAL from MCMV-neg (29%) mice compared with MCMV-AV (19%, 
*p<0.05)  and  the  MCMV  +  antiviral  (11%,  *p<0.001)  treated  mice.  It  has  been  shown 
 
experimentally that CD127 is down-regulated as a result of IL-7 and also IL-4 stimuli [357] 
and in the context of HIV infection CD127 loss is associated with T-cell activation which is 
partially restored by HAART [358]. Furthermore, loss of CD127 results in impaired CD8+ T-cell 
proliferation [357], therefore it is possible that MCMV exposed mice may have had impaired 
proliferative responses to IAV on an individual cell basis that was not detected by measuring 
cell frequencies. 
 
 
 
There were multiple phenotypic differences in the NP-response from the CMLN in the 
MCV+AV group of animals. The NP-memory subsets in the CMLN have a similar distribution, 
approximately 20% TCM  and 75% TEM  CD8
+  T-cells, amongst the untreated MCMV-AV and 
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MCMV-neg mice (Figure 4.10 C). In contrast, the MCMV+AV treated mice displayed 
significantly reduced frequencies of TEM  NP-specific CD8
+  T-cells (55%) in comparison with 
the MCMV-neg (*p<0.05) and MCMV-AV (**p<0.01) mice. The decrease in TEM was offset by 
an increased frequency of TCM NP-specific cells in the CMLN of MCMV+AV treated mice. This 
finding  indicates  that  the  less  differentiated NP-specific cells  are  retained preferentially 
within CMLN. Further to the increase in TCM  NP-response those tetramer specific cells also 
displayed significantly elevated levels of CD127 on their surface in MCMV+AV than the 
MCMV-AV group of mice (*p<0.01) (Figure 4.9 D). 
 
 
 
Previously Figure 4.8 A+B showed that the NP-specific cells within the spleen did not vary in 
frequency between the three groups and here the memory status of NP-tetramer specific 
CD8+ T-lymphocytes was consistent between groups (Figure 4.10 E). The NP-response in the 
spleen most closely resembled that in the BAL fluid with the predominant subset being the 
TEM  population (80%) (Figure 4.10 E). The TCM  NP-tetramer specific response in the spleen 
ranged from 8% to 11%, which was higher than what was observed in the BAL but lower 
than that was detected in the CMLN (Figure 4.9 E). There were no significant alterations to 
the percentage expression of CD27, CD44, CD62L, CD122 or CD127 on the NP-tetramer 
positive cells. The NP-tetramer specific response from the spleen was judged as highly 
differentiated and independent of MCMV seropositivity and antiviral treatment. 
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Figure 4.9.       Altered NP-specific CD8+  T-cell immunity in the BAL, CMLN and spleen 10 
days post-IAV challenge. Memory-subsets of NP-specific CD8+ T-cells in BAL (A), CMLN (C) 
and spleen (E). Percentage expression of CD27, CD44, CD62L, CD122 and CD127 on the NP- 
specific CD8+ T-cells in the BAL fluid (B), CMLN (D) and spleen (F). Mean +/- SEM (n=4-6). 
Data   analysed  by   2way-ANOVA  plus  Bonferroni  post-test  (*p<0.05,  **p<0.01  and 
***p<0.001). 
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4.7. THE CD4+ T-CELL IMMUNE RESPONSE WAS LEAST 
DIFFERENTIATED IN THE CMLN OF VALACICLOVIR 
TREATED MICE 10 DAYS POST-IAV CHALLENGE 
Because  of  the  observation  that  the  CTL  response  sampled  from  the  CMLN  was  most 
different between the three groups of mice, the memory and phenotypic status of the CD4+ 
T-cells from the CMLN was also examined for phenotypic changes. It was surprising to see 
how similar the MCMV-AV and MCMV-neg mice were concerning their CD4+ T-cell response 
within the CMLN compared to the MCMV+AV group of mice. Both the MCMV-neg and 
MCMV-AV mice CD4+ T-cell response was primarily of a TEM phenotype (57-58%) which was 
significantly higher than that detected from the treated MCMV+AV group (43%) (*p<0.05) 
(Figure 4.10 A). The reduced frequency of TEM  CD4
+  T-cells in the valaciclovir treated mice 
was due to a slight increase in less differentiated TN  and TCM  subsets of CD4
+  T-cells. To 
 
coincide with the reduced TEM  population it was confirmed that the percentage expression 
of CD44 was significantly reduced (*p<0.05) and CD62L significantly elevated (*p<0.05) on 
the CD4+  T-cell populations from the CMLN of the MCMV+AV animals (Figure 4.11 A). No 
differences were observed in the levels of CD27, CD122 or CD127. Overall, the CD4+  T-cell 
phenotype would best be described as CD44+  CD62Lint  CD27int  CD122-  and CD127int  (where 
intermediate [int]  is  between  40-60%) in  all  groups  independent  of  MCMV  infection  or 
 
treatment. 
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Figure 4.10.    The  CD4+   T-cells  in  response  from  the  CMLN  is  least  differentiated  in 
MCMV+AV treated group of animals. The frequency of each memory subset (A) and 
phenotype (B) of CD4+  T-cells from the CMLN 10 days post IAV-challenge. Mean+/- SEM 
(n=4-6). Data analysed by 2way ANOVA plus Bonferroni post-test (*p<0.05). 
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4.8. ANTIVIRAL TREATMENT OF MCMV CAN RESTORE CD4:CD8 T- 
CELL RATIOS TO THAT OF MCMV NEGATIVE ANIMALS 
The IRP states a CD4:CD8 T-cell ratio below one (in the peripheral blood) is a predictor of 
poor immune function in the elderly. Therefore, as an aside to the factors which directly 
contribute to the control of IAV, the ratio of CD4+ to CD8+ T-cells was determined in the BAL 
fluid, CMLN and spleen to  re-examine if the expansion of CD8+  T-cells is reversed with 
 
valaciclovir treatment. 
 
 
 
 
The BAL fluid contained large proportions of infiltrating lymphocytes of which the majority 
were CD8+ (47-61%) rather than CD4+ T-cells (14-19%) in all three groups of clone 7a infected 
animals. The presence of high frequencies of CD8+ T-cells in this localised tissue is most likely 
a direct response to the IAV burden and a requirement therefore for cytotoxic lymphocytes. 
The MCMV-AV mice had the lowest average CD4:CD8 ratio (0.23) compared to both the 
MCMV-neg (0.36) and MCMV+AV (0.35) treated mice (Figure 4.11 A). If were are to assume 
that the optimum ratio of CD4+  to CD8+  T-cells would occur in uninfected MCMV-neg mice 
then the valaciclovir treatment appeared to have rejuvenated the accumulation of MCMV- 
specific CD8+ T-cells restoring the CD4:CD8 ratio in the BAL. 
 
 
 
Within the CMLN of the untreated MCMV-AV group only 13% were CD8+  and 20% CD4+  T- 
lymphocytes, therefore the  remaining lymphocytes  are most  probably  B-cells. In 
comparison, the MCMV+AV group had elevated frequencies of both CD8+ (31%) and CD4+ T- 
lymphocytes (30%). The MCMV-neg CD4:CD8 ratio equalled 1.14 which suggests that for 
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normal immunological control of IAV infection alone an equal ratio of CD4+ and CD8+ T-cells 
are required in the CMLN. This ratio was most closely upheld within the lymph node of the 
MCMV+AV group (0.97) whereas the untreated MCMV-AV mice had a CD4:CD8 ratio of 1.51 
(*p<0.05) approximately 50% more CD4+ T-cells than CD8+ T-cells (Figure 4.11 B). 
 
 
 
The  spleens  are  a  site  of  large  populations  of  circulating  lymphocytes  in  young  mice, 
however in the 18-month-old mice the number of viable lymphocytes was markedly reduced 
due to hyposplenism; therefore, memory inflation should further skew the T-cell ratio. 
Additionally, at day 10 post-clone 7a  challenge, one mouse from the MCMV-neg group had 
severe splenomegaly although the CD4:CD8 ratio was comparable to the other members of 
the group and a second animal from the same group was excluded due to insufficient cells to 
test  the  CD4:CD8  ratio.  Unsurprisingly,  the  untreated  MCMV-AV  mice  had  the  highest 
proportion of  CD8+   T-cells  (17%) in  the spleen  due to  the expansion  of  MCMV-specific 
 
inflationary T-cells. However, the untreated MCMV-AV group also had the highest frequency 
of CD4+ T-cell (36%) resulting in the largest CD4:CD8 ratio (2.20). In contrast, the MCMV+AV 
treated mice had a much lower frequency of CD4+ T-cells which resulted in that group having 
the lowest CD4:CD8 ratio (1.54) which was most similar to the MCMV-neg group (1.87) 
(Figure 4.11. C). These findings are contrary to what is observed in the peripheral blood of 
HCMV-seropositive humans and indicate that this parameter o the IRP is not directly 
transferable to lymphocytes populations from mice. 
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Figure 4.11.    Antiviral  treatment  restores  the  CD4:CD8  T-cell  ratio  to  resemble  an 
uninfected animal. The CD4:CD8 T-cell ratios determined in the BAL (A), CMLN (B) and 
spleen (C). Mean +/- SEM (n=4-6). Data analysed by Kruskal Wallis (*p<0.05). 
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4.9. UNTREATED MCMV INFECTION LEAD TO SIGNIFICANTLY 
ELEVATED INFLUENZA VIRUS TITRES IN THE LUNG 
The lungs are the primary site of IAV replication; therefore, clone 7a viral titres were 
determined by plaque assay 10 days p.i. (Figure 4.12. Table 4.4) and were comparable to the 
day 10 titres observed by Toapanta et al (2009) following similar infection models in elderly 
mice (up to 104 PFU/lung) [359]. 
 
 
 
The untreated MCMV-AV group of animals had the highest IAV titre of approximately 5500 
 
PFU/lung which was significantly higher than the 1216 PFU/lung detected in MCMV-neg 
mice (*p<0.05).  Treatment with valaciclovir reduced the IAV titre of the MCMV+AV mice to 
just below 2000 PFU/lung. This is a relative reduction of approximately 70% when compared 
with the MCMV-AV group (*p<0.05). These findings suggest that the elevated titres are due 
to a lack of immune control of the clone 7a infection some of which is mediated by the CD8+ 
T-cell response. 
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Figure 4.12.    Untreated MCMV infection leads to elevated IAV titres. The IAV titres were 
determined 10 days post-IAV challenge in the lung by plaque assay. Mean +/- SEM (n=4-6). 
Data analysed by 2way-ANOVA plus Bonferroni post-test (*p<0.05). 
 
 
 
 
 
 
Table 4.4. IAV titres in the lung 10 days post-IAV challenge. Mean +/- SEM. 
 
 
 MCMV-neg (n=5) MCMV-AV (n=6) MCMV+AV (n=4) 
PFU/Lung 1216 +/- 620 5478 +/- 2258 1920 +/- 797 
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4.10. RESULTS CHAPTER 2: CONCLUSIONS 
 
 
Antigen is essential for priming cytotoxic CD8+  T-cell proliferation during primary infection 
and pathogen re-exposure. In cases of high antigenaemia, e.g. LCMV infection (in mice) [360] 
or untreated HIV infection (in humans) there is an associated high frequency of antigen- 
specific CD8+  T-cells detected in the circulation [361, 362]. The experiments in this chapter 
sought to determine whether MCMV reactivation - and therefore the availability of antigen - 
is responsible for generating memory inflation in elderly mice with chronic/latent MCMV 
infection. To block MCMV-reactivation mice were administered valaciclovir hydrochloride (1 
mg/ml) in their drinking water for up to 12 months. 
 
 
 
This study is not the first to demonstrate that blocking viral-replication/reactivation will lead 
to a reduction in the corresponding CD8+ T-cell response. Both Gray et al (1999) and Weekes 
et al (2006) documented an attrition in the frequency/number of HIV-specific CD8+ T-cells in 
patients  undergoing  HAART  [361,  362].  HAART  medications  typically  include  ziovudine 
(nucleoside analogue of thymidine) and lamvudine (nucleoside analogue reverse- 
transcriptase inhibitor) which  in  combination  can  ablate  HIV-1  RNA levels and  in  those 
studies the absence of viral-RNA correlated with significant reductions in the circulating HIV- 
specific CTL response. A murine model of memory inflation utilising systemic HSV-1 infection 
generates  high  frequencies  of  circulating  gB-specific  CD8+    T-cells  that  are  similar  in 
phenotype to those associated with MCMV infection (i.e. CD8+ CD62L- CD127int CD27-) [363, 
 
364]. The transfer of gB-specific CD8+ T-cells into SPF mice showed these cells to rely on the 
presence of latent virus to maintain cell number. Furthermore, Lang et al (2009) 
demonstrated that memory inflation of gB-specific CD8+ T-cells can be reduced by 75% if the 
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systemic HSV-1 infection was treated with famciclovir (2 mg/ml) for one month [363]. 
Famciclovir treatment was most effective if administered prophylactically (seven days before 
infection) and in addition, treatment resulted in a less differentiated gB T-cell surface 
phenotype (CD8+ CD62Lint CD127+ CD27+). The authors remarked that the population of HSV- 
1 specific T-cells is maintained by periodic yet subclinical reactivation of the latent persistent 
 
virus.  Unfortunately, it  is  impossible  to pre-empt herpesvirus infection  therefore 
prophylactic treatment may not always be an option even though antiviral treatment has the 
potential to modulate T-cell frequency and diversity. 
 
 
 
Here, MCMV infected mice were left to develop memory inflation of the CD8+ T-lymphocyte 
for six months before antiviral treatment was administered for 12 months. In doing so, the 
study aimed to replicate the clonal expansions of HCMV-specific CD8+ T-cells seen in the 
elderly population. A limitation of studying the immune response in an aged population of 
mice (>18 months) is that fewer lymphocytes can be obtained from the spleen in comparison 
to those experiments where younger animals were sampled. The spleen is a secondary 
lymphoid organ and like the thymus undergoes atrophy [365]. Here there was not observe 
an obvious decrease in size of the spleen size however there was an age associated decline 
in the number of lymphocytes isolated from the spleen of older mice. This form of 
hyposplenism occurred in 50% of MCMV-AV mice whereas treatment with valaciclovir 
resulted in hyposplenism in only 25% of cases; however, the sample size was insufficient to 
prove that untreated MCMV accelerated hyposplenism. 
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Valaciclovir treatment was provided for 12 months which is four times greater than the 
longest estimated half-life of the inflationary MCMV-specific T-cell response [165]. During 
this  time  MCMV  would  be  expected  to  reactivate  an  unknown  number  times  in  the 
untreated mice but the administration of valaciclovir would supress viral DNA-replication. It 
is a limitation of this study that both lytic MCMV and viral genomes were not detected after 
the resolution of acute infection. Therefore, there is uncertainty that antiviral treatment 
successfully suppressed MCMV reactivation entirely as the process may have been partially 
incomplete with virus replicating in niche cells/organs partially explaining why the CTL 
response was not ablated. 
 
 
 
These are the first series of experiments to investigate the effect of long-term antiviral 
suppression  of  a  non-modified  MCMV  in  C57BL/6  mice.  Previously  Snyder  et  al  (2011) 
showed that prophylactic famciclovir treatment of mutant MCMV infection (MCMV-TK) 
resulted in approximately 50% reduction in the frequency of M38 and m139 specific CTLs. 
Furthermore, the frequency of IE3-specific CTLs was significantly reduced by almost 90% 
(from >8% in untreated mice compared to <1%) because of prophylactic antiviral treatment 
[193]. The data presented within this chapter also demonstrated that memory inflation is 
also sensitive to the effects of 12 months of valaciclovir treatment. The IFNγ response to the 
five immunodominant peptides totalled approximately 35% of CD8+ T-cells in the MCMV-AV 
 
mice  compared  to  less  than  10%  in  the  MCMV+AV  group.  Reductions  were  observed 
towards all five epitopes assayed, however the effect of treatment was most pronounced 
towards the IE3-epitope. The frequency of cytotoxic CD8+  IFNγ+  IE3-specific cells was 95% 
higher in  the untreated mice compared to the antiviral treated  group 18 months after 
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MCMV infection. The frequencies of MCMV-specific cells reported by Snyder et al (2011) 
following prophylactic treatment and here after 12 months of treatment are very similar and 
prove that antigen partially maintains memory inflation and the sensitivity of each individual 
immune response varies to treatment. 
 
 
 
Immunity to a variety of pathogens is known to wane in old age as leukocytes lose function 
and the capacity to control infections [331, 364, 366-369]. For example, studies of pp65- 
specific CD8+ T-cells in the very old were shown to be dysfunctional as on a per cell basis the 
cells produced less IFNγ and IL-10 upon stimulation [370]. Here there was no functional 
impairment (IFNγ or TNFα production) of the inflationary lymphocytes in response to ex vivo 
peptide stimulation in the MCMV-AV and MCMV+AV treated mice. However, the surface 
phenotype  of  the  IE3-specific  CD8+   T-cells  showed  evidence  that  not  treating  MCMV 
infection causes the most highly differentiated phenotype associated with memory inflation. 
The  majority of  IE3-tetramer specific  lymphocytes from the  MCMV-AV mice were CD8+ 
CD27-   CD44+   CD62L-   CD122-   CD127-   whereas  in  the  MCMV+AV  group  those  same  IE3- 
 
tetramer specific lymphocytes were CD8+  CD27int  CD44+  CD62Lint  CD122-  CD127int, which is 
representative of less differentiation. 
 
 
 
The reduced frequencies of TEM  CD8
+  T-cells seen in the antiviral treated mice seemed to 
rejuvenate the CTL pool to that of MCMV-neg mice. There was a concern that the antiviral 
was having an immunosuppressive effect on lymphocyte output from the  bone marrow 
[371, 372]. However, the reduced MCMV-specific immune response and decline in TEM  in 
 
CD8+   T-cells  was  not  a  global  effect  on  all  other  lymphocyte  subset/phenotypes.  For 
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example, in the spleen and BAL the distribution of CD4+ T-cell memory subsets was not 
significantly altered between MCMV+AV and the MCMV-neg control mice. The antiviral 
treatment only reduced the proportion of TEM CD4
+ T-cells in the CMLN, which may be 
attributable to the IAV infection. Additionally, if valaciclovir were immunosuppressive the de 
novo NP-specific T-cell response the memory subsets and NP-specific T-cell phenotypes 
should have been affected in all three sites and not only the CMLN. 
 
 
 
The elderly are at the greatest risk of non-pandemic IAV infection [373-375] and numerous 
publications have shown an age associated immune senescence of antigen-presenting cells, 
innate immunity and adaptive immune response towards influenza in mice [359, 376, 377]. 
Here, it was intriguing and somewhat illogical to see that the MCMV+AV animals had 
abrogated  clinical  effects  during  the  IAV-infection  and  generated  perhaps  the  most 
proficient NP T-cell response in the CMLN. It would be expected that the MCMV-neg mice to 
maintain their body weight best of the three groups due to these animals never having 
generated an MCMV response and therefore should be most capable of generating an 
effective cytotoxic IAV-specific immune response. The accumulation of MCMV-specific T- 
cells and the corresponding memory inflation in the MCMV-AV mice would be predicted to 
cause senescence towards IAV similar to that observed in elderly HCMV seropositive humans 
[353]. However, antiviral treatment may unmask a potential benefit and perhaps symbiotic 
effect of underlying MCMV infection. CMV are highly immunogenic and here may have 
generated a pro-inflammatory environment within the lung with elevated levels of 
lymphocytic cytokines such as interleukins, IFNγ and TNFα which are normally impaired in 
aged mice during IAV infection [359]. The underlying MCMV infection could help prime the 
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APCs for cross-presentation of IAV epitopes or via bystander activation of innate or cross- 
reactive leukocytes [378] which may have resulted in reduced IAV viral titres. 
 
 
 
 
 
Post-IAV inoculation there was no significant differences in the average frequency of NP- 
tetramer specific lymphocytes (% CD8+  T-cells) in the BAL, CMLN and spleen. However, the 
IAV response in the CMLN was unique and it is known that antigen presentation within the 
CMLN is critical for the control of influenza [379]. The CMLN is a large unpaired node located 
behind the heart and is a reservoir of lung associated T-lymphocytes. Here the MCMV-AV 
mice had the largest number of lymphocytes in the CMLN but the lowest percentage of CD8+ 
and CD4+ T-cells. The lack of T-lymphocytes in the CMLN suggests MCMV-AV have impaired 
 
T-cell recruitment to the lymph node therefore future experiments should consider 
chemokine receptor levels, e.g. CCR7. The remaining lymphocytes in the node are likely to 
be B-cells that are probably required to compensate for the impaired T-cell recruitment. It 
would be interesting to compare the ability of the animal’s serum to inhibit 
haemagglutination of erythrocytes as an additional determinant of immune senescence. 
 
 
 
Valaciclovir is an inhibitor of the herpes-virus DNA-polymerase (M54) and therefore should 
not affect the IAV which are RNA viruses and do not contain an ortholog of the M54 gene. 
However, future experiments should include a further control group that received the same 
dose of antiviral treatment as the MCMV+AV group but were themselves not infected with 
MCMV. The additional group would help to prove that the low IAV titres in MCMV+AV mice 
were not a result of antiviral treatment but was due to immunological factors. There is no 
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evidence of aciclovir(s) having anti-IAV properties in the literature however a including 
valaciclovir to an in vitro plaque assay type experiment could show that the antiviral is highly 
specific and not a confounding factor of these experiments. 
191  
 
5. RESULTS   3:      tsm5   DOES   NOT   GENERATE   MEMORY 
INFLATION AND THEREFORE LYTIC REPLICATION IS KEY TO 
CD8+ T-CELL MEMORY INFLATION 
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5.1. ATTENUATION OF MCMV REPLICATION AND ITS IMPACT 
UPON MEMORY INFLATION OF CD8+ T-LYMPHOCYTES 
In the previous two chapters, administration of the prolonged course of 12 months 
continuous valaciclovir treatment to latently MCMV infected mice significantly reduced the 
frequency of MCMV-specific CD8+ T-cells. The antiviral blocks progress of the viral DNA- 
polymerase and prevents herpesvirus replication (Chapter 1 Figure 1.4). Therefore, the 
question was raised whether an attenuated virus could maintain the high frequencies of 
virus-specific T-cells. 
 
 
 
There have been previous attempts to investigate the immune responses to an attenuated 
MCMV strain [193, 380]. For example, Snyder et al (2010, 2011) generated an attenuated 
viral strain by deletion of the entire gene that encodes for an essential surface glycoprotein 
(ΔgL-MCMV) [193, 380]. The ΔgL-MCMV remains infective, however, upon the first round of 
viral replication virions were incapable of spreading to neighbouring cells and therefore the 
virus is unable to fully disseminate and establish a genuine latent infection [380]. It was 
reported that following systemic administration of the ΔgL-MCMV into either BALB/c or 
C57BL/6 mice that memory inflation still occurred but at a lower magnitude to that observed 
with infection with a non-attenuated MCMV [193]. 
 
 
 
The temperature-sensitive mutant 5 (tsm5) is a live-attenuated, replication defective MCMV 
strain generated by chemical mutagenesis of the K181-Birmingham variant of MCMV [315]. 
The stock of tsm5 contains multiple viruses with a number of non-synonymous mutations 
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including five in essential viral genes: M27, M36, M98, M56 and M70. The M70 ORF encodes 
for the MCMV DNA-primase and a truncating mutation (C890Y) alone sufficiently impedes 
the DNA primase-helicase complex and prevents DNA-synthesis [381, 382]. Although tsm5 is 
attenuated, it was previously uncovered that inoculation of BALB/c mice with tsm5 can 
induce primary immune responses. In fact, inoculation with a dose of as few 40 PFU of tsm5 
induced protective immunity to subsequent challenge towards salivary gland passaged K181 
[383]. The tsm5 virus is capable of establishing a latent infection as viral DNA has been 
detected in multiple organs (salivary glands, lung, spleen, liver, kidney, and heart) during 
latency, however, viral RNA transcripts have never been detected [383, 384]. 
 
 
 
To test whether the replication defective tsm5 virus would cause memory inflation a group 
of C57BL/6 mice were inoculated i.p. with tsm5. The frequency of MCMV-specific CTLs was 
measured in the spleen at one, seven, 14 and 52 weeks p.i. (Figure 5.1). Detection of lytic 
viral replication within the salivary glands, liver, lungs, kidneys and heart were assessed by 
plaque assay. 
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Figure 5.1. Experiment design: six to eight week old C57BL/6 mice were inoculated i.p. 
with 1x104 PFU of tsm5 virus. The MCMV-specific immune response was subsequently 
measured in the spleen at one (n=4), seven (n=4), 14 (n=4) and 52 (n=4) weeks p.i. by ICS. 
Tetramer staining for m139 and IE3-tetramer specific cells was performed 52 weeks p.i. 
The salivary glands, liver, lungs, kidneys and heart from each animal were used to detect 
the presence of lytic tsm5 virus. 
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5.2. LYTIC  tsm5  IS  UNDETECTABLE  IN  C57BL/6  INFECTED 
MICE 
The tsm5 virus is replication defective because of a switch from cysteine to tyrosine at 
position 890 of the M70 ORF resulting in a truncated DNA-helicase/primase complex. 
However, the tsm5 viral stock is impure and contains an unknown number of other mutant 
viruses, many but not all of which contain the M70 mutation. tsm5 replication is partially 
under immune control as replicates with delayed kinetics infection in immunodeficient SCID 
[381, 383]. To determine if tsm5 replicated to detectable levels within C57BL/6 mice the lytic 
viral titres were assessed by explant culture of tissue homogenate onto MEFs. Normally, 
MCMV titres are highest in the salivary gland during acute infection, here at one-week p.i. 
there was no evidence of CPE of the MEF monolayer (Figure 5.2). If lytic replication did 
occur, it was below the limit of detection by conventional plaque assay. In addition, lytic 
tsm5 virus was not found in the kidneys, liver, lungs or heart at one-week p.i. The plaque 
assay method was performed at all subsequent time points and lytic virus was always below 
the limit of detection in C57BL/6 mice. 
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Figure 5.2. Lytic tsm5 is undetectable in C57BL/6 infected mice. tsm5 plaque assay. Briefly, 
salivary glands from four C57BL/6 mice, one week post-tsm5 inoculation, were removed 
and homogenised in 1 ml of RPMI, then the supernatant was serially diluted (1x10-1, 1x10-2 
and 1x10-3) and added to confluent MEFs in 24 well plates (in duplicate). Plates were 
 
returned to the incubator for one week after which the homogenate was removed and the 
 
MEF stained with crystal violet, visible plaques were counted at x10 magnification. 
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5.3. INFECTION WITH tsm5 DOES NOT ELICIT MEMORY 
INFLATION 
The tsm5 virus has previously been demonstrated to be immunogenic, promoting normal 
humoral immune responses with immunoglobulin titres comparable between tsm5 and K181 
infected mice and acute cytotoxic CD8+ T-cell responses to m04 (YGPSLYRRF) and M84 
(AYAGLFTPL) peptides in BALB/c mice [383, 385]. However, it was uncertain whether tsm5 
would promote a cytotoxic CD8+ T-cell response during infection in C57BL/6 mice due to the 
different MHC-I antigens and the interaction between Ly49h receptor in the mouse and the 
viral protein m157. 
 
 
Firstly, i.p. inoculation of the tsm5 virus did elicit a detectable primary CD8+ T-cell response 
in C57BL/6 mice. CTL specific for the same five immunodominant MCMV-specific CD8+ T-cell 
epitopes used throughout this study (M38, M45, M57, m139 and IE3) were evident by ICS 
for IFNγ (Figure 5.3, Table 5.1). However, the primary MCMV-specific immune response to 
this replication defective strain was not as robust as the proliferation of virus-specific CD8+ T- 
 
cells seen one week post-inoculation if K181 or Smith strains of MCMV were used [165]. The 
frequencies of the CD8+ T-cell responses were highest towards the M57 epitope (1.46%) and 
lowest towards the IE3 epitope (1.01%). However, the range of CTL frequencies, of the five 
epitopes,  was  narrower  and  could  coincide  with  a  lower  initial  antigen  burden.  The 
frequency  of  MCMV-specific  CTLs  ranged  from  approximately  1-2%  of  CD8+   T-cells  per 
epitope (Figure 5.3, Table 5.1), which is very similar to the MCMV acute response observed 
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in the peripheral blood by Snyder et al (2010) when they infected C57BL/6 with their 
attenuated ΔgL-MCMV [380]. 
 
 
 
I then sought to determine whether the replication defective tsm5 virus could promote 
memory inflation over the course of 52 weeks of tsm5 infection. It is important to note that 
lytic replication was never evident by explant culture in those infected mice. Seven weeks 
p.i. the immune response to tsm5 showed a small contraction in the frequency of M38, M45, 
M57 and m139 specific CD8+ T-cells in the spleen from day seven. This is likely a reflection of 
the resolution of acute infection and the lymphocytes undergoing programmed cell death 
and natural decay in the absence of antigen [165]. The frequency of M38, M45, M57 and 
m139-specific CTLs declined from approximately 1.3-1.5% at one week p.i. to below 1% of 
the CD8+ T-cell pool by week seven (Figure 5.3, Table 5.1). The IE3-specific immune response 
was the only one measured not to undergo a phase of contraction remaining stable at 
approximately  1.1%  of  CD8+   T-cells  at  week  seven  (Figure  5.3,  Table  5.1).  Again  it  is 
important to note that these changes are only small fluctuations in the frequency of virus 
specific CTLs and are not statistically significant between week one and seven. 
 
 
 
Memory inflation tends to coincide with the induction of latent infection therefore the 
frequency of the tsm5-specific CD8+ T-cells was measured at the later time points of 14 and 
52 weeks p.i. Here the most apparent finding is that the frequency of MCMV-specific CD8+ T- 
 
cells did not undergo memory inflation. Critically, the frequency of IFNγ-specific CTLs in the 
spleen remained below 1.5% of the total CD8+ T-cell pool for each individual MCMV epitope 
(Figure 5.3). There had been a change in the immunodominance hierarchy with the m139 
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and IE3 specific immune response becoming the most abundant, however this pattern of 
immune response is entirely different to the memory inflation seen with Smith infected 
C57BL/6 mice. 
 
 
 
To prove that the failure to detect memory inflation is not due to a loss of IFNγ synthesis 
which would not be accurately determined by ICS, the frequency of tsm5-specific CD8+  T- 
cells was determined using MHC-I tetramer reagents specific for the inflationary m139 and 
IE3 CD8+ T-cells (Figure 5.4 A). Here, 52 weeks post-tsm5 infection, the frequency of m139- 
specific CTLs was approximately 0.5% of the entire splenic CD8+ T-cell population (Figure 5.4 
B). Likewise, the frequency of IE3-specific cells was also very low with approximately 0.1% of 
the CD8+ T-cell pool being tetramer specific (Figure 5.4 B). The evidence presented in Figure 
5.3  and  5.4  clearly  show  that  memory  inflation  does  not  occur  with  tsm5  infection. 
Therefore, the M70 mutation, which attenuates the virus, is likely to prevent sporadic viral 
lytic reactivation and T-cell proliferation. 
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Figure 5.3. tsm5 does not promote MCMV-specific T-cell accumulation (ICS). Frequency of 
IFNγ-producing CD8+ T-cells following peptide stimulation of splenocytes at weeks one, 
seven, 14 and 52 post-tsm5 infection. Mean +/- SEM (n=4 per time point). 
 
 
 
Table 5.1. Frequency of  tsm5-specific CD8+  T-lymphocytes detected within the spleen, 
 
using ICS for IFNγ, expressed as a percentage of CD8+ T-cells. Mean +/- SEM. 
 
 I FNγ  CD8 + T-cell (% CD8) (n=4) 
 
 
Epitope Week 1 Week 7 Week 14 Week 52 
M38 1.36 +\- 0.27 0.96 +\- 0.19 1.09 +\- 0.19 0.69 +\- 0.31 
 
M45 
 
1.31 +\- 0.33 
 
0.94 +\- 0.10 
 
1.07 +\- 0.14 
 
0.73 +\- 0.34 
 
M57 
 
1.46 +\- 0.32 
 
0.77 +\- 0.16 
 
1.15 +\- 0.16 
 
0.90 +\- 0.40 
 
M139 
 
1.32 +\- 0.23 
 
0.70 +\- 0.11 
 
1.42 +\- 0.29 
 
1.29 +\- 0.49 
 
IE3 
 
1.10 +\- 0.20 
 
1.05 +\- 0.10 
 
1.44 +\- 0.28 
 
1.21 +\- 0.46 
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Figure 5.4. tsm5 does not promote MCMV-specific T-cell accumulation (tetramer). A) 
Representative m139 and IE3-tetramer staining in uninfected and tsm5 infected mice 52 
weeks p.i. B) Frequency of m139 and IE3-tetramer specific CD8+ T-cells splenocytes 52 
weeks post tsm5 infection. Mean +/- SEM (n=4). 
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5.4. tsm5 DOES NOT DRIVE THE VIRUS SPECIFIC CD8 T-CELLS 
TO A HIGHLY DIFFERENTIATED TEM PHENOTYPE 
A hallmark of HCMV infection is the accumulation of highly differentiated, TEMRA HCMV- 
 
specific CD8+ T-cells [145, 386, 387]. Similarly wt MCMV infection of C57BL/6 mice generates 
an accumulation of highly differentiated lymphocytes (CD8+ CD44+ CD62L-) indicative of 
repeated antigen exposure [165]. Having previously shown that tsm5 infection does not 
cause an accumulation of virus specific CD8+ T-cells (Figure 5.3 + 5.4) the level of 
differentiation of the virus-specific and wider CD8+ T-cell pool was assessed. 
 
 
 
Following infection with MCMV Smith, C57BL/6 mice showed an accumulation of TEM CD8
+ T- 
lymphocytes  which  includes  high  frequencies  of  m139  and  IE3-tetramer  specific 
lymphocytes; in contrast tsm5 infected mice do not develop the same accumulation of highly 
differentiated T-cells. The phenotype of the m139-specific CTLs, 52 weeks post-tsm5 
infection, was a more even distribution of TCM  (40%) and TEM  T-cells (55%) (Figure 5.5 A). 
Likewise, the IE3-tetramer specific cells were more equally distributed between TCM  (43%) 
and TEM (42%) T-cells (Figure 5.5 A). It was proposed that the inflationary subset associated 
with Smith infection is replenished through the repopulation of less differentiated cells (TN 
and TCM) [45] and the data supports this hypothesis because attenuation of viral replication 
has blocked both the accumulation of and high differentiation status of MCMV-specific T- 
cells. 
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The mean fluorescence intensity (MFI) of CD27, CD44, CD62L, CD122 and CD127 were 
recorded on the m139 and IE3-tetramer labelled cells and compared to the TEM CD8
+ T-cells 
from tsm5-infected mice 52 weeks p.i. (Figure 5.5 B). MFI rather frequencies were used for 
this analysis, as there was no direct group to compare the expression of the phenotypic 
markers. It was observed that there was a significant decline in the fluorescence intensity of 
CD44 on the m139 (***p<0.001) and the IE3-tetramer (*p<0.05) cells compared with the 
overall TEM CD8
+ T-cells. This shift in CD44 florescence is likely to be a reflection of the high 
proportion of tetramer specific cells that are less differentiated belonging to the TCM 
population (Figure 5.5 A). In addition, the MFI of CD127 was elevated on the m139-specific 
cells in comparison to the effector memory CD8+ T-cells (p>0.05). Expression of CD122 
(***p<0.001) and CD127 (**p<0.01) were statistically elevated on the IE3-tetramer specific 
cells compared with the overall effector memory population. The higher expression of these 
cytokine receptors, 52 weeks p.i., suggests the cells have retained the molecules needed for 
homeostatic proliferation. In addition, CD27 and CD62L were expressed at a greater intensity 
on the tetramer specific cells (Figure 5.5 B). These findings further suggest that lytic 
replication  is  responsible  for  heightened  T-cell  differentiation  associated  with  MCMV 
infection. 
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Figure  5.5.  The  tsm5-tetramer  specific  CD8+   T-cell  response  is  less  differentiated.  A) 
Memory status of m139 and IE3-tetramer specific CD8+ T-cells, detected in the spleen, 52 
weeks post tsm5 infection. Mean +/- SEM (n=4). B) MFI of CD27, CD44, CD62L, CD122 and 
CD127 on the TEM  CD8
+  T-cell population and the m139 and IE3-tetramer specific CD8+  T- 
cells.  Mean +/-  SEM (n=4). Data analysed by  2-way ANOVA plus Bonferroni post-test 
(*p<0.05, *p<0.01, ***p<0.001 and ****p<0.0001). 
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5.5. INOCULATION WITH tsm5 GENERATES A CTL RESPONSE 
BUT DOES NOT EXPAND THE TEM CD8
+ T-CELL POOL 
In the previous chapters, Smith infection was shown to expand the TEM pool at the expense 
 
of the naïve T-cell pool. The low frequency of naïve CD8+  T-cells was linked to these mice 
responding less well to IAV challenge than MCMV seronegative animals. The frequency of 
each memory subset of the CD8+ T-lymphocyte pool was determined using a combination of 
CD44 and CD62L labelling 52 weeks p.i. 
 
 
 
Overall the distribution of CD8+ T-cell memory subsets in tsm5 infected animals was less 
differentiated than that observed in mice infected with MCMV Smith and was more similar 
to an MCMV negative animal (NB the uninfected SPF animals were not litter mates but were 
aged matched) (Figure 5.6 A+B). For example, the most predominant subset of CD8+ T-cells 
in tsm5 infected animals was the TN  subset with over 65% of CD8
+  T-cells expressing the 
 
combination of CD44-  and CD62L+  (Figure 5. 6 B). Only 10% of MCMV-specific CD8+  T-cells 
displayed the TEM  phenotypic combination. The frequency of non-inflationary TCM  CD8
+  T- 
cells was similar for tsm5 and MCMV negative animals. Inoculation with tsm5 did not expand 
the TEM  pool and naïve lymphocytes remained the most abundant cell type 52 weeks after 
the initial viral challenge. 
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Figure 5.6. Inoculation of tsm5 does not expand the TEM T-cell pool, 52 weeks p.i. A) FACS 
plots showing CD8+ T-cell memory subsets in uninfected and tsm5-infected mice. B) 
Frequency of TN, TCM, TEM and TDN CD8
+ T-cells. C) Phenotype of splenic CD8+ T-cells. Mean 
+/- SEM (n=4). Data analysed by 2way-ANOVA plus Bonferroni post-test (****p<0.0001, 
 
***p<0.001). N.B uninfected mice are aged matched but not litter mates. 
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5.6. RESULTS CHAPTER 3: CONCLUSIONS 
 
 
In older individuals, HCMV seropositivity dramatically skews the constitution of the immune 
system towards an IRP. Oligoclonal HCMV-specific CD8+  T-lymphocyte expansions, specific 
for a number of immunodominant epitopes, are readily detectable in the peripheral blood 
and accumulate to a large frequency with an increase in age [147]. Likewise, large CD8+ T-cell 
expansions can be detected in latently MCMV infected mice [165]. Both the inflationary 
HCMV [312] and MCMV [165] subsets of virus-specific CD8+ T-cells are relatively short-lived 
(compared to other memory subsets) and their accumulation is paradoxical. Having 
previously shown that administration of long-term valaciclovir therapy can significantly 
reduce the MCMV-specific CD8+  T-cell response. The valaciclovir treated mice retained a 
greater proportion of naïve CD8+ T-cells that also corresponded with improved control of IAV 
 
infection. 
 
 
 
 
To prove that lytic MCMV reactivation was the event that drives memory inflation the 
immune response to the MCMV live-attenuated virus tsm5 was tested. During latent 
HCMV/MCMV infection there is potentially sufficient viral reactivation to provide a frequent 
source of stimuli to replenish the virus-specific CD8+ T-cell pool. This hypothesis is difficult to 
prove, as latent HCMV/MCMV is notoriously difficult to detect in explant cultures due to the 
low number of latently infected cells and even fewer lytic reactivation events. 
 
 
 
The tsm5 virus provides a unique opportunity to study memory inflation with a replication 
defective MCMV strain. The tsm5 virus is a live-attenuated virus generated by chemical 
mutagenesis   (N-methyl-N’-nitro-N-nitrosoguanidine)   [315].   Non-synonymous   mutations 
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were mapped to genes essential for viral pathogenesis including mutations in immune 
evasion genes, DNA encapsulation genes and the DNA-primase ORF (M70) [381]. The M70 
mutation alone (or in combination with the M56 and/or M98 mutations) renders the virus 
replication defective in DNA synthesis [382] and restricts growth at normal murine body 
temperature [313-315]. 
 
 
 
Previously the immune response to the attenuated ΔgL-MCMV was declared to cause an 
accumulation of MCMV-specific CD8+ T-cells albeit at a much lower frequency than infection 
with the non-mutant virus [193]. The ΔgL-MCMV is able to undergo one round of replication 
and therefore there is small chance of the virus recovering gL-expression, through 
homologous recombination, that could serve to provide the antigen for memory inflation. In 
contrast, the tsm5 virus is replication defective due to mutated DNA-helicase/primase 
complex  therefore  homologous  recombination  is  theoretically impossible.  However,  the 
tsm5 viral stock is impure and contains contaminating viruses that do not contain the M70 
mutation. It was previously shown that tsm5 is capable of replicating although with delayed 
kinetics following inoculation in SCID mice [381], however, here lytic tsm5 was not detected 
at any phase of infection in immunocompetent C57BL/6 mice. The lack of lytic virus during 
the  acute  infection  would  suggest  that  immunological  control  is  sufficient  to  control 
aberrant replication of non-M70 mutants without initiating memory inflation. 
 
 
 
Snyder et al (2011) had stated that the attenuated ΔgL-MCMV is not eradicated from the 
host and drives memory inflation through repeatedly generating viral antigens [193]. Here 
memory inflation was not observed at any phase of tsm5 infection. The frequency of tsm5- 
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specific CD8+ IFNγ+ T-cells never exceeded 1.5% of CD8+ T-cell pool for each of the five 
immunodominant peptides used for ex vivo stimulation (Figure 5.3). The absence of lytic 
virus (Figure 5.2) and the low frequencies of MCMV-specific T-cells generated by tsm5 
infection again indicate that viral replication is somewhat responsible for memory inflation. 
This finding is contrary to the conclusions of Snyder et al (2011) when they infected animals 
with their attenuated ΔgL-MCMV [193]. The difference in immune response between these 
two viruses is likely due to the mechanism through which they are attenuated. The ΔgL- 
MCMV virus is infective however virions are incapable of spreading to neighbouring cells, 
transcription remains possible and could therefore could serve to generate the viral antigens 
that elicit memory inflation [193]. Similarly, the establishment of a systemic latent infection 
may be crucial to the subsequent T-cell response. The route of HSV-1 infection was shown to 
be critical for the generation of high-frequencies of gB-specific CD8+ T-cells [363] and 
correspondingly footpad inoculation of ΔgL-MCMV does not elicit the characteristic memory 
inflation [193]. 
 
 
 
At one year post-tsm5 infection there was not the typical accumulation of TEM T-cells as seen 
following Smith infection. Within the spleen of tsm5 infected mice, approximately 70% of 
CD8 +  T-cells have the TN  phenotype, 20% were TCM  and only 10% were the most 
differentiated TEM  populations (Figure 5.6 B). HCMV is associated with the accumulation of 
the most differentiated CD8+ and CD4+ T-cells therefore it is attractive property of the 
attenuated tsm5 that inoculation does not cause the memory inflation. 
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In spite of lytic reactivation not being detected, the tsm5 virus is likely to establish latent 
infection in C57BL/6 mice as it has previously been noted in BALB/c and SCID mice [381, 
383]. It  is  unknown  if  tsm5  reactivation occurs naturally and here the lack of  memory 
inflation suggests that tsm5 does not undergo lytic replication. However, the viral stock 
contains variants that lack the M70 mutation. These non-attenuated variants could be 
responsible for most differentiated antigen-specific lymphocytes observed in Figure 5.5. 
 
 
 
The  term  “latency”  is  sometimes  loosely  to  describe  the  absence  of  lytic  replication; 
however, post-inoculation each virus particle would operate independently and be in 
different  stage  of   its  lifecycle.  Therefore,  although   the  virus  is  not   detectable  by 
conventional techniques there maybe virus within specific cell types or ecological niches that 
is either truly latent, undergoing sporadic lytic replication or subverting the immune system. 
The process of abortive reactivation could serve as a method of priming memory inflation 
whilst evading the brunt of the immune response. “Normal” T-cell memory development 
requires endogenous peptide to be processed by the immunoproteasome and presented via 
MHC-I interacting with the cognate TCR [189] or the cross-presentation of exogenous 
proteins from professional and non-professional antigen presenting cells [388]. However, 
the controlled process of abortive reactivation sees the virus utilising the activation of T-cells 
to impair NK-cell mediated cytotoxicity at the expense of sensitising CTLs. Stimulation of 
CD8+  T-cells is less significant to MCMV survival as deletion of MHC-I presentation evasins 
 
does not alter the magnitude of the CD8+ T-cell response [380]. 
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The tsm5 virus would serve to be an excellent model for designing a vaccine for use in 
human  trials.  Firstly,  the  virus  generates  protective  immunity  at  very  low  doses,  as 
inoculation 40 PFU of tsm5 induced protective immunity to subsequent challenge with 
salivary gland passaged K181 MCMV [383]. Secondly, the virus does elicit CD8+ T-cell 
responses without the deleterious accumulation of highly differentiated virus-specific T-cells 
and the naïve T-cell pool remains more akin to an uninfected animal. Thirdly, tsm5 also 
contributes to normal immunoglobulin titres which are comparable to infection with non- 
replication defective MCMV [383]. Therefore, if a live attenuated HCMV vaccine is generated 
with a similar mutation in the DNA-primase, and is proved replication defective, it has the 
potential provide additional immunity that could have large implications for health. 
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6. DISCUSSION:   ANTIVIRAL THERAPY CAN REVERSE THE 
DEVELOPMENT  OF  IMMUNE  SENESCENCE  IN  ELDERLY 
MICE WITH LATENT CYTOMEGALOVIRUS INFECTION 
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6.1. CMV AND IMMUNE SENESCENCE 
 
 
In 1998, a Swedish longitudinal study examined a series of immune parameters including T- 
cell frequencies and related those findings to the age of donor. It was concluded that a high 
number of CD8+ T-lymphocytes and low number of CD4+ T-cell in the peripheral blood were 
associated with a significant increase in two-year mortality in individuals over 80 years old 
[148]. These findings were confirmed in samples taken from octogenarians in the Swedish 
longitudinal OCTO immune study. The observed expansion of CD8+ T-cells in the peripheral 
blood caused an inversion of the CD4:CD8 T-cell ratio in almost a third of donors [216]. 
Furthermore, the accumulation of differentiated CD8+  CD28-  CD57+  T-cells was specifically 
associated with increased mortality [216]. In the following Swedish NONA-Immune study, 
the elevated risk of mortality was analysed in greater detail and the expansion of the highly 
differentiated CD8+  CD27-  CD28-  CD56+  CD57+  CD45RA+  T-cells occurred most commonly 
within those individuals who were HCMV-seropositive [217]. Subsequently, HCMV 
seropositivity was confirmed as an indicator of poor health outcomes in the elderly. The 
acquisition of HCMV early in life and having expansions of virus specific CTL was estimated to 
alter the CD8+ T-cell compartment with an equivalent 'ageing effect' of the CD8+ T-cells by 35 
years [308]. Importantly HCMV is often acquired at an early age and is highly prevalent, 
through an annual rate of HCMV seroconversion in adults (18-60 years) of 0.55% [91, 389]; 
therefore  immune  senescence  associated  with  HCMV  is  an  issue  that  will  continue  to 
develop unless therapeutic intervention is successfully made. 
 
 
 
The precise mechanism(s) through which HCMV infection causes senescence of the immune 
system is not known. Both epidemiological and laboratory based evidence has illustrated 
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that individuals with the highest anti-HCMV IgG titres are at the highest risk of failing to 
developing sufficient antibody titres towards a trivalent Influenza vaccine [353]. Likewise, 
the oligoclonal expansion of highly differentiated CD8+ T-lymphocytes are more common in 
HCMV-seropositive individuals and their presence is implicated in a six-fold reduction in EBV- 
specific CD8+ T-cells [146] which could be due adaptive immunity being a finite system. The 
process of thymic atrophy results in the naïve T-cell pool having a more limited TCR diversity 
in old age and as a consequence de novo immune responses are weakened in the elderly. As 
the magnitude of the CMV-immune response also increases with advancing age, it raises the 
question whether the accumulation of CMV-specific immunity is an additional cause or an 
indicator of immune senescence. 
 
 
 
Previous adoptive transfer studies of MCMV-specific T-cells into naïve and infected mice 
have estimated that the half-life of the inflationary MCMV-specific T-cells is up to 60 days 
[165]. However, in a separate study in thymectomised mice, 100 days post MCMV-infection, 
there was a relative expansion of memory CD8+  T-cells (CD8+  CD44hi) which included M38 
and m139 peptide-specific T-cells but not IE3-specific CD8+  T-cells [390]. These conflicting 
 
reports show that the relative T-cell half-live does vary between institutional MCMV models. 
When prolonged valaciclovir treatment was administered, equivalent to four times the half- 
live of MCMV-specific CD8+ T-cells there was almost an 80% reduction in the combined CD8+ 
T-cell response to the five immunogenic peptides (m38, M45, M57, m139 and IE3). The mice 
in these experiments had been infected for at least 6 months prior to starting antiviral 
therapy and therefore this model parallels the acquisition of HCMV at an early age, many 
years prior to potential consideration of antiviral therapy. 
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Measuring the rate of decay of the MCMV-specific T-cells, the half-life for the five- 
immunodominant  CTL  populations  (relative  difference  in  frequency  to  the  untreated 
controls) was between 200-250 days when taken over a 12-month period of treatment 
(Figure  6.1).  This  estimated  half-life  is  considerably  longer  than  has  previously  been 
measured in the adoptive transfer of MCMV-specific CTLs [165]. The difference between 
these two measurements again may similarly be due to differences within the institutional 
models or could relate to the completeness of the antiviral treatment. In the setting of 
adoptive transfer into SPF animals the transferred CTLs are entering an environment 
completely devoid of viral replication and transcription whereas the treatment was given to 
virally infected mice to prevent viral replication but not transcription of genes prior to DNA- 
synthesis. Consequently, it would be expected that the presence of MCMV transcripts 
produced during latency provide additional stimuli to the immune system and continue to 
repopulate the CTL response to the virus. In addition to the longer half-life the kinetics of T- 
cell decline were not linear. There was a tendency for the t1/2 of decay to become more rapid 
with time and the IE3-specific response was the most marked in this regard, as IE3 CTLS 
declined at a t1/2 rate of only 40 days in the last six months of treatment that could suggest 
as near complete absence of viral antigen. Studies of HCMV-specific T-cells, utilising 
deuterated glucose, had shown that although the pp65-specific T-cells remain clonal (stable 
Vβ TCR chain usage) and at a high frequency, although individually the cells are disappearing 
at a rate 1-2% per day [312]. Therefore, the rate of decay of MCMV and HCMV inflationary 
CTLs are both estimated to be measured in months rather than years which is different to 
virus-specific immune responses to most other pathogens [391]. 
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Figure 6.1. The estimated rate of decay of the MCMV-specific CD8+ T-cells. The data is 
obtained from the independent experiments that show the effects of three and six months 
antiviral treatment (Figure 3.10, Table 3.3) and 12 months of treatment (Figure 4.3, Table 
4.1) relative to the frequency of MCMV-specific CD8+ T-cells in untreated animals. 
 
 
 
 
Carries of HCMV have markedly increased numbers of memory cells in the peripheral blood 
and reduced numbers of naïve T-cells [386] which is mirrored in our MCMV models. 
Importantly, in the MCMV model, valaciclovir treatment reversed the skewing of the CD8+ T- 
cell phenotype. In MCMV-neg mice, the naïve T-cells compartment comprised 37% of CD8+ 
 
T-cells at age 18 months (Figure 4.5 B). Compare this with the MCMV-AV group of mice in 
which only 15% of CD8+  T-cells had a naïve phenotype. Remarkably, valaciclovir treatment 
completely restored the frequency of naïve CD8+  T-cell pool to 42% of CD8+  T-cells. 
Additionally, the effector memory CD8+  T-cell pool almost doubled in the MCMV-AV group 
to almost 80% of CD8+  T-cells compared to MCMV-neg mice and following 12 months of 
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antiviral treatment suppressed the TEM  population  to  a more normal frequency of  40% 
(Figure 4.5 B). Furthermore, tsm5 infected mice do not develop high frequencies of TEM  at 
the expense of TN  CD8
+  T-cells (Figure 5.5 A) showing that viral replication is critical to the 
accumulation of virus-specific TEM CTLs. It is tempting to hypothesise that the data presented 
throughout this thesis is directly applicable to the treatment of HCMV; however, there are 
differences in how humans and mice maintain the peripheral naïve T-lymphocyte pool in old 
age. The human CD8+ T-cell pool is repopulated primarily by homeostatic divisions of naïve 
lymphocytes following atrophy and involution of the thymus whereas in aged mice the naïve 
T-cell pool is sustained by greater thymopoiesis than in humans [392]. Consequently antiviral 
treatment of HCMV would be needed prior to the exhaustion of thymopoiesis and is only of 
value if treatment was shown to improve the functional immune capacity of the host. 
 
 
 
 
To assess whether treatment was successfully improved immune function in the elderly mice 
the animals were also challenged with influenza. This is a relevant model as influenza 
infection remains a major cause of infectious death, and HCMV-specific immunity has been 
shown to be an important determinant of vaccine-dependent immunity in some, but not all, 
studies [353, 393]. It was of interest that the most severe clinical features, e.g. shaking, 
ataxia and rapid breathing only occurred in the MCMV-AV group following IAV challenge. 
These symptoms were observed within the first few days of infection and therefore MCMV 
infection seemed to impair elements of the innate response. Valaciclovir therapy did prevent 
the most significant clinical features of the infection and prevented the death of the mice 
(Figure 4.7 A). Weight loss was also measured as a non-immunological parameter during the 
period of IAV challenge. Somewhat mysteriously, the MCMV+AV mice lost the least weight 
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of all groups with a plateau phase reached and maintained between day five and 10 p.i. 
(Figure 4.6 B). It was expected that the MCMV+AV mice would have the largest IAV specific 
immune response and lowest viral titres. Here, the MCMV+AV treated mice did not generate 
the largest NP-specific CD8+ T-cell response in the BAL, CMLN or spleen (Figure 4.7-4.8) yet 
antiviral treatment did seem to reduce IAV titres to an equivalent levels to MCMV-neg mice 
(Figure  4.12).  Unfortunately  samples  were  not  taken  before  day  10  (post-Influenza 
challenge) and therefore the immediate mechanism was not elucidated but is likely include a 
number of other immune cells such as pulmonary CD103+ dendritic cells that transport IAV 
antigens from the lung to the CMLN and present processed antigens via MHC-I [379]. MCMV 
infection of mice that lack CD103+ dendritic cells (Batf3-/-) do not generate memory inflation 
therefore the suppression of the MCMV replication with valaciclovir may partially activate 
and licence a greater number/frequency of DCs to present IAV antigens which consequently 
improved the IAV response in the antiviral treated mice. 
 
 
 
In addition to memory inflation of the virus-specific CD8+ T-cell pool there is a high incidence 
of elevated immunoglobulin titres in the serum of elderly individuals. Studies have shown 
that elderly individuals (>60 years) with the highest quartile of anti-HCMV IgG compared 
with lower quartiles, were at an elevated (1.43 times) risk of all-cause mortality and cardio 
vascular disease mortality [218]. In addition, a high anti-HCMV specific IgG titre (>50 UA/ml) 
was shown to be linked to the proportion of non-responders to a tri-valent anti-influenza 
vaccine (A/Beijing/262/95 (H1N1), A/Sydney/5/97 (H3N2) and B/Beijing/184/93) [353] with 
HCMV was accepted as an accelerator of immune senescence of the B-cell response towards 
unfamiliar pathogens. More recently conflicting evidence obtained from elderly residents of 
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long-term  care  facilities  which  concluded  HCMV  seropositivity  did  not  affected  the 
generation of a protective immune response to influenza vaccination (A/Nanchang/933/95 
(H3N2), A/Johannesburg/82/96 (H1N1) and B/Harbin/7/94) [393]. A limitation of these 
studies is that only humoral parameters were measured and the cytotoxic T-lymphocyte 
response was not assessed. Here, in the animal model, neither three nor six months of 
antiviral treatment reduced the titres of anti-MCMV-specific IgG compared to untreated 
mice (Figure 3.12 B) whereas longer periods of treatment did help to reduce the MCMV 
specific CTL response (Figure 3.13 C – 4.2). 
 
 
 
Acycloguanosine antivirals are highly specific as the drug are selectively incorporated into 
the replicating viral genome; however, prolonged periods such as those used here have been 
associated with neurotoxicity and nephrotoxicity. However, during the experimental 
procedure, there was no increased risk of death associated with valaciclovir treatment. In 
addition, the valaciclovir treated mice displayed no aversion to prolonged periods of 
treatment and necropsy did not reveal any notable alterations to organ pathology. Herpes 
infections are often successfully treated for long periods with acycloguanosine antivirals 
without serious side effects. Aciclovir is one of the least toxic and has a safety index of 
approximately 3,000 (concentration associated with toxicity divided by therapeutic 
concentration) [394]. In addition, aciclovir and its metabolites are generated within virally 
infected cells meaning that any toxicity should be localised. With this in mind, aciclovir has 
been proposed to have direct immunosuppressive effect upon T-lymphocytes through 
inhibiting the actions of cellular purine nucleoside phosphorylase (PNP) enzymes. PNP are 
involved in guanine base synthesis and inhibition of PNP results in selective deficiency of T- 
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cell proliferation [395]. Aciclovir and its metabolites have been shown to have in vitro and in 
vivo immunotoxicity primarily towards CD8+ T-cells in mice [195]. In vitro measures of both 
murine and human T-cell proliferation to mitogen/antigen stimuli seems to be inhibited at 
aciclovir concentrations in excess of 100 μM [195, 394, 396]. It is estimated that although 
the antiviral treated mice received high doses of antiviral the actual in vivo concentrations 
were below this threshold as 3.8 mg/day of treatment equates to 117 μM of which only 55% 
is bioavailable after the first round of metabolism. Furthermore, if the valaciclovir treatment 
suppressed CD8+ T-cell proliferation the antiviral treated mice would have been more 
lymphopenic that the other mice, however this was not the case as hyposplenism was most 
common in MCMV infected mice and cellularity of the spleen was not affected by 12 months 
of treatment. Additionally, preventing CD8+ T-cell proliferation would result in elevated 
CD4:CD8 T-cell ratios and this did not occur. Antiviral treatment actually restored the 
CD4:CD8 T-cell ratio to that of MCMV naïve mouse in the BAL, CMLN and spleen (Figure 
4.11). Consequently, we would suggest that prolonged valaciclovir is safe for trial in humans. 
 
 
 
 
HCMV is a highly prevalent virus and often contracted in the first few years, consequently 
individuals are likely to carry and potentially shed HCMV for the majority of their life. It is 
possible that as human and herpesvirus evolution occurred in parallel that acquiring HCMV 
could have beneficial/symbiotic effects. A high profile study into herpes virus co-infection in 
mice concluded that the presence of herpes viruses is beneficial under specific experimental 
circumstances. The study concluded that acute infection with either MCMV (or γHV68) 
provided a degree of short-term protection against Listeria monocytogenes and/or Yersinia 
pestis   challenge   [378,   397].   The   acute   herpes   viral   infection   induced   a   transient 
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proinflammatory environment that activated macrophages and led to reduced bacterial 
loads. The same symbiotic effect was not apparent when testing later time-points (28 days 
p.i.) which the authors remarked corresponded to the latent phase of infection. 
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6.2. SUMMARY 
 
 
The  data  presented  throughout  this  thesis  could  have  important  implications  for  the 
potential treatment of patients with high levels of HCMV-specific immunity – i.e. display an 
IRP – and are therefore at the greatest risk of immune senescence [398]. Using the MCMV 
model it was shown that memory inflation is reversible with prolonged treatment. 
Unfortunately, it was not possible to prove that antiviral treatment did lead to a reduction in 
lytic reactivation events, as MCMV was undetectable so far out from the initial infection. 
However, treatment of latent infection lead to a partial rejuvenation of the CD8+ T-cell pool 
as increased frequencies of naïve CD8+ T-cells were detected in the spleen, and valaciclovir 
 
treated mice did appear to have superior control during acute influenza challenge. 
Valaciclovir is routinely administered for many years in order to suppress reactivation of 
genital herpesvirus and is well tolerated. Viral resistance to valaciclovir is rare and is most 
commonly during immune suppression. The amount of valaciclovir used in our study was 
equivalent to the dose administered for treatment of acute VZV infection or control of 
HCMV replication in patients undergoing immune suppression. However, the dose of 
valaciclovir that would be required to suppress HCMV replication in immunocompetent 
subjects and reduce the magnitude of the HCMV immune response may be much less than 
this and will be the subject of future investigations. In addition, it may now also be 
appropriate to consider the use of an attenuated HCMV vaccine to provide additional 
immunity without the side-effects of memory inflation with the aim to provide successful 
anti-HCMV therapeutic intervention and improve health other outcomes such as IAV 
vaccinations success. 
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